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Angiogenesis is the development of new capillary vessels from pre-existing ones. It involves 
the proliferation, migration and differentiation of endothelial cells. It is activated by different 
stimuli and requires the coordination of several signalling pathways. The most important 
growth factor for angiogenesis is VEGF. However, other factors also play an important role. 
For example, H2S is a gaseous molecule that exerts its pro-angiogenic effect through 
activation of the pro-survival Akt signalling pathway. In vitro studies have further shown the 
ability of H2S to enhance endothelial cell proliferation, adhesion, migration, and tube 
formation. 
The ERK5 signalling cascade is the most recently discovered mammalian MAPK (mitogen-
activated protein kinase) pathway. ERK5 knockout mice die due to impaired heart 
development and endothelial cell dysfunction. Furthermore, VEGF promotes ERK5 
activation in primary endothelial cells and ERK5 is required for VEGF-induced tubular 
morphogenesis. Importantly, VEGF activates ERK5 in endothelial cells, which in turn 
activates the AKT pro-survival pathway to suppress apoptosis of endothelial cells. As H2S 
also mediates its vasoprotective effect through AKT activation, the hypothesis of this thesis 
was that H2S protects endothelial cells by activating the ERK5 pathway. The aim of this 
thesis was therefore to investigate whether H2S activates ERK5 and to develop the 
necessary tools to further investigate the mechanisms involved. 
In this thesis, an assay detecting and quantifying an electrophoretic mobility shift by western 
blotting has been developed to measure ERK5 activation in mammalian cells. Furthermore, 
ERK5 could be shown to be activated by H2S in HeLa cells. Importantly, H2S also activated 
ERK5 in endothelial cells, demonstrating that ERK5 signalling mediates the pro-survival 
response of H2S in endothelial cells. To further analyse ERK5 activation in response to 
various stimuli, including H2S, additional tools to determine ERK5 phosphorylation were 
evaluated, including mass spectrometric determination of phosphorylation sites and the 
characterisation of a novel phosphor-specific antibody. 
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1.1. General overview of the cardiovascular system 
It is well-known that there is a global epidemic of cardiovascular diseases (CVDs), which 
have serious implications in public health and comprise an extraordinary amount of 
healthcare expense. In association to high morbidity and mortality rates, the CVD may 
represent a significant role in increasing the problems on the global medical and economic 
levels (Deveza et al. 2012). CVD has been listed as the number one cause of death 
worldwide, according to the World Health Organization (WHO). It has been documented 
that, and in the United States of America alone, 32.8% of the approximately 2.5 million 
deaths are accounted for CVD in 2008 (Roger et al. 2012). In 2016, CVD represented the 
leading cause of death in the United States, responsible for 840,768 deaths (635,620 
cardiac) (Benjamin et al. 2018). CVD has been reported to be one of the 15 leading 
conditions that induce functional disability for those that have experienced one CVD event, 
thereby it can be said that the quality of life and the ability to work are both affected (Deveza 
et al. 2012). Narrowing or even occlusion of blood supply of the vascular beds is a general 
characteristic of CVD, where it is caused by atherosclerosis (Libby and Theroux 2005, 
Jawad and Arora 2008). Even though there are a number of modified (controllable) risk 
factors, such as hypertension, smoking, obesity, lack of physical activity and diabetes, other 
unmodified risk factors may arise such as age, gender, and family history (Goff et al. 2014). 
1.1.1. The cardiovascular system 
Three main components can classify the cardiovascular system: heart, blood vessels and 
blood. Further, three types of distinct blood vessels can be categorized in term of anatomical 
and functional properties: arteries, veins and capillaries. In order to deliver the oxygenated 
blood and nutrients from the heart to target organs and tissues, the arteries seem to play a 
critical role in fulfilling this function. Thicker and more elastic vessel walls are distinctive 
features of the arteries, where the high blood pressure for blood delivery from the heart 
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would be complemented. Carrying deoxygenated blood to the heart would be accomplished 
by the veins, together with waste products and other factors excreted by the tissues. In 
comparison to the arteries, veins can be distinguished to have larger luminal areas, thinner 
vessel wall and valves to accommodate the pressure changes. Capillaries play a key role 
in connecting together the arteries and veins, and allow the direct exchange between the 
target tissues and the blood of the oxygen and nutrients with carbon dioxide and waste 
products. In general, three layers are major components of the vessel walls: the tunica 
intima, tunica media and tunica adventitia (Figure 1.1). The underlying layer is composed 
of the tunica intima, that contains a single layer of endothelial cells (ECs) and connective 
tissues, both of which superimpose the internal elastic lamina. It has been found that, based 
Figure 1.1: Blood vessels structure. 
The figure demonstrates the major anatomical parts of the blood vessels. In general, the 
blood vessel is composed of three predominant layers: tunica intima, tunica media, and 
tunica externa. As it appears from the figure that tunica intima is the innermost layer of the 
blood vessel, which contains endothelium, subendothelial layer, and internal elastic 
membrane. On the other hand, the outer layer (tunica externa), forms of external elastic 
membrane. The capillary is only composed of basement membrane and endothelial cells. 
It can be inferred from the figure that the lumen of artery is narrow and more elastic due to 
the presence of the internal elastic membrane to meet the pressure changes in delivering 
the blood from heart to the tissues. The lumen of vein is wider and has valves to deliver the 
blood back to the heart from the tissues. Image taken from (Kizirian 2020). 
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on its structure, the tunica intima can perform a distinctive role as a selective permeable 
barrier between the extravascular space, the vascular wall and the blood. Muscular 
elements of blood vessels can reside in the tunica media, between the tunica intima and 
the tunica adventitia, and comprises peripherally organized smooth muscle cells 
surrounded by a layer of external elastic lamina. Finally, the exterior layer, the tunica 
adventitia, contains connective tissues and matrix-secreting fibroblasts. It has been found 
that the tunica adventitia plays a critical role in the protection of vascular structure and 
anchoring the vessels in the right place in accordance to the surrounding tissues. Capillaries 
on the other hand compile non-muscular vessels and only consist of an internal elastic 
lamina preserved by a monolayer of ECs, which provides exchangeable surface area 
allowing transport of molecules between vessels and tissues. 
1.1.2. Endothelial cells and their impairments in CVDs 
Vascular endothelial cells (ECs) play an essential role in the integrity of the entire circulatory 
system as they overlay the innermost layer of the vascular system. Acting as a semi-
selective and non-adherent barrier between the lumen of vessels and the underlying tissues 
is a distinctive property of the vascular endothelial cells, where regulation of tissue perfusion 
and movement of inflammatory cells can be attained between them (Aird 2007). The 
vascular endothelial cells (vECs) have been reported to be a major regulator for the vascular 
permeability, blood flow, vascular tone and blood coagulation as well as their essential role 
involving vascular remodelling in response to diverse physiological and pathological stimuli 
(Chiu and Chien 2011). Upon secretion of anti-coagulant factors for instance prostacyclin, 
nitric oxide (NO) and prostaglandin-E2, vECs can induce a preliminary role at the 
physiological level as anti-coagulant and anti-thrombotic. It has been found also that vECs 
can maintain vascular homeostasis by reducing inflammatory cell adhesion (van Hinsbergh 
2012). In order to create vascular remodelling, numerous pathological events have been 
found to be caused by increasing the vascular permeability, stimulating extravasation of 
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immune cells, which are activated by vascular injury or pro-inflammatory cytokines. 
Endothelial nitric oxide (NO) synthase (eNOS) is an enzyme which plays a key role in 
synthesis and formation of the vasodilator NO (Forstermann and Sessa 2012). Therefore, 
repressing activity of eNOS results in alleviation of vEC secretion of vasodilator NO, which 
it has been found to be a major contributor to aggravation of vascular pathogenesis 
(Alderton et al. 2001). The pathophysiology of many CVDs, for example hypertension and 
atherosclerosis, is strictly bound to occurrence of endothelial dysfunction, which in turn 
being provoked by different factors such as environmental and genetic (Favero et al. 2014). 
Eventually, the vECs dysfunctions display a potential target for drug development in terms 
of therapeutic approaches (Versari et al. 2009). 
1.1.3. Cardiovascular disease 
A wide range of problems would arise within the cardiovascular system including 
endocarditis, rheumatic heart disease, abnormality in the conduction system (Olvera Lopez 
et al. 2020). CVD or heart disease can be classified into 4 predominant entities. First, 
coronary artery disease (CAD) which may also be referred to as Coronary Heart Disease 
(CHD), results from decreased myocardial perfusion that induce angina, myocardial 
infarction (MI) and/ or heart failure. In general, the previous examples of the CAD may 
account for the majority of the cases of CVD (one third to one half). Secondly, 
cerebrovascular disease, that includes stroke and transient ischemic attack (TIA). Third, 
peripheral artery disease (PAD), which involves particularly arterial disease in the limbs 
resulting in claudication. Fourth and finally, aortic atherosclerosis that includes thoracic and 
abdominal aneurysms. 
Infectious myocarditis is another problem that may occur within the cardiovascular system. 
In general, infection of the heart by some microbes, such as cardiotropic viruses and T. 
cruzi, may procure the manifestation of myocarditis. However, it remains obscure which cell 
types are particularly infected in many myocarditis-associated viruses. Furthermore, cardiac 
vasculature represents another target for infection in the cardiovascular system. To be 
21 
specific, in order to infect the heart, the endothelium of the cardiac microvasculature would 
play a key role as a first barrier to encounter infectious agents. Infection of human and / or 
animal endothelial cells can be acquired by T. cruzi and more than 20 viruses associated 
with myocarditis. One outstanding observation demonstrates among others that endothelial 
activation, damage, and permeability can be induced by infection of the cardiac 
endothelium. For example, it has been shown that in patients with viral myocarditis, 
induction of endothelial microparticles reflecting endothelial damage would be caused upon 
the role of cardiac endothelial cells infection. However, it remains unknown how non-viral 
mechanisms would cause the changes to cardiac (micro) vasculature seen in infectious 
myocarditis, when encountered in vivo (Woudstra et al. 2018). 
 
1.1.3.1. Aetiology 
The aetiology of CVD may directly appear from different causes such as rheumatic fever 
resulting in valvular heart disease, blood clot in patient with arterial fibrillation causing 
ischemic stroke (Olvera Lopez et al. 2020). Development of atherosclerosis and other 
associated factors can be addressed with high importance because it plays an essential 
role in the pathophysiology of CVD. During the last few decades, a resultant shift to 
sedentary life style from physically demanding in the industrialized economy, along with 
consumption demanding and technology-driven culture which require long working hours 
and less recreational time, may justify the increase in the incidence of CVD. In particular, 
development of atherosclerosis and other metabolic defects such as metabolic syndrome, 
diabetes mellitus, and hypertension can arise associating to lack of physical activity, 
consuming a high calorie-diet, fats, and sugars (Fox et al. 2004, Vasan et al. 2005, Benjamin 
et al. 2018, Force et al. 2018). Smoking, dyslipidaemia, hypertension, diabetes, abdominal 
obesity, psychosocial factors, low consumption of fruits and vegetables, regular alcohol 
consumption, and limited physical activity are all 9 modifiable risks factors concluded from 
INTERHEART study which recruited subjects from 52 different countries, including high, 
middle, and low-income countries. The main goals of establishing this study were to detect 
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the strength of correlation between different risk factors and acute myocardial infarction and 
to emphasize if there is a significant variations between geographic regions, ethnic origin, 
sex or age. Another significant objective was to determine the PAR (Population Attributable 
Risk) for risk factors and their combinations at overall population and in different subgroups 
(Yusuf et al. 2004). Thus, 90% of the risk of having a first myocardial infarction (MI) is 
accounted for by those 9 modified risks factors (Yusuf et al. 2004). Affirmative association 
and predictive value of dyslipidaemia, high blood pressure, smoking, and glucose 
intolerance have been concluded from other robust studies such as the Farmingham Heart 
Study and the Third National Health and Nutrition Examination Survey (NHANES III). 
Therefore, 60% to 90% of CHD occurrence would be attributed in individuals with at least 
one risk factor. 
Family history, age, and gender are non-modified factors that have been addressed in 
different implications. Suggestive evidence was revealed stating that the presence of CVD 
risk factors would variably affect gender (Fox et al. 2004, Fox et al. 2008). For example, in 
women compared to men, increasing CVD risk is typically associated with diabetes and 
smoking more than 20 cigarettes per day (Njolstad et al. 1996). Significantly, within each 
decades of life, the risk and prevalence of CVD is increased (Savji et al. 2013). It remains 
controversial that consumption of specific diet factors like meat, limited fibre, and coffee are 
associated with CVD, and that is because of the alignment in significance seen in 
epidemiological studies (Ioannidis 2013, Trepanowski and Ioannidis 2018). 
1.1.3.2. Epidemiology 
Since 1975, CVD is the second-leading cause of death in the United States with 1 in every 
4 deaths. In 2015, heart disease has been categorized as the leading cause of death 
followed by 595,930 deaths from cancer (Benjamin et al. 2018). According to the WHO, the 
number 1 cause of death globally is CVD with an estimated 17.7 million deaths in 2015. By 
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the year 2030, more than 23,3 million people have been projected to die from CVD globally 
(WHO 2020). 
In spite of the incremental declining over time in the age-adjusted rate and acute mortality 
from MI due to the progress in diagnosis and treatment over the last couple of decades, the 
calculated percentage of heart disease risk in the general population remains high with 50% 
risk from the age of 45 (Lloyd-Jones et al. 1999, Fox et al. 2008). The significant increase 
in incidence is associated with age, with taking into consideration that some variations 
between genders are likely to occur. 
1.1.3.3. Pathophysiology 
In term of pathophysiology, atherosclerosis is a prominent example for the CVD. It can be 
defined as a pathogenic process resulting from decreased or absent blood flow from the 
blood vessels stenosis in the arteries and the aorta that cause a disease (Libby et al. 2011). 
Dyslipidaemia, immunological reactions, inflammation, and endothelial dysfunctions are 
multiple involving factors which are believed to enhance fatty streak formation, leading to 
development of the atherosclerotic plaque (Figure 1.2) (Davies et al. 1988). This process is 
complex including thickening of the intima followed by accumulation of lipid-laden 
macrophage (foam cells) and extracellular matrix, with subsequent aggregation and 
proliferation of smooth muscle cells comprising the atheroma plaque formation (Sata et al. 
2002). It is widely accepted that macrophages play a key role in progression of 
atherosclerotic lesion. To be specific, the recruitment of monocyte-derived cells into the 
sub-endothelial space would mediate an immune response, where they eventually 
differentiate into macrophage that engulf the normal and modified lipoproteins, transforming 
them into the cholesterol-laden “foam cells”. At this stage, macrophages play a decisive role 
by secreting pro-inflammatory cytokines and chemokines, maintaining the local 
inflammatory response (Moore et al. 2013). Within the expansion of lesions, occurrence of 
apoptosis in the deep layers would be promoted, depositing more macrophage that within 
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time could form atherosclerotic plaque upon their calcification and transition. Intra-plaque 
haemorrhage and arterial remodelling are other mechanisms that play a decisive role in the 
acceleration of the progression of atherosclerotic CVD by delay and acceleration. 
Monocytes adhesion to the endothelium may develop upon occurrence of injury, which on 
turn loses the endothelial cell junctions, and migrating monocytes under the endothelium, 
to be differentiated into macrophages. Upon permeability of the endothelium, more LDL 
would be allowed to get in the intima of the artery, thereafter, the LDL would be engulfed by 
macrophages by phagocytosis. Foam cells are a terminology referred to transformation of 
macrophage to lipid laden from ingested LDL, where their appearance may create fatty 
streaks. Also, the figure demonstrates the role of T-lymphocytes in the intima. T-
lymphocytes have the ability to secret some cytokines, which eventually may promote 
migration of smooth muscle cells from the media to the intima. Thereafter, these smooth 
muscle cells, and under the effect of growth factors, may start to proliferate. In time, there 
would be a progressive aggregation of lipid and smooth muscle cells in the intima, which 
eventually may lead to growing of the endothelium, and surpass the lumen of artery. Image 
from (LaMorte 2016, Kizirian 2020). 
Figure 1.2: The steps of evolving a fatty streak in atherosclerosis. 
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1.2. Angiogenesis 
The development of functional vessels is complex (Udan et al. 2013). It is important to 
differentiate between vasculogenesis and angiogenesis. In the early embryo, a new 
synthesis (de novo) and assembly of endothelial cells into vessels in the absence of a pre-
existing vascular system is referred to as vasculogenesis. On the other hand, angiogenesis 
is defined as the development of capillary vessels from pre-existing ones (Betz et al. 2016). 
Angiogenesis literally means creation of new blood vessels. The word “angio” means blood 
vessels while “genesis“ means creation. Based on the nature of the vessel, angiogenesis 
would be defined as either arteriogenesis or lymphangiogenesis. In both cases, 
Figure 1.3: The angiogenic process. 
Four major steps can illustrate and summarize the angiogenic process. (A) It is important 
for the endothelial cells localised in the outer surface of a blood vessel to receive initially 
pro-angiogenic signals from Angiogenin (ANG), Vascular Endothelial Growth Factors 
(VEGF), Platelet Derived Growth Factor (PDGF), Placental Growth Factor (PGF), 
Epidermal Growth Factor, Growth Factor Form Fibroblast (FGF), Transforming Growth 
Factor Beta 1(TGF B), and Tumor Necrosis Factor Alpha (TNF-α). Several receptors have 
their corresponding ligands (angiogenic growth factors) on the surface of endothelium, for 
example VEGFR1/2, TGFBR1/2, TNFRS. (B) In order to conduct the degradation of the 
basement membrane, the MMPs should firstly escape the blood vessels at the same time 
as increasing the blood vessel pores to form fenestrations. (C) Then the migration and 
proliferation of endothelial cells would be evolved, through a process named partial 
endothelial to mesenchymal transition at the place of fenestration, resulting in the budding 
and formation of a new blood vessel. (D) Once the new tube is obtained, a variety of 
signals, such as RASIP1 and ARHGAP29, would be received from the environment, which 
in turn gives the newly formed network, a well-organized and 3-D structure. At the end of 
this stage, it has been found that the pericytes inhabiting the exterior of the blood vessels, 
are responsible for contraction of the blood vessel and beginning to establish the newly 
formed network. Image taken from (Zimta et al. 2019). 
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angiogenesis is mediated via two distinguished pathways: splitting and sprouting. Increased 
in micro-vascular shear stress leads to the intraluminal splitting of the micro-vessel linear 
into two vessel, on the other hand, tissue hypoxia stimulates sprouting angiogenesis and 
budding of a new capillary sprout laterally from a pre-existing vessel. This process requires 
a high level of coordination by a series of angiogenic factors and inhibitors (Figure 1.3) 
(Folkman 2007). Some of the normal physiological situation where angiogenesis is required 
include those of wound healing and formation of the placenta during pregnancy. (Michiels 
2003) 
1.2.1. Biological and molecular role of vascular endothelial cells 
Blood vessel walls form a unique and selective barrier, while permitting the transport of 
molecules between the blood and tissues (Rajendran et al. 2013). They form a complex 
interface structure, with a total area measuring around 350 m2 in the human body (Augustin 
et al. 1994). Endothelial cells make up the tunica intima, the interior lining of the vasculature 
(Mazurek et al. 2017). They exert their function by responding to various neurotransmitters, 
hormones and vasoactive agents that induce vasomotion, thrombosis, and inflammation. 
The endothelium is composed of a continuous monolayer structure, with the individual cells 
linked to each other by various types of cell-to-cell junctions (adhesiveness) (Dorland and 
Huveneers 2017). Three types of junctions have been identified in endothelial cells: gap 
junctions, adherens junctions, and tight junctions (Bazzoni and Dejana 2004). 
It has long been believed that the endothelium is just a “cellophane wrapper”, with no other 
functions than selective barriers for passaging water and electrolytes between the blood 
and tissues (Wilson et al. 2001, Rajendran et al. 2013, Kruger-Genge et al. 2019). However, 
more recent research has allowed a better understanding of endothelial cells, discovering 
that they play critical roles in controlling many vascular functions. For example, they 
contribute to the secretion of several mediators that enhance and maintain vascular 
hemodynamics in the normal physiological state. Endothelial cells also perform a unique 
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function in fluid filtration processes (e.g., in the glomeruli of the kidneys) (Durand and 
Gutterman 2013). In spite of their distinctive roles in participating in all aspects of vascular 
homeostasis, endothelial cells are also a potent contributor to pathological conditions such 
as thrombosis, inflammation, and vascular wall remodelling (Michiels 2003, Gimbrone and 
Garcia-Cardena 2016). Furthermore, it has been shown that vECs regulate blood pressure 
and blood flow upon secreting vasodilator (e.g., nitric oxide and prostacyclin PGI2) as well 
as vasoconstrictor molecules (e.g., endothelin and platelet-activating factor) (Sandoo et al. 
2010). Endothelial cells have also been shown to regulate the trafficking of immune cells 
(Barton et al. 2012) as well as contribute to coagulation processes initiated through turbulent 
blood flow, which is pivotal for the onset of blood vessel repair (Cines et al. 1998, Kruger-
Genge et al. 2019). Other areas where endothelial cells play a major role are in inflammatory 
reactions and in the neoangiogenesis of tumours (Michiels 2003). Overall, a complex 
interaction between vasoregulatory pathways is required for the vascular response to carry 
out particular regulatory function, including under pathophysiological circumstances 
(Rajendran et al. 2013). 
1.2.2. Endothelial dysfunction 
Endothelial dysfunction is typically associated with inflammatory conditions and reactions 
(Stenvinkel 2001, Steyers and Miller 2014). Inflammation in general can be defined as an 
immunological response to injury or destruction at a localized site of body tissues. 
Inflammation provides the necessary protection by diluting and destroying the injured tissue 
and the causative agent at the location. The acute form of inflammation can be distinguished 
from the chronic one by appearance of such common signs as pain (dolor), heat (color), 
redness (rubor), and swelling (tumor, edema). In the endothelium, inflammatory reactions 
are mainly initiated upon the migration of leukocytes to the inflammatory location. If the 
inflammation has not been resolved after some time, it can lead to excessive (chronic) 
inflammation as a pathological consequence. Interestingly, migration of leukocytes to the 
site of injury (inflammation) involves a complex series of events and mediators, including 
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dilation of vessels (venules, arterioles, and capillaries), increased blood flow and 
permeability, and perfusion of fluids (Nathan 2002, Sumagin and Sarelius 2013). On the 
other hand, numerous inflammatory mediators such as NFκB, IL-1, and TNF-α play an 
indispensable role in regulating each individual step of the inflammatory reaction (Lawrence 
2009). Atherosclerosis is an example of these inflammatory reactions which leads to the 
dysfunction of the endothelium (Rajendran et al. 2013, Kany et al. 2019). Vulnerability to 
atherosclerosis may vary based on several factors, including hypertension, diabetes, and 
hypercholesterolemia (von der Thusen et al. 2003). Changes in the endothelial cells initiate 
the proinflammatory and prothrombotic phase of atherosclerosis (Landmesser et al. 2004, 
Gimbrone and Garcia-Cardena 2016). A reduction of endothelium-derived NO production 
is noticed in lesions of the aorta and coronary arteries. Increased levels of c-reactive protein 
promote atherosclerosis by reducing the level of eNOS-mediated NO in the plasma 
(Rajendran et al. 2013). A number of endothelial mechanisms enhance the atherogenesis 
process. For example, the inflamed endothelium releases chemoattractant substances that 
recruit circulating monocytes and activate their endothelin B (ETB) receptors. Upon the 
activation of macrophages by endothelin 1 (ET-1), inflammatory mediators such as IL-6, IL-
8, TNFα and superoxide anion may be secreted (Rajendran et al. 2013). Alongside smooth 
muscle cell migration effect, ET-1 promotes hypertrophy and the secretion of fibroblast 
growth factor 2, which in turns provides responsiveness to angiotensin 2. After the 
stimulation of fibroblast proliferation, chemotaxis, and matrix synthesis by ET-1, P-selectin 
expression and PKC (protein kinase C) activation would be augmented upon the role of ET-
1, as well (Best and Lerman 2000). However, impaired endothelial cells are able to secrete 
plasminogen activator inhibitor-1, which is highly efficient in suppressing fibrinolysis levels 
(Behrendt and Ganz 2002). 
1.2.3. Signal transduction pathways in angiogenesis 
Analyzing the required molecular events that initiate and preserve vascular development, 
has been investigated in a detailed study of rat embryos in which the genes for polypeptide 
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growth factors or their trans-membrane receptors (receptor tyrosine kinases), have been 
switched off. In this study, vascular endothelial growth factor (VEGF) was identified as the 
most potent and critical factor of vascular development (Ho and Fong 2015). Vascular 
endothelial growth factor (VEGF), also known as VEGF-A, is a member of the VEGF 
platelet-derived growth factor (PDGF) family of structurally related mitogens. Other family 
members including placental growth factor (PIGF), VEGF-B, VEGF-C and VEGF-D, 
demonstrate some degree of variation of homology with VEGF (Ferrara and Davis-Smyth 
1997). VEGF is a homodimeric glycoprotein with a molecular weight of approximately 45 
kDa (Carmeliet 2005). Furthermore, it is widely known as a mitogen for vascular endothelial 
cells derived from arteries, veins and lymphatics, but is deprived of consistent mitogenic 
activity for other cell types (Ferrara 2000). There are at least four main isoforms of VEGF 
existing as a result of alternative splicing. These isoforms are 121,165, 189 and 206 amino 
acids long. It is important to mention that 165-amino acid form exemplifying the major and 
dominant species of VEGF. Recently, it has been recognized that another family of growth 
factors known as angiopoietins (Ang) and some members of the ephrin family (e.g., 
ephrinB2) would also have unique roles in the endothelium by conducting subsequent 
actions on further remodelling and maturation. Therefore, an incorporated model of known 
vascular-specific growth factors would include vascular formation and expansion. In order 
to maintain the quiescence and integrity of the mature vasculature, Ang1 appears 
additionally to play a continuing role in fulfilling this function (Gale and Yancopoulos 1999, 
Michiels 2003, Rajendran et al. 2013). 
A number of cellular signalling pathways have been shown to regulate angiogenesis 
downstream of the VEGF receptor by modulating the proliferation, migration and tube 
formation of endothelial cells (Patel-Hett and D'Amore 2011) (Figure 1.4). For example, 
VEGF-induced ERK1/2 MAPK activation is essential for endothelial cell proliferation 
(Takahashi et al. 2001, Kiec-Wilk et al. 2010). Cell proliferation and migration is further 
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induced by VEGF-mediated PLC-γ/PKC activation (Wang et al. 2008). VEGF activation also 
leads to the activation of p38 MAPK, which stimulates endothelial cell migration (Lamalice 
et al. 2004). In addition, VEGF also activates the PI3K/AKT pathway, which mediates 
endothelial cell survival (Fujio and Walsh 1999, Dayanir et al. 2001). The ERK5 MAPK 
pathway has been shown to play a decisive role in angiogenesis through activation of the 
AKT pathway and the promotion of endothelial cell survival (Roberts et al. 2010). 
Figure 1.4: Signal transduction pathways in angiogenesis. 
The figure demonstrates the major characteristic pathways activated by VEGF-A/VEGF 
receptor-2 and how it is distinguished from other pathways induced by the IL-1 and EGF 
receptor in endothelial cells. In order to elicit the angiogenic/proliferative response, activation 
of the Ca++ /calcineurin and PKC/MAPK pathways has to be induced by VEGF-A coupled 
with Tyr1175 to PLC-γ, which it turns to procure to the activation of the transcription factor 
NFAT and EGR-1 that are important for part of the VEGF-induced gene repertoire. On the 
other hand, promotion of cell survival, migration, and potentially permeability would be 
attained by activation of other pathways via PI3K/Akt, TsAd, Src and p38. IL-1 receptor, and 
via NF-κB, would promote genes to a large magnitude. It may also appear that a significant 
portion of the NF-κB-induced genes is up-regulated by VEGF-A-induced NFAT. It is more 
relevant to notice that MAPK pathway would be activated by EGF. NF-κB activation is 
seemingly not activated to a significant extent by VEGF-A or EGF. Image taken from (Hofer 
and Schweighofer 2007). 
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1.3. MAPK signalling pathways 
1.3.1. MAPK pathways in mammalian cells 
MAPKs are thoroughly conserved enzymes in eukaryotic cells that regulate many cellular 
processes. Examples of those critical processes are cell growth, differentiation, and 
apoptosis (Cargnello and Roux 2011). MAPK signalling pathways consist of three-
component hierarchical cascades and are named according to the downstream protein 
kinase (Figure 1.5). Classically, 4 pathways are distinguished at the molecular level of 
eukaryotic cells: ERK1/2 (extracellular signal-regulated kinase 1/2), p38MAPK (with 
different isoforms α/β/γ/δ), c-Jun NH2-terminal kinases (JNK) 1/2/3 and ERK5 (Krishna and 
Narang 2008, Morrison 2012). 
Each part of this cascade performs a crucial function according to their distinctive structure 
(Dhillon et al. 2007, Plotnikov et al. 2011). The first protein in the signalling pathway is 
entitled MAPK kinase kinase (MAPKKK), whose role is to respond to extracellular 
stimulation, for instance cellular stress or growth factors. Then, at the second level, is 
MAPKK. These proteins contain particular motifs of serine (Ser; S) and threonine (Thr; T) 
amino acids that are dual-phosphorylated by the MAPKKK in order to activate the MAPKK. 
Then, the downstream MAPK would be phosphorylated by the MAPKK, thereby activating 
it (Cargnello and Roux 2011). MAPK activation then leads to the modification of a set of 
regulatory molecules such as structural proteins, transcription factors, and phospholipids, 
which in turn maintain or regulate cellular activity (Krishna and Narang 2008, Cargnello and 
Roux 2011). 
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1.3.2. MAPK activation and inactivation 
MAPKs are activated by a large number of environmental stimuli, including osmotic and 
oxidative stress as well as growth factors. Each MAPK cascade can be stimulated by one 
or more specific stimuli (Dhillon et al. 2007, Munshi and Ramesh 2013). The ERK1/2 
pathway, which was discovered first, is generally activated by mitogenic growth factors such 
Four distinctive MAPK pathways can be found in mammalian cells, termed ERK1/2, JNK, 
p38 MAPK, and ERK5 MAPK. Activation and stimulation of MAPK pathways can be 
attained upon the impact of a variety of extracellular stimuli including: mitogens, cytokines 
and growth factors, as well as environmental stress factors such as oxidative stress and 
osmotic stress. Upon activation of the apical MAPKKK, activation of the downstream 
MAPKK is achieved by dual phosphorylation. The activated MAPKK then phosphorylates 
the MAPK at specific amino acid motifs (TXY) to activate it. Regulation of a variety of 
crucial cellular functions (e.g.,cell proliferation, differentiation, apoptosis, cell migration, 
and inflammation) is a consequence of transcriptional and non-transcriptional regulation 
by the MAPK pathways. 
Figure 1.5: Mitogen-activated protein kinase (MAPK) signalling pathways in 
mammalian cells. 
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as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF) and platelet-derived growth factor (PDGF). It has been well-established 
that the activation of this pathway was governed and well-understood during the 1990s 
(Meloche and Pouyssegur 2007). In contrast, the p38 and JNK MAPK pathways are 
characterised as stress-activated MAPK pathways, as they respond preferentially to 
environmental stress and cytokines (Coulthard et al. 2009). Finally, the ERK5 pathway has 
been shown to be activated by growth factors (e.g., FGF, VEGF), cytokines (e.g., IL-6, IL-
8) and environmental stresses (e.g., osmotic stress, shear stress) (Rose et al. 2010). Upon
stimulation of the pathway, activation of the terminal MAPKs is achieved by dual 
phosphorylation at TXY motifs of the activation loop, which is located in the kinase domain, 
by the upstream MAPKK (Krishna and Narang 2008). The middle residue of the motif (X) 
varies between the four MAPKs. The JNK MAPK contains a proline (P) at this position, while 
p38 contains a glycine (G). Interestingly, both ERK1/2 and ERK5 share the same activation 
motif (TEY), containing a glutamic acid residue at the equivalent position (Figure 1.6). 
Inactivation of MAPK signalling can be achieved by various means. The most common 
mechanism is the dephosphorylation of the TXY motif in the activation loop, as MAPKs 
require the phosphorylation of both the threonine and tyrosine residues for full kinase 
activity (Caunt and Keyse 2013). A number of enzymes have evolved to perform this 
function, including Type 1/2 Ser/Thr phosphatases, protein tyrosine phosphatases and dual-






***:**            :* **.**:*****: 
Figure 1.6: Sequence alignment of the activation loop of human MAPKs 
The protein sequence of the activation loop of representative members for the 
4 mammalian MAPK families is shown and the sequences around the 
conserved TxY motif (highlighted in yellow) are aligned. While the TxY motif is 
fully conserved between the different proteins, ERK5 and ERK1/2 share an 
aspartate residue in the x position. 
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MAPK proteins (Keyse 2000). The largest and best-studied group of MAPK phosphatases 
(MKPs) that specifically regulate MAPK activity are the dual-specificity MAPK phosphatases 
(DUSPs) (Caunt and Keyse 2013). In mammalian cells, the nuclear proteins DUSP1/MKP-
1, DUSP2, DUSP4/MKP-2 and DUSP5 dephosphorylate ERK1/2, p38 and JNK. Another 
group includes the cytoplasmically located ERK1/2-specific phosphatases DUSP6/MKP-3, 
DUSP7/MKP-X and DUSP9/MKP-4 and the final group contains the p38/JNK-specific 
phosphatases DUSP8 (MKP3/6), DUSP10/MKP-5 and DUSP16/MKP-7. Interestingly, there 
have not been any MKPs/DUSPs identified to date that can dephosphorylate and inactivate 
ERK5 (Seternes et al. 2019). 
 
1.4. ERK5 
1.4.1. ERK5 discovery 
1995 was the discovery of ERK5. Initially, Dixon and co-workers (Zhou et al. 1995) used a 
yeast two-hybrid assay with MEK5 as bait to identify its binding partners, including ERK5. 
At the same time, another group discovered BMK1 (big mitogen kinase 1), which eventually 
was recognised to be identical to ERK5 (Lee et al. 1995). This identification was 
accomplished by screening a cDNA library from placenta tissue to identify novel MAPKs. 
The ERK5 gene is located on chromosome 17p11.2, and it extends to 5.79kb. ERK5 shows 
significant homology with ERK1/2, in particular at the kinase domain level. Expression of 
ERK5 can be identified in a variety of cell types, including skeletal muscle, heart, brain, 
placenta, and lung (Lee et al. 1995, Buschbeck and Ullrich 2005). ERK5 and ERK1/2 can 
both be dual phosphorylated at TEY motifs in the kinase domain, and both proteins contain 
an oligomerisation domain. On the other hand, ERK5 contains additional sequences, 
particularly at the C-terminus. These additional sequences make the ERK5 protein the 
biggest mammalian MAPK and allow it to be regulated in a more complex way 
(Nithianandarajah-Jones et al. 2012). 
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1.4.2. ERK5 structure 
ERK5 is larger than the other MAPKs and the regulation of ERK5 (also known as MAPK7) 
is more complex (Nishimoto and Nishida 2006). The ERK5 gene is composed of 5824 
bases, with an open reading frame of 2451 base pairs, which in turn encodes a protein with 
816 amino acids (Nithianandarajah-Jones et al. 2012). It contains 6 exon and there are 11 
transcripts, seven of which are protein coding (Inesta-Vaquera and Cuenda 2010). The 
unique structure of ERK5 can be divided into several domains, corresponding to their 
function (Figure 1.7). Firstly, a cytoplasmic targeting domain is located at the N-terminus of 
ERK5 (a.a.1-77). Then, the predominant part is the kinase domain (a.a. 78-406). The kinase 
domain contains three other motifs: a MEK5 binding region (a.a. 78-139), an oligomerisation 
domain (a.a. 140-406), and a common docking (CD) domain (a.a. 350-358). The CD domain 
is a negatively charged sequence that binds to the substrate and is present in all MAPKs. 
ERK5 consists of 816 amino acids. It contains an N-terminal kinase domain that includes 
a region for cytoplasmic targeting (a.a. 1-77). The Kinase domain (a.a. 78-406) contains 
the activating sites that are phosphorylated by MEK5 (Thr218/Tyr220). In addition, the kinase 
domain includes a MEK5 binding region (a.a. 78-139), a common docking domain (CD) 
(a.a. 350-358), and the oligomerisation region. The extended C-terminal tail consists of two 
proline-rich (PR) domains PR1 (a.a. 434-485) and PR2 (a.a. 578-701), a MEF2 interacting 
region (a.a.440-501), the nuclear localization signal (NLS) (a.a. 505-539) and the 
transcriptional activation domain (a.a. 664-789). Figure modified from (Nithianandarajah-
Jones et al. 2012). 
Figure 1.7: ERK5 structure and functional domains. 
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The kinase domain also contains the activation motif (TEY), which is phosphorylated by the 
upstream MEK5. 
 
What makes ERK5 twice as big as the conventional MAPKs is the extended C-terminal 
domain, which performs additional functions. For instance, a nuclear localization signal 
(NLS; a.a. 505-539) is located in the C-terminal domain, which facilitates nuclear 
translocation (Morimoto et al. 2007). Interestingly, it has been shown that the C-terminal 
half of ERK5 also contains a unique transcriptional activation domain. This domain is 
essential for the activation of gene expression by ERK5 (Morimoto et al. 2007) and is not 
present in any other mammalian MAPKs. Also, two proline-rich regions, PR1 (a.a. 434-465) 
and PR2 (a.a.578-701), are found within the C-terminal domain. These regions bind Src-
homology 3 (SH3) domain-containing proteins that can further regulate ERK5 activity. 
Importantly, the PR1 region has been shown to specifically interact with myocyte enhancer 
factor 2 (MEF2) (a.a. 440-501) (Yan et al. 2001), a major substrate of ERK5 (Roberts et al. 
2010, Tubita et al. 2020). 
 
1.4.3. ERK5 activation / inactivation and downstream targets 
ERK5 can be activated by a number of stimuli. Laminar-shear-stress and hypoxia are 
prominent examples for ERK5 being activated by physiological and pathological stress 
factors (Abe et al. 1996, Pearson et al. 2001, Tubita et al. 2020). In addition, extracellular 
growth factors, such as VEGF, EGF, FGF, and PDGF, have been shown to activate ERK5 
(Kato et al. 1998, Hayashi et al. 2004, Kesavan et al. 2004, Tubita et al. 2020). In neurons, 
ERK5 could also be activated by brain-derived neurotrophic factor (BDNF) and nerve 
growth factor (NGF) (Cavanaugh et al. 2001, Watson et al. 2001). Furthermore, certain 
inflammatory cytokines, for instance interleukin 6 (IL-6) and interleukin 8 (IL-8), were 
identified to activate and stimulate the ERK5 pathway (Carvajal-Vergara et al. 2005). 
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The activation process of ERK5 is complex (Figure 1.8) (Buschbeck and Ullrich 2005, 
Kondoh et al. 2006). In the unphosphorylated (inactive) state, ERK5 exists in a folded, 
closed conformation due to a molecular, non-covalent interaction between the C- and N-
terminals. This conformation activates its nuclear export signal (NES) and inhibits its NLS, 
leading to the cytoplasmic sequestration of ERK5. Once Thr218 and Tyr220 are 
phosphorylated by MEK5, ERK5 undergoes conformational changes due to a reduction of 
the interaction between the C- and N-terminals. This conformational change inactivates the 
NES and exposes the NLS, leading to the translocation of ERK5 to the nucleus. In addition, 
a number of C-terminal residues are autophosphorylated, leading to the full activation of 
ERK5 (Pearson et al. 2020). 
In the unphosphorylated (inactive) state, ERK5 exists in a folded, closed conformation 
due to a molecular interaction between the C- and N-terminals. This conformation 
activates its nuclear export activity and inhibits its nuclear localisation signal, leading to 
cytoplasmic sequestration of ERK5. Upon activation by MEK5 phosphorylation, the 
interaction between the C- and N-terminals is reduced, exposing the nuclear localization 
signal, leading to the translocation of ERK5 to the nucleus as well as autophosphorylation 
of a number of C-terminal residues (Figure from Nithianandarajah-Jones, 2012). 
Figure 1.8: The ERK5 activation process. 
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Much less is known about the inactivation of ERK5. Typically, MAPKs are inactivated 
through dephosphorylation of their TXY motif in the activation loop of the kinase domain 
(Dickinson and Keyse 2006). While a specific DUSP (dual-specificity phosphatase) that 
dephosphorylates these residues has not yet been discovered, ERK5 has been shown to 
be dephosphorylated by the phosphotyrosine-specific phosphatase PTP-SL (protein 
tyrosine phosphatase STEP-like), which leads to its inactivation and inhibition of its nuclear 
translocation (Morimoto et al. 2007, Tubita et al. 2020). 
Significantly, it has been shown that ERK5 regulates the activity of several transcription 
factors (Kato et al. 1997, Kasler et al. 2000, Barsyte-Lovejoy et al. 2004), for instance 
MEF2C, a member of the myocyte enhancer factor (MEF) family consisting of MEF2 A, C, 
and D. MEF2C and the other family members promote the activity of the c-Fos promoter by 
activating c-Myc, CREB, and Sap1a. KLF2 and KLF4 (krüppel-like transcription factors) are 
other examples of more recently discovered transcription factors activated by ERK5 
(Sunadome et al. 2011). Activation of KLF2 by ERK5 leads to the downregulation of p21-
activated kinases (PAKs) (Komaravolu et al. 2015), which play an important role in 
cardiovascular development and endothelial cell migration, likely by activating Cdc42 and 
the small Rho GTPase Rac. Interestingly, it has been demonstrated that the transactivation 
activity of ERK5 is highly dependent on the activated kinase activity of ERK5, implying that 
autophosphorylation of the C-terminal half of ERK5 is required for its ability to directly 
activate transcription (Morimoto et al. 2007, Tubita et al. 2020). 
1.4.4. Physiological roles of ERK5 
At the molecular level, targeting the ERK5 gene by deletion has opened the avenue to 
identify the physiological significance of the ERK5 signalling pathway. It has been shown 
that knocking out either the Erk5, Mek5, or Mekk3 gene in mice is embryonic lethal, with 
death occurring between embryonic day E9.5 and E11.5 as a consequence of irregularity 
in the development of the cardiovascular system (Yang et al. 2000, Yan et al. 2003, Wang 
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et al. 2005). Immature vasculogenesis and lack of organization in endothelial cells are lethal 
consequences, which lead to death due to haemorrhage and leakage in the vascular 
system. In addition, Mef2c-/- knock-out mice also exhibited embryonic lethality as a result of 
the loss of vascular integrity (Lin et al. 1997, Lin et al. 1998, Bi et al. 1999). Because mice 
with gene ablation in all components of the ERK5 signalling axis share the same phenotype, 
it can be inferred that a crucial role of the ERK5 signalling cascade is to regulate 
angiogenesis and/or vasculogenesis. Interestingly, knocking out the ERK5 gene globally or 
conditionally in endothelial cells resulted in the same phenotype: disturbed cardiovascular 
integrity and vascular haemorrhage disorders (Hayashi et al. 2004). In contrast, knocking 
out Erk5 specifically in hepatocytes (Hayashi and Lee 2004) and cardiomyocytes (Hayashi 
et al. 2004, Kimura et al. 2010), displayed no effects on development and maturation. 
Interestingly, in adult mice, inducible ERK5 ablation generated leakage of blood vessels as 
a result of endothelial cell apoptosis, resulting in death within 2-3 weeks (Hayashi et al. 
2004). Even though ERK5 is expressed in a variety of cell types, the most crucial function 
therefore appears to be within the context of vascular integrity. 
1.4.5. The role of ERK5 in angiogenesis 
While the results from the knock-out studies demonstrated a requirement for ERK5 in 
angiogenesis, these studies did not clarify where in the process ERK5 is needed. VEGF is 
a well-known inducer of angiogenesis and is important for vascular development in 
embryogenesis and early life (Carmeliet et al. 1996, Gerber et al. 1999, Ferrara 2000, Haigh 
2008). Importantly, a recent study showed that ERK5 plays an essential role as a critical 
mediator of the VEGF-dependent survival of endothelial cells (Roberts et al. 2010). VEGF 
induced sustained ERK5 activation in primary endothelial cells (HDMEC; human dermal 
microvascular endothelial cells). Interestingly, reduction of ERK5 activity by siRNA-
mediated gene silencing disrupted tubular morphogenesis of HDMEC cells without reducing 
proliferation. In contrast, overexpression of constitutively active MEK5 and ERK5 stimulated 
tubular morphogenesis in the absence of VEGF, clearly demonstrating the ability of ERK5 
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to induce angiogenesis. An important observation was that ERK5 regulated AKT 
phosphorylation and activation, leading to the VEGF-mediated phosphorylation (and thus 
inactivation) of the pro-apoptotic protein BAD and increased expression of the anti-apoptotic 
gene BCL2. This resulted in decreased caspase-3 activity and the suppression of apoptosis. 
Together, these results demonstrated that ERK5 is required for the survival of endothelial 
cells during angiogenic processes (Roberts et al. 2010). 
 
1.5. The role of ERK5 MAPK in the integrity of vascular 
endothelial cells 
Knocking out ERK5 in mice provided outstanding evidence of the role of ERK5 MAPK in the 
integrity of the endothelium (Hayashi and Lee 2004). Cardiovascular defects and death 
have been caused in knocked out endothelial ERK5-/- mice around E10.0. This can be 
explained as enhancing the survival of endothelial cells and inhibition of endothelial 
apoptosis are major regulatory functions of ERK5 MAPK in endothelial cells (Roberts et al. 
2010). MEF2C is a transcription factor attributed to protect endothelial cells from apoptosis 
(Roberts et al. 2009). It is well-known that ERK5 can phosphorylate and activate MEF2C, 
thus enhancing the survival of cells. However, under unusual condition such as targeted 
deletion of the ERK5 or Mef2C gene, cardiac and vascular malformation was acquired, 
demonstrating the phenotypic similarity between ERK5-/- and Mef2C-/- mice, with embryonic 
lethality in both mouse lines (Lin et al. 1998, Bi et al. 1999). 
 
It is important to discuss the profound role of ERK5 in connecting the growth factor receptors 
to cell survival. ERK5 has been reported to regulate PKB/Akt phosphorylation in vitro 
through different mediators and conditions, such as the phosphorylation of PKB/Akt at 
Ser473 and Thr308 in mouse embryonic fibroblast under osmotic stress status (Wang et al. 
2006), and activation of PKB/Akt through platelet-derived growth factor (PDGF) in porcine 
aortic endothelial cells (PAEs) (Lennartsson et al. 2010). Furthermore, in human dermal 
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microvascular endothelial cells (HDMECs), the mediatory action of VEGF is supported by 
ERK5, which activates Akt and enhances the expression of pro-survival protein BCL-2 as 
well as phosphorylation and inactivation of the pro-apoptotic protein BAD (Roberts et al. 
2010). In summary, it can be concluded that PKB/Akt activation is regulated by ERK5, 
although the precise mechanism remains to be resolved. Consequently, cell survival and 
tubular morphogenesis of the endothelial cells are fully dependent on ERK5 activity, due to 
inhibition of apoptosis. 
Atherosclerosis is an inflammatory condition starting by accumulation of leukocytes in the 
sub-endothelial area, followed by depositing of fatty streak and other inflammatory agents 
in the wall of arteries leading to formation of atherosclerotic lesions (Lusis 2000, Rafieian-
Kopaei et al. 2014). Inhibition, or even blocking of blood flow is a fatal consequence 
triggered by atherosclerosis. Therefore, keeping a steady laminar blood flow can be defined 
as an atheroprotective agent, where harmful factors such as oxidative stress and 
inflammatory cells would be suppressed (Chiu and Chien 2011). In in vitro studies of both 
bovine lung microvascular endothelial cells (BLMECs) and human umbilical vein endothelial 
cells (HUVECs), shear-stress mediated ERK5 activation has been shown to play a 
remarkable regulatory role by stimulating an anti-apoptotic (BLMECs) and atheroprotective 
effect (HUVECs) (Figure 1.9). The exact mechanism of this regulatory role can be 
demonstrated upon mediating flow-dependent inhibition of TNFα signalling (Akaike et al. 
2004, Pi et al. 2005). In terms of maintaining vascular quiescence, ERK5 is required for 
Kruppel-like factor 2 gene expression (KLF2) (Parmar et al. 2006), which induces a prompt 
decrease in angiogenesis and inflammation processes. Moreover, KLF2 decreases the 
adhesion of leukocytes and reduces the anti-inflammatory response by inhibiting nuclear 
factor κB (NF-κB). KLF2 is additionally involved in regulating endothelial cells as it enhances 
the synthesis of endothelial nitric oxide synthase (eNOS) and thrombomodulin, which 
possess potent properties as anti-thrombotic and anti-inflammatory agents, influencing 
vasoprotection (Nithianandarajah-Jones et al. 2014). 
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1.6. Regulation of vascular tone 
Vasoactive factors can be classified into two main groups based on their biological effect 
on the blood vessels. The main source of these vasoactive factors was identified to be the 
endothelium (Vanhoutte and Mombouli 1996). These vasoactive factors would be grouped 
as vasodilatory or vasoconstrictory factors. Examples of vasodilatory factors include: nitric 
oxide (NO) and prostacyclin (PG2). Thromboxane (TXA2) and endothelin-1 (ET-1) are 
examples of vasoconstrictive factors (Sandoo et al. 2010). 
Nitric oxide (NO) has long been identified as a vasodilator and regulator of blood vessel 
tone (Levine et al. 2012). To be precise, the underlying smooth muscle layer of the 
endothelium is the main target of nitric oxide action (Jin and Loscalzo 2010). Upon 
Figure 1.9: The role of ERK5 in endothelial cells. 
The figure shows that the ERK5 pathway is activated by multiple stimuli in endothelial cells, 
including VEGF and shear stress. Activation of ERK5 in turn leads to several pro-
angiogenic and survival responses through the activation of several effector molecules as 
shown. Image taken from (Nithianandarajah-Jones et al. 2014). 
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stimulation of nitric oxide synthase enzyme (NOS), formation of NO is chemically achieved 
through the conversion of the amino acid L-arginine. Compounds such as acetylcholine, 
histamine, and angiotensin II were shown to be involved in enhancing NO generation. Three 
different isoforms of NOS, eNOS (endothelial NOS), nNOS (neuronal NOS) and iNOS 
(inducible NOS), are distributed through various types of cells (Michiels 2003, Forstermann 
and Sessa 2012). Various kinds of actions and effects can be concluded of those different 
inducible isoforms, which would also be allocated in context of neurons, macrophage and 
endothelium. Cardiac myocytes, platelets, skeletal muscle, and hippocampus are also 
examples of tissues where these isoforms occur (Prast and Philippu 2001). Production of 
NO is highly dependent on the level of Ca2+ in the cells, whether it is originated from the 
inner endoplasmic reticulum or from extracellular resource. The importance of Ca2+ 
abundance can be explained in terms of the binding to the eNOS enzyme; where 
dissociation of eNOS from calcium-calmodulin complex can be observed under the 
reduction of Ca2+ levels. Thereafter, eNOS becomes inactivated via their induced binding 
to caveolin (Govers and Rabelink 2001, Forstermann and Sessa 2012). Interestingly, shear 
stress is a consequence of increasing the blood flow in the vessels, which it turns mediates 
a remarkable effect via protein kinase B (Akt) to phosphorylate eNOS. Upon production, 
NO diffuses to the endothelium to bind to the soluble guanylyl cyclase enzyme (sGC) that 
resides in the adjacent smooth muscle. As a result, the level of cGMP in the muscle is 
dramatically increased (Figure 1.10). The well-known actions of increased cGMP in the 
smooth muscle can be summarized in terms of reducing muscle tension and contraction 
(Sandoo et al. 2010). 
 
It is also important to discuss the opposite action of prostacyclin (PGI2) with thromboxane 
(TXA2) in generating vasoconstriction as a regulatory mode for vascular tone. In brief, the 
level of intracellular Ca2+ in the smooth muscle is augmented by cyclooxygenase catalysis 
(Griendling and Alexander 1997). Homeostasis of healthy vessels can be envisaged in their 
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regulatory role of balancing the activity of PG2 and TxA2. Thus, resting vascular tone is also 
affected by interaction between endothelial constituted products (e.g., PGI2 and TXA2) 
(Masferrer et al. 1994). 
Endothelin is another agent of regulation of vascular tone, which has been identified as an 
endothelium-derived 21 amino acid peptide playing a potent role with long lasting effects on 
vasoconstriction (Yanagisawa et al. 1988). Endothelin synthesis is a de novo phenomenon, 
dependent on response to various chemicals (e.g., thrombin, angiotensin II, cytokines) and 
physical agents (e.g., hypoxia, shear stress), as the endothelin is not stored in endothelial 
cells (Michiels 2003, Kruger-Genge et al. 2019). Three isoforms of endothelin have been 
identified in the body, ET-1, ET-2, and ET-3 (Alonso and Radomski 2003). EndothelinA (ETA) 
and endothelinB (ETB) are both coupled to G proteins with different locations in the blood 
vessels. ETA receptor is located on the vascular smooth muscle cells whereas ETB receptor 
is situated on the endothelial cells. In terms of affinity, it is well-known that the ETB receptor 
has a tendency of binding to the three endothelin isoforms, while the ETA receptor is 
constrained with high affinity for binding to both ET-1 and ET-2, excluding ET-3 (Kedzierski 
ACh= acetylcholine; BK= bradykinin; eNOS= endothelial nitric oxides; sGC= soluble 
guanylyl cyclase; cGMP= cyclic guanosine-3’, 5’-monophosphate. 
Figure 1.10: Illustrating schematic for nitric oxide production and how it affects the 
vascular smooth muscle. 
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and Yanagisawa 2001). As ET-1 is selectively released from endothelial cells, it is possibly 
to further explore their exact function. First, endothelin converting enzyme is the main agent 
responsible for converting big ET-1 to ET-1. The level of secretion and production of ET-1 
can be affected by several factors. Inflammatory factors such as interleukins and TNF-α can 
enhance ET-1 production, while ET-1 release can be diminished by the effects of NO and 
PGI2. In addition to the mitogenic activity of ET-1 on smooth muscles cells, vasoconstriction 
can be exerted by binding to the ETA receptor, or by activating other growth factors such as 
platelet-derived growth factor. The phospholipase C pathway appears to be involved in 
generating smooth muscle cell contraction. However, binding of ET-1 to ETB2 in the 
endothelium causes vasodilation after the release of NO and PGI2. Overall, it is crucial for 
vascular response that many vasoactive pathways would interact with each other, creating 
the proper result of regulation to vascular tone (Sandoo et al. 2010). 
The integrity of vascular endothelial cells plays a pivotal role in the stability of circulation. 
For this reason, vascular endothelial cells were found to be a source of many regulatory 
substances and chemicals as well as their physical barrier role. Hence, manifestation of 
cardiovascular diseases such as hypertension and atherosclerosis is a strict consequence 
of endothelium-dependent regulatory system dysfunction (Rajendran et al. 2013). In 
addition, upon the efforts of Furchgott and Zawadzki (Furchgott and Zawadzki 1980), it has 
been shown that the integrity of the endothelium would induce a vasodilation effect on the 
vascular smooth muscle in response to acetylcholine (Furchgott and Zawadzki 1980). 
Vascular homeostasis is a remarkable phenomenon requiring the release of specific 
regulatory substances from the lining of the endothelial cells including endothelium-derived 
NO and prostacyclin under certain conditions and stimuli, such as physical stimulation, 
hormones, and platelet-derived substances. Vascular relaxation and platelet function 
inhibition are the result of those modulations (Denninger and Marletta 1999). However, 
while inducing vasoconstriction is somehow a response to pathophysiological conditions, it 
remains an important factor in the regulation of vascular tone. The onset of some 
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pathophysiological disorders including high blood pressure and hypoxia, the vascular 
endothelial cells can produce several contracting agents (e.g., endothelin, thromboxane A2, 
angiotensin II, superoxide). Significantly, the release of such vasoactive substances (e.g., 
NO, endothelin, and angiotensin II) by the endothelium has also been found to perform a 
major role in vascular growth processes. 
 
1.7. H2S: a gaseous signalling molecule 
Hydrogen sulphide (H2S) has been recognized as a toxic agent and environmental hazard 
for many decades (Szabo 2018). It can be defined as a reactive thiol which has distinctive 
chemical properties. H2S is a water-soluble, flammable, colourless gas with offensive odour 
of rotten eggs (Elsey et al. 2010, Szabo et al. 2013). However, it can be also secreted and 
synthesized in significant amounts in mammalian cells (including human cells). Synthesis 
of H2S can be endogenously attained in different mammalian tissues from metabolizing L-
cysteine or L-methionine (Giuffre and Vicente 2018). Cystathionine β-synthase and 
cystathionine γ-lyase are both pyridoxal-5’-phosphate-dependent enzymes for H2S 
synthesis. The relevant substrate could be sourced from endogenous proteins or even from 
nutrients (Wang 2002, Fiorucci et al. 2006). Trans-sulphuration of L-methionine can be a 
pathway to produce H2S with the assistance of homocysteine (i.e. being the mediator). In 
addition, endogenous H2S can be synthesized by the 3-MST (3-mercaptosulfurtransferase) 
enzyme and one of the following substrates: 3-MP (3-mercaptopyruvate) by CAT (cysteine 
aminotransferase), thioredoxin, dihydrolipoic acid and D-cysteine along with DAO (D-amino 
acid oxidase) (Pan et al. 2017). 
 
It is crucial to characterize the organ-specific and molecular source of these enzymes (CBS 
and CSE), where the eventual product of them is going to be H2S formation. The liver and 
kidney are the predominant organs for expression of CBS, as well as the nervous system 
and brain. Meanwhile, the liver is mainly responsible for expression of CSE in additional to 
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vascular and non-vascular smooth muscle (Elsey et al. 2010). However, thiosulphate and 
sulphate are major products of sulphide degradation being released by specialized 
enzymes from intestinal epithelium. Therefore, enterobacterial flora can be a source for H2S 
production, perhaps the main function is to hinder excess entry of H2S to the circulation 
(Fiorucci et al. 2006, Szabo 2007).It has been brought to the attention with strong evidence 
that the cardiovascular system (e.g., vasculature and heart) would be the endogenous 
source of H2S generation including H2S-generating enzymes CBS, CSE, and 3-
mercaptosulfurtransferase MST (Furne et al. 2001, Pan et al. 2017). 
H2S, together with CO and NO are well known as gas-transmitter molecules implementing 
various biological effects at key targets (Kolluru et al. 2017). They are typically small 
molecules with a simple molecular composition and structure. Fast diffusion through the cell 
membrane due to their lipophilic nature is a distinctive feature of gasotransmitter molecules. 
In addition, based on the structural similarities with H2O, it was proposed that aquaporines 
and some ion channels (e.g., KATP channels, Ca2+ channels) may facilitate H2S 
transportation across the cellular membrane (Mathai et al. 2009). Interestingly, 
gasotransmitters share common features (labile gas, rapidly eliminated by mammals) that 
result in influencing a wide range of cytotoxic and cytoprotective effects (Szabo 2007). It is 
important to mention the bio-molecular interaction between H2S and CO at the physiological 
level, although it is not fully understood how they react with each other as well as with NO 
synthase (NOSs) (Elsey et al. 2010, Wu et al. 2018). In vitro studies using Na2S or NaHS 
have shown that H2S neutralizes and interacts with a variety of oxyradical species, 
peroxynitrite, homocysteine and hypochlorous acid and that it can generate cytoprotective 
actions (anti-necrotic or anti-apoptotic effects) (Whiteman et al. 2004, Whiteman et al. 2005, 
Rinaldi et al. 2006, Szabo 2007). Interestingly, many researchers have used inorganic 
sulphide salts (e.g. Na2S) and sodium hydrogen sulphide (NaHS) as H2S equivalents. It has 
been shown that treating cells, tissues, or animals with sulphide salts would induce a 
protective effect against a number of diseases. It has been confirmed by the Lefer group 
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that using Na2S as an exogenous H2S donor would attenuate ischemia-induced heart failure 
upon long-term H2S therapy (Calvert et al. 2010). In addition, sulphide salts have shown a 
significant role as a protective agent against other diseases such as inflammation and 
Osteoarthritis (OA). Significantly, treatment of human cells with NaHS is critical to alleviate 
IL-6 and IL-8 expression levels, which may account for the anti-inflammatory role of H2S 
against OA. Also, it is significant to take extra care when NaHS is used as it has been found 
that pro-inflammatory characteristic would be acquired instead of the anti-inflammatory 
effects of NaHS upon extended of the incubation from 15 minutes to 1 hour. It is clear that 
sulphide salts, as H2S donors, may have a positive effect in boosting H2S concentration 
rapidly. However, it would be hard to control H2S concentration when the compounds 
release H2S synergistically at the time the solution is prepared. In addition, under laboratory 
condition, it has been found that H2S would be lost from solution because it can be quickly 
volatilized in aqueous solution. Carefulness has to be taken in purchasing commercial 
sulphide salts, especially NaHS, where it has been noted that it contains significant amount 
of impurities (Zhao et al. 2014). The concentration of endogenous H2S is profoundly 
significant in modulating the generated actions, for example cytotoxic and cytoprotective 
effects (Whiteman et al. 2004, Whiteman et al. 2005, Rinaldi et al. 2006). At micromolar 
concentrations, the cytoprotective effects (antinecrotic or anti-apoptotic) of H2S have been 
reported in multiple studies, to be generated in vitro from Na2S or NaHS (a H2S donor), that 
may associate with its capacity to neutralize different reactive species, for example 
oxyradicals and peroxynitrite, hypochlorous acid and homocysteine. Also, modulation of 
intracellular caspases and or kinase pathways can be one of these cellular effects of H2S 
concentration. On the other hand, in order to upregulate the cytotoxic effect of exogenous 
H2S, endogenous H2S has been shown to be initially inhibited, which shows the cytotoxic 
effects of low (physiological) levels of endogenous sulphide. Exposure of the cells to high 
(millimolar) H2S has a negative impact shown in form of cytotoxicity, and that due to 
generation of high level of free radical and oxidant, calcium mobilization and glutathione 
depletion (Szabo 2007).). Moreover, various studies have shown that endogenous 
49 
antioxidant systems would be upregulated (activated) upon low levels of H2S production 
(low micromolar), examples of those antioxidant agents include N-acetylcysteine, 
glutathione, and superoxide dismutase (Whiteman et al. 2004, Yang et al. 2004, Ezerina et 
al. 2018). It has been reported in various studies that H2S can induce anti-inflammatory 
action by up-regulation of specific genes such as haeme oxygenase 1 (HO1) (Qingyou et 
al. 2004, Oh et al. 2006). Thus, anti-inflammatory and cyto-protective effects would be 
initiated upon triggering the production of CO. Examples of those effects include the 
inhibition of the Nuclear Factor-κB pathway (NFκB) and downregulation of NO synthase 
expression (Oh et al. 2006, Ryter et al. 2006). On the other hand, H2S may also exhibit a 
pro-inflammatory role (Li et al. 2006). It has been shown that exposure to endogenous H2S 
may correlate with toxicity and cell death in the lung and other organs. Currently, supportive 
evidence of a pro-inflammatory effect of H2S in vivo has been concluded from animal 
models of endotoxic or septic shock (Li et al. 2006). It has been reported that preliminary 
role of excessive activation of KATP channels to vasoconstrictor agents may occur in 
lipopolysaccharide (LPS)-induced hypotension and hyporeactivity, which in turn raise the 
probabilities that septic or endotoxic shock may be a result of abnormal synthesis or activity 
of H2S (a potential natural ligand for KATP channels). Other group has demonstrated that 
H2S formation is likely upregulated in various tissues from LPS-injected mice and rats (Hui 
et al. 2003). Inhibition of CSE-mediated H2S formation by propargylglycine (PGA), would 
contribute to reduce both the inflammation and the multiple organ dysfunction in endotoxic 
shock and employee a protective effect in haemorrhagic shock. 
In regard to H2S metabolism, numbers of different metabolic pathways have been reported 
to be involved, with oxidation in mitochondria and cytosolic methylation being the most 
important metabolic pathways (Beauchamp et al. 1984, Cao et al. 2019) . In various studies 
and reports the concentrations of H2S in the blood and many tissueswere measured under 
conditions while around 100 μM in the human blood and 160 μM in the human brain were 
detected (Elsey et al. 2010). In in vitro studies by Zhao et al (Zhao et al. 2001), the rat liver 
showed higher production of H2S than in vascular tissue, which stresses the importance of 
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the regulation and maintenance of H2S in the circulation by the liver (Zhao et al. 2003). 
Under certain intracellular conditions, regulating the H2S availability can be achieved with 
sulfane sulfur (Ishigami et al. 2009). In spite of the unreliability of H2S assay methods, total 
sulfate and sulfite measurements may demonstrate some efficiency (Elsey et al. 2010). 
Furthermore, the methylene blue technique has been recently used with high efficiency in 
the literature to measure hydrogen sulphide in biological samples (Shen et al. 2015). 
Excretion of H2S from the body would eventually be regulated by the kidney in both forms 
(free or conjugated sulfate) (Beauchamp et al. 1984, Cao and Bian 2016). 
It is fundamental to discuss the bio-molecular role of H2S on the cardiovascular system 
(Figure 1.11). In the cardiovascular domain, it has been found that H2S may induce its effect 
by interacting with other signalling pathway components and biological mediators, although 
a specific thiol receptor has not been detected yet (Elsey et al. 2010). It has been further 
demonstrated that H2S properties vary from other gasotransmitters, typically these 
variations are centred in its dissociation ability. Under normal conditions and in aqueous 
solutions at pH 7.4, the pKa for H2S is 6.77, leading to over three quarters of H2S to 
dissociate to HS-anion. It has long been believed that the H2S pool contains H2S, HS- and 
S2-. In order for H2S to play different biological effects, it has been regarded that protein 
persulfidation, or protein S-sulfhydration is a significant molecular mechanisms. More 
precisely, it is important to notice that modification of cysteine residues from the –SH to –
SSH group can represent the main differences. The properties of –SH and –SHH groups 
are profoundly different. In comparison to their corresponding thiols (-SH) and 
hydrosulphide (-SSH), they have generally distinguished nucleophilic ability, for stronger 
chemical reactivity (Zhang et al. 2017). It has been found that H2S gas would be involved 
as a mediator of physiological changes in many different cell types and tissues. Examples 
of these key roles including angiogenesis, vascular permeability, inflammatory cell function, 
vasoconstriction/vasodilation, and smooth muscle growth, as well as apoptosis (Szabo and 
Papapetropoulos 2011). There is also evidence that H2S is produced in significant amounts 
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in intrauterine tissues (Patel et al. 2009) and that it can inhibit endometrial contractility in 
the rat uterus (Sidhu et al. 2001). Evidently, the action of H2S on the cardiovascular system 
can be essentially characterized based on its source. In other words, endogenous H2S can 
regulate vascular NO production while exogenous H2S is believed to affect vascular smooth 
muscle upon activation of KATP channels (including vasodilator or vasoconstrictor effect), 
depending on its concentration (Gheibi et al. 2018). However, alteration of H2S production 
has been found to be a causative agent in influencing vascular tone associated with disease 
states (Elsey et al. 2010).  
Figure 1.11: Mechanisms of cardioprotection mediated by H2S. 
The figure demonstrates the various exerted effects of endogenous regulation or 
exogenous administration of H2S in physiological concentrations, on infarct-sparing, anti-
apoptotic, anti-oxidant, anti-inflammatory and pro-angiogenic benefits in the heart 
secondary to different stressors. These involve myocardial infarction, pressure/volume 
overload, doxorubicin or alcohol toxicity and cardiac arrest/resuscitation. It can be also 
recognized from the figure that attenuation of myocardial scar formation and oxidative 
stress may result from the combined preservative effects of H2S, promoted angiogenesis 
and adequate remodelling resulting in protection of function. Image taken from (Salloum 
2015). 
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In terms of angiogenesis, a pro-angiogenic role of H2S was reported involving activation of 
the prosurvival PI3-kinase/Akt and ERK1/2 MAPK signalling pathways (Cai et al. 2007). In 
vitro studies have shown the ability of H2S to enhance pro-angiogenic factors including 
proliferation, adhesion, migration, and tube-like formation was recognized using endothelial 
culture assay. Furthermore, increasing Akt phosphorylation was observed upon exposure 
to NaHS, whereas the presence of the PI3-kinase inhibitor LY294002 inhibits Akt 
phosphorylation. Otherwise, it has been demonstrated in vivo using a mouse matrigel plug 
assay that exogenous H2S at a concentration of 10-50 μmol kg -1 day -1 can exert a pro-
angiogenic role. Several studies and reports have also shown the inhibitory role of H2S on 
smooth muscle proliferation by influencing apoptosis (Elsey et al. 2010). The capacity of 
H2S to produce sulphide can attribute to cardio-protective effects by reducing neutrophil 
adhesion. As reactive nitrogen species exert a pathological effect on myocardial infarction, 
it has been proven that ischaemia reperfusion is a beneficial outcome of the ability of H2S 
to react and neutralize these cytotoxic reactive species (e.g., peroxynitrite). In case of 
coronary disease, sulphide replacement therapy has been considered, where the level of 
endogenous sulphide is dropped down in such cardiac disease (Pan et al. 2017). Finally, 
while it is not clear how does hydrogen sulphide (H2S) work in the body and reacts with 
other molecules such as NO and CO, there is an explicit evidence that there are some 
interaction between these gaseous signalling molecules at the molecular level that warrants 
further studies (Carson et al. 2004). 
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1.8. Hypothesis and Aims 
A number of observations have led to the hypothesis of this thesis. First, ERK5 is well known 
to play a major role in the vascular system, mainly as a vascular protective factor. Second, 
H2S has been shown to protect vascular cells from damage and death. Third, H2S has been 
shown to enhance vascular and placental health and to be deficient in vascular disease, 
including pre-eclampsia. Finally, H2S and ERK5 signalling have both been shown to activate 
the AKT pro-survival pathway. The hypothesis of this work is therefore that: 
H2S activates ERK5 to mediate vascular protection. 
The specific aims of the thesis are to: 
- Establish a reproducible assay to measure ERK5 activation in endothelial cells and
tissues;
- determine whether ERK5 can be activated by H2S in mammalian cell lines
- investigate ERK5 activation by H2S in endothelial cells














2. Materials and Methods
2.1. Cell culture 
2.1.1. Culture of established cell lines 
Established cell lines were purchased from LGC Standards (ATCC lines), where the cells’ 
identity was validated. The cells were stored under liquid nitrogen and used for a maximum 
of 25 passages. HEK293 and HeLa cell lines were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% 
Penicillin/Streptomycin antibiotic (containing 5000 Units /ml of penicillin and 5000 µl/ml of 
streptomycin) in T-75 cell culture flasks at 37°C in a humidified air incubator containing 5% 
(v/v) CO2. The cells were propagated 3-4 times a week by washing with PBS, incubation 
with trypsin (Lonza, catalogue number BE02-007E; containing 0.5 g/L trypsin and 0.2 g/L 
Versene EDTA) at 37°C, thereafter, rinsing the surface of culture flask with DMEM media. 
2.1.2. Culture of primary endothelial cells (HUVEC) 
Primary Human Umbilical Vein Endothelial Cells (HUVEC; purchased from PromoCell, 
catalogue number C-12203) were maintained in Endothelial Cell Basal Medium 2 
(purchased from PromoCell, Cat. Number: C-22211) containing 1x FCS-10, 1x hEGF-2.5, 
1x HC-100, 1x VEGF-0.25, 1x hb FGF-5, 1x R3 IGF-1, 1x AA-500, and 1x Hep-11.25 
(Supplement Pack Endothelial Cell GM2, purchased from PromoCell, catalogue number: 
C-37320, C-30224, C-31063, C-30321, C-31700, C-31750, and C-31650, respectively) in
T-75 cell culture flasks at 37ºC in a humidified air incubator containing 5% (v/v) CO2. Cells
were propagated by washing with Hepes BSS (PromoCell, catalogue number C-40010), 
incubation with 0.04% Trypsin/ 0.03% EDTA (PromoCell, catalogue number C-41010), and 
0.05% Trypsin Inhibitor, 0.1% BSA (PromoCell, catalogue number C-41110) at 25ºC (room 
temperature) and dislodging them from the culture flask by rinsing and pipetting the surface 
several times. 
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2.1.3. Storage and recovery of cells 
The cells were harvested as described above and spun at 200 x g for 5 minutes. The cells 
were then resuspended in freezing media [10 % DMSO (Sigma, catalogue number D8418); 
20 % FCS; 70% DMEM] at a concentration of 5 × 106 cells / ml. For HUVECs, the freezing 
media (Cryo-SFM) were purchased from PromoCell (catalogue number C-29910). 1.5 ml of 
cell suspension was then transferred into a freezing vial (ThermoFisher, 5000-0020) and 
placed into a special freezing container (Thermo Scientific, catalogue number 5100-0001), 
to allow a controlled cooling down period. The closed freezing container was placed at – 
80°C over night, after which the cells would be transferred to liquid nitrogen storage. 
For thawing, the frozen vial was removed from the liquid nitrogen storage and quickly 
thawed in a 37°C water bath. As soon as the cells are thawed, the cell suspension would 
be carefully be transferred to a centrifuge tube and 10 ml of warm culture medium addded. 
The cell suspension would be gently spun at 200 x g for 5 minutes. After removing the 
medium without disturbing the pellet, the cells were suspended in 10 ml of fresh culture 
medium, placed in a small T 25 flask and incubated in a cell culture incubator with 5 % CO2.  
2.1.4. Experimental treatments and lysis of cells 
The cells were plated on 60 mm dishes after being trypsinised as illustrated above and 
counted in a haematocytometer. The density of cells was 1.2 x 105 cells/well for 6-well 
dishes and 5.5 x105 cells/dish for 60 mm dishes. In order to starve the cells, the media was 
replaced with Endothelial Cell Basal Medium 2 without the supplemental materials and 
reagents (HUVEC) or Dulbecco’s Modified Eagle’s Medium (DMEM) media containing no 
FBS. After 3 hours, the cells were treated with either epidermal growth factor (EGF; Sigma, 
catalogue number E9644), Sorbitol (Sigma), GYY4137 (Sigma SML0100-10MG), hydrogen 
sulfide (NaHS; Sigma 161527-100G) or the appropriate vehicle PBS or DMSO (Sigma, 
D2650, maximum concentration 0.2%) at the concentration indicated in the results. Upon 
following the times shown in the experimental section, PBS and 1x RIPA 
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(Radioimmunoprecipitation) buffer solution (Merck Millipore, catalogue number 20-188; 10x 
solution containing 0.5 M Tris-HCL, pH 7.4, 1.5 M NaCl, 2.5 % deoxycholic acid, 10% NP-
40, 10 mM EDTA), were used to wash and lyse the cells, respectively. Thereafter, the cells 
were centrifuged at 4°C, 15000 x g for 5 minutes to remove cell debris and stored at -20 °C 
until needed. 
 
2.2. SDS PAGE and Western Blot analysis 
2.2.1. Determination of protein concentration (BCA Assay) 
In order to quantify the total protein in a sample, the BCA (Bicinchoninic Acid) protein assay 
would be used and implemented according to the instructions of the manufacturer. Briefly, 
samples were mixed with the appropriate amount of the working solution and incubated for 
30 minutes at 37°C. The absorbance reading would then be taken at 562 nm. BSA solutions 
of known concentrations were used to construct a standard curve. 
 
2.2.2. Standard SDS gel electrophoresis 
Discontinuous polyacrylamide sodium dodecyl sulphate (SDS) gel was used to separate 
the proteins of interest based on their molecular weight. Thus, the resolving gels (10 ml per 
cassette) consists of 2.5 ml 1.5 M Tris/HCL pH 8.8, 2.33 ml (for 7% gels), 3.33 ml (for 10% 
gels) or 4.21 ml (for 14% gels) acrylamide (30%/0.8%), 100 µl 10% SDS, 90 µl APS (10%), 
and 10 µl TEMED. The stacking gel (5 ml) contains 0.67 ml acrylamide (30%/ 0.8%), 1.25 
ml 0.5 M Tris/HCL pH 6.8, 50 µl 10% SDS, 45 µl APS (10%), and 5 µl TEMED. Then, the 
gels were loaded with 30 µl of sample containing the lysed protein of interest, 1x NuPAGE 
LDS Sample Buffer (from 4x concentrated stock; ThermoFisher, #1225644) and 3 µl DTT 
(0.5 M). 7.5 µl of protein standard (NEB, P7712S) was also used. The gels were run for 1.5 
-2.0 hours at 125 volts. 
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2.2.3. SDS-PAGE gel electrophoresis (large gels) 
30 ml of resolving gel 7% were prepared consisting of 7.5 ml 1.5 M Tris/HCL pH 8.8, 6.9 ml 
of acrylamide (30%/0.8%), 300 µl 10% SDS, 270 µl APS (10%), and 30µl TEMED. The 
stacking gel (15 ml) contains 2.01 ml acrylamide (30%/0.8%), 3.75 ml 0.5 M Tris/HCL pH 
6.8, 150 µl 10% SDS, 135 µl APS (10%), and 15 µl TEMED. 15 µl of a protein standard 
(NEB, P7712S) was used for the large gel preparations. The gel was run at constant current 
(10 mA) overnight. 
2.2.4. SDS-PAGE gel electrophoresis using PhosTag reagent 
Phos-tag reagent is a highly selective phosphate binding molecule in combination with 
dinuclear metal complexes [e.g., mangane (II) and zinc (II)-Phos-tag]. Based on the number 
and location of the phosphate group the method allows the differentiation of different 
isoforms of phosphoproteins. In the presence of divalent metal ions and once the 
phosphorylated proteins bind to the reagent, their movement on SDS-PAGE gels would 
slow down. Therefore, 7% resolving gels were prepared by following the standard protocol 
of SDS gel electrophoresis (see Section 2.2.2). Phos-Tag reagent with a final concentration 
of 5 mM would be added. The gels were run at 9 mA overnight (at least 17 hours). The gels 
then were soaked for 10 minutes in transfer buffer containing 5 mmol/L EDTA (with gentle 
agitation) after electrophoresis in order to remove the metal ions. 
2.2.5. Western blotting 
Transferring the proteins to nitrocellulose membrane after the gel electrophoresis was 
performed using the XCell II blot module from Invitrogen. The transfer buffer contained 25 
mM Tris, 192 mM Glycine, and 20% methanol. Further, Tris buffered saline TBS (137 mM 
Sodium Chloride, 20 mM Tris) containing 0.1% Tween-20 (TBST) was used to wash the 
membrane, which was then incubated for 1 hour at room temperature (or overnight at 4°C 
) in blocking solution, consisting of 3% BSA in TBST. Three times of washing the membrane 
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were applied with TBST, and thereafter membranes were incubated in primary antibody as 
illustrated in Table 2.1. Then, an appropriate secondary antibody conjugated with 
horseradish peroxidase (Table 2.2), was incubated with the membranes after being washed 
three times with TBST. ECL reagent, together with a gel documentation system (Genesys) 
was used to visualize the Western blots. 
Table 2.1: Primary antibodies used for western blot. 
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8727 1:1000 1 hour 25°C
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Table 2.2: Secondary antibodies used for western blot. 



















A0545 1:2000 1 hour Room Temp. 
Goat anti 
Mouse 
Invitrogen 31439 1:15000 1 hour Room Temp. 
 
2.2.6. Quantification of results 
GeneTools software from Syngene was used to analyse the final image obtained from the 
blotted membrane. Upon selecting the manual quantification track and drawing a rectangle 
of consistent size around each band, analyzing the quantity of each band of interest was 
performed by calculating the pixel density of each rectangle, which is relative to the protein 
quantity. ERK1/2 activation was quantified by dividing the afforded value of activated 
ERK1/2 (pERK1/2) to the obtained value for the total ERK1/2 protein (tERK1/2). Activation 
of ERK5 was quantified by dividing the value of activated ERK5 (pERK5, the sum of the 2 
upper bands) to the value of the total ERK5 (the sum of all three bands).  
 
2.2.7. Statistical Analyses 
The statistical functions of the Excel software were used to analyze statistically the 
generated values. Unpaired t tests were conducted to analyze the difference between 
specific time points compared to the control where 2 groups were compared. Thereafter, 
differences between more than 2 groups would be calculated using a one-way ANOVA test 
followed by a Tukey’s HSD post-hoc test for pairwise comparisons of all means using SPSS 




2.3.1. Amplification of Adeno-Virus 
After plating the HEK293 cells at 4x106 cells per T-75 flask, the required amount of crude 
adenovirus containing the gene of interest (e.g., 50-150 µl) was added to the cells in 10 ml 
of DMEM media. Typically, the infected cells in the plate would grow efficiently at 37°C in a 
humidified air incubator containing 5% (v/v) CO2 within 2 to 3 days. In order to harvest the 
cells, both infected cells and cell supernatant containing adenovirus particles were collected 
to a sterile, capped tube. First, both the harvested cell and cell supernatant containing 
adenovirus particles were centrifuged for 15 minutes at 3500 x g. Then, the cell supernatant 
containing the adenovirus particles were pipetted to new, sterile capped tube and store at 
4°C (-80°C for longer periods of time). The cell pellet was resuspended in 2 ml of the 
supernatant and the cells lysed by freezing and thawing (-80°C for 30 minutes followed by 
37°C for 15 minutes), three times. The samples were centrifuged for 15 minutes at 2000 x 
g and the supernatant containing the adenovirus particles were collected and added to the 
previous supernatant. 1 µl of nuclease enzyme (Benzonase) was added to each 1 ml culture 
volume. The sample mixture was then incubated at 37°C in a water bath for 30 minutes to 
digest cellular nucleic acid. The digested cell supernatant was transferred to a Vivaclear 
Maxi spin column (Yellow capped spin column), and centrifuged for 5 minutes at 500 x g. 
After adding 10 fold of loading buffer to the collected flow-through, the 10x of washing buffer 
was prepared in deionized water. In order to equilibrate the AdenoPACK Maxi spin column, 
5 ml of diluted washing buffer were added and centrifuged for 5 minutes at 500 x g. Then, 
the sample volume were loaded into the Adeno PACK Maxi insert and spun for 5 minutes 
at 500 x g. In order to elute the adenovirus particles containing the sequence of interest, it 
was necessary before to wash properly the spin column two times with adding 18 ml of 
washing buffer and spun for 5 minutes at 500 x g. The adenovirus-containing eluent was 
then collected in a fresh, sterile capped tube after being incubated for 10 minutes, and then 
centrifuged for 5 minutes at 500 x g in AdenoPACK Maxi membrane. For the titration 
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purpose, it is significant to concentrate the adenovirus particles containing the sequence of 
interest using Vivaspin 20 centrifugal concentrator and physiological buffer containing 20 
mM Tris/HCL, 25 mM NaCl, 2.5% Glycerol (w/v), pH 8.0 at 22°C. 
 
2.3.2. Adenovirus titration 
Adenoviruses were titrated using the Quick Titer ELISA Kit from Cell Biolabs. HEK293 cells 
were harvested and resuspended in culture medium at 5 x 105 cells/ml, 100 µl of the cells 
were seeded in each well of a 96-well plate and incubated at 37°C, 5% CO2 for one hour. 
Then, Ad-β gal positive control and the viral sample were prepared for a serial dilution in 
culture medium. Dropwise, 50 µl of diluted viral sample were added to each well of 96-well 
assay plate and performed in duplicate. The infected cells were incubated at 37°C, 5% CO2 
for 2 days. Afterward, the immunoassay was conducted by fixing the infected HEK293 cells 
in 100 µl of cold methanol, and incubated for 20 minutes at -20°C. After washing the cells 
three times with 1x PBS, the 293 cells were blocked for one hour with 200 µl of 1% BSA in 
PBS at room temperature. To probe the fixed cells, 100 µl of diluted 1x anti-Hexon antibody 
solution were added to each well and incubated for one hour at room temperature. After 
washing the fixed cells three times with 1x PBS, 100 µl of diluted 1x secondary antibody 
solution were added to each well and incubated for other one hour at room temperature. 
Then, the fixed cells were again washed with 1x PBS, five times. In order to add 100 µl of 
TMB substrate to the fixed cells, TMB substrate was warmed to room temperature and 
incubated with the fixed cells at room temperature for 5-10 minutes. Before measuring the 
optical density of the reaction at 450 nm on a 96-well plate reader, the reaction was stopped 
by adding 100 µl of stop solution to each well. The final calculation of the viral titration was 
obtained based on the standard curve from Ad-β gal positive control titration.  
 
2.3.3. Transduction with Adenovirus 
HeLa or HUVEC cells were plated in p60 (60 mm) dishes after being counted using a 
haematocytometer at a density of 6x105 cells/dish on p-100 (100 mm) dishes or at a density 
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of 1.5x106 cells/dish on p60 (60 mm) dishes. The appropriate full cell culture media was 
employed in this assay. The cells were left in the incubator at 37°C in a humidified air 
incubator containing 5% (v/v) CO2, for two days. Meanwhile, the entire plated cells were 
transduced with Adeno-Virus ERK5 (wildtype human ERK5) and /or Adeno-Virus MEK5DD 
(constitutively active human MEK5 α with the following mutations: S313D, T317D) (Raviv 
et al. 2004). The Adenoviruses were a generous gift from Dr Michael Cross (University of 
Liverpool). The media were changed after 6 hours with new media containing 5% 
Penicillin/Streptomycin (containing 5000 Units of penicillin and 5000 µg/ ml of streptomycin), 
but without fetal bovine serum or growth factors prior to running each experiment within at 
least 24 hours. 
2.4. Immunoprecipitation assay 
2.4.1. Cell lysis 
The cells were washed with PBS and lysed in 1x RIPA (Radioimmunoprecipitation) buffer 
solution (Merck Millipore, catalogue number 20-188; 10x solution containing 0.5 M Tris-HCl, 
pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10 mM EDTA) using 350 µl per 60 
mm dish or 700 µl per 100 mm dish. Lysed cells were centrifuged at 4°C, 15000 x g for 5 
minutes to remove cell debris. 
2.4.2. Preparation of antibody-protein A/G agarose beads 
Protein A/G agarose beads (Thermo Scientific, catalogue number: 20423; 20 µl for each 
sample) were carefully washed and centrifuged three times with 1x RIPA 
(Radioimmunoprecipitation) buffer solution (1ml and 1 minute at 300 x g). 20µl of protein 
A/G agarose beads were transferred to each microtube containing the relevant cell lysates. 
2µl of Anti-FLAG antibody (Purchased from Sigma, catalogue number F7425-2MG, 
Concentration ~ 8 mg/ml), were added to the mixture and placed on a rotating shaker at 
4°C for 3-4 hours. Afterward, the immunoprecipitates were carefully washed with 1 ml of 1x 
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RIPA buffer and centrifuged at 500 x g for 30 seconds, five times to remove any non-specific 
proteins. Finally, 2x NuPAGE LDS Sample Buffer (ThermoFisher, #1225644) was added to 
the washed immunoprecipitations as well as 50 mM DTT. The mixture was heated for 5 
minutes at 95°C. 
 
2.5. Coomassie gel staining 
A Coomassie Based Staining Solution (Expedeon, catalogue number: ISB1L) was used to 
identify the migrated bands of interest. The Coomassie Based Staining Solution was 
carefully added to the gel and incubated for at least one hour on the orbital shaker, at room 
temperature. Destaining was performed with several changes of distilled water. 
 
2.6. Immunofluorescent Staining 
After 24 hours of transfection, cells were fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 20 minutes at room temperature and then permeablized with 0.5% 
Triton X-100 in PBS for 5 minutes. After being blocked with 3% bovine serum albumin in 
PBS, the cells were then incubated with indicated primary antibodies (Table 2.3) for 1 hour 
at room temperature and then incubated with a goat anti-rabbit secondary antibody (Table 
2.4) for 1 hour at room temperature. Cells were finally mounted in Prolong Diamond Antifade 
Mountant with DAPI (Life technology, reference : p36962, lot: 1796977) and examined using 
a confocal microscope (Bio-Rad). 
 
Table 2.3: Primary antibodies used for immunostaining. 
















Table 2.4: Secondary antibody used for immunostaining. 











Abcam A11034 1:500 1 hour In the dark 
Room Temp. 
25ºC 
2.7. Antibody affinity purification 
2.7.1. Coupling procedure  
To prepare the affinity column, the peptide was immobilised onto the resin containing 
functional aldehyde groups reacting with the primary amines of the peptide. All 
centrifugation steps were performed at 1,000 x g for one minute unless otherwise indicated. 
First, the AminoLink Plus Spin Column (Thermo Scientific; catalogue number 20475) and 
reagents were equilibrated at room temperature. Afterward, the column was placed in a 
collection tube and centrifuged at 1,000 x g for two minutes. The column was washed twice 
in 300 µl of Coupling Buffer (PBS: 0.1 M Na phosphate, 0.15 M NaCl; pH 7.2). 140 µl (100 
µg) of peptide (unphosphorylated ERK5) dissolved in coupling buffer was added directly 
into the resin. In the following step and in a fume hood, 2 µl of Sodium Cyanoborohydride 
Solution were added to the reaction slurry and the reaction was mixed. The column was 
incubated at room temperature for 4 hours with mixing the reaction every hour. The column 
was placed in a collection tube and centrifuged to remove the liquid. 300 µl of Coupling 
Buffer was added and centrifuged to wash the resin. The previous step was repeated two 
more times. 
For blocking the remaining active binding sites, 300 µl of Quenching Buffer (1 M Tris HCl, 
0.05% NaN3, pH 7.4) was added onto the resin and mixed. The column was then placed in 
a collection tube to be centrifuged and flow-through would be discarded. After repeating the 
previous steps, 200 µl of Quenching Buffer was added onto the resin and mixed. In a fume 
hood, 4 µl of the Sodium Cyanoborohydride Solution were added to the reaction slurry. 
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Afterward, the column was mixed thoroughly. It was important to mix the reaction every 15 
minutes upon its incubation at room temperature for 30 minutes. The column was then 
placed in a collection tube to be centrifuged and the flow-through was discarded. For 
washing and storing purposes, sodium azide would be added to the Coupling Buffer at a 
final concentration of 0.02 % for long-term storage (i.e. > 2 weeks).  
2.7.2. Affinity purification 
The resin containing the immobilized antibody was equilibrated to room temperature. 300 
µl of Wash Solution (1 M Tris-HCL, 0.05 % NaN3, pH 7.4) were added and the reaction was 
mixed. Then the column was placed in a collection tube to be centrifuged, and flow-through 
were discarded, with taking into consideration to repeat this step two more times. 500 µl of 
the antibody (phosphor-ERK5; FT2; rabbit 541) to be purified were directly added to the 
resin. Then, the cap was replaced, and the reaction was mixed. Gentle agitation or end-
over-end mixing was applied to the incubated reaction overnight at 4°C). The column was 
placed in a collection tube to be centrifuged, the flow-through would be saved and 
represented the phosphor-specific antibody. Reducing the possible nonspecific interaction 
would be attained by preparing 1 ml of 0.5 M NaCl containing a final concentration of 0.05 
% Tween-20. The following few steps would be repeated two times to achieve a highest 
efficiency. First, adding 300 µl of the solution and 10 times of gentle inversions were applied 
to the column. Thereafter, the tube was centrifuged and the flow-through was discarded. 
After repeating the previous steps two more times, 300 µl of Coupling Buffer were added, 
the cap was replaced, and the tube was inverted 10 times. Centrifugation and discard flow-
through would be applied after placing column in a collection tube. Then, 300 µl of Coupling 
Buffer were added in increments of 100 µl, on the inside surface of the column to wash 
down the resin. The plug was then removed, and the column was placed in a collection tube 
to be centrifuged. The flow-through was discarded.  
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For elution purpose, 100 µl of elution buffer pH2.8 was added along sides of the column 
onto the resin. The cap and column were replaced and mixed. It is significant to incubate 
the column at room temperature for 10 minutes. Then, the column was placed in a collection 
tube to be centrifuged. In order to neutralize the low pH of the eluted fraction, 5 µl of 1 M 
Tris, pH 9.0 was added. The resulting fraction represents the total anti-ERK5 antibody (not 
phosphor-specific). Regeneration of the resin has been executed after elution by washing 
three times with 300 µl of Coupling Buffer containing 0.02 % sodium azide, then storing the 
column at 4°C. 
2.8. DNA sequencing  
DNA sequencing was performed by Source Biosciences. For each sequence, 10 µg of 
plasmid DNA in a total volume of 10 µl was sent to the company in a sealed Eppendorf 
tube. The specified primers were provided by the company and the results were received 
by email. 
2.9. Mass spectrometry 
2.9.1. Protein digestion 
Proteins were digested either at the University of Warwick as part of the mass spectrometry 
service or locally at Bradford University. The gel slice identified by Coomassie staining was 
diced into small cubes and destained in 50% EtOH / 50 mM ammonium bicarbonate 
((NH4)HCO3) at room temperature. The samples were then dehydrated in 100% EtOH for 5 
minutes at room temperature and reduced and alkylated with 50 mM TCEP / 200 mM CAA 
(Tris-(2-carboxyethyl) phosphine hydrochloride / 2-chloroacetamide) for 5 minutes at 70°C. 
The gel slices were then washed twice in 50% EtOH / 50 mM (NH4)HCO3 for 20 minutes at 
room temperature. Samples were dehydrated in 100% EtOH and the dried gel slices 
rehydrated with 2.5 ng/µl of the required enzyme (trypsin or pepsin). 50% EtOH / 50 mM 
(NH4)HCO3 was added to fully cover the gels and digestion was carried out over night at 
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37°C. Peptides were extracted twice in 25% acetonitrile / 5% formic acid using a sonication 
bath for 10 minutes each. Peptides were concentrated in a Speed-Vac dryer and 
resuspended in 2% acetonitrile / 0.1% tri-fluoroacetic acid (TFA) to a final volume of 50 µl. 
 
2.9.2. Mass spectroscopy 
Mass spectroscopy was carried out at the University of Warwick by the WPH Proteomics 
RTP, Gibbet Hill Road, University of Warwick, UK as a paid service. An aliquot containing 
20 µl (from a total of 50 µl) of extracted peptides was analysed by means of nanoLC-ESI-
MS/MS using the Ultimate 3000/Orbitrap Fusion instrumentation (Thermo Scientific) using 
a 60 minute LC separation on a 50 cm column.  
 
2.9.3. Database searching 
Tandem mass spectra were analyzed using MaxQuant (Max Planck Institute of 
Biochemistry, Martinsried, Germany; version 1.6.2.6). MaxQuant was set up to search the 
Homo_sapiens_uniprot-proteome_AUP000005640_March2017 database assuming the 
relevant digestion enzyme. MaxQuant was searched with a fragment ion mass tolerance of 
0.50 Da. Carbamidomethyl of cysteine was specified in MaxQuant as a fixed modification. 
Oxidation of methionine, acetyl of the N-terminus and phospho of serine, threonine and 
tyrosine were specified in MaxQuant as variable modifications. 
 
2.9.4. Criteria for protein identification 
Scaffold (version Scaffold_4.10.0, Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein identifications. Peptide identifications were 
accepted if they could be established at greater than 95% probability by the Peptide Prophet 
algorithm (Keller et al. 2002) with Scaffold delta-mass correction. Protein identifications 
were accepted if they could be established at greater than 95.0% probability and contained 
at least 2 identified peptides. Protein probabilities were assigned by the Protein Prophet 
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algorithm (Nesvizhskii et al. 2003). Proteins that contained similar peptides and could not 
be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. Proteins sharing significant peptide evidence were grouped into clusters. 
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Chapter 3 
Detection of ERK5 activation 
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3. Detection of ERK5 activation
3.1. Introduction 
The elementary goal of this chapter is to establish and characterize an assay to reliably 
measure ERK5 activation within human cells. ERK5 is activated by dual phosphorylation of 
T218/Y220 in the kinase activation loop, analogous to other MAPKs. Following this 
phosphorylation event, ERK5 is further phosphorylated at several sites in the C-terminus, 
which leads to its translocation to the nucleus (see Figure 1.8). However, there are several 
challenges associated with detecting ERK5 activation experimentally. While the antibodies 
recognising the activating phosphorylation sites of ERK1/2 (pT202/pY204) have been very 
reliable and instrumental in deciphering many functional aspects of ERK1/2 signalling (Lai 
and Pelech 2016), the corresponding antibodies for ERK5 (pT218/pY220) have given less 
reproducible results. Several batches of the commercial antibody demonstrate high 
background in Western Blots and often are not sensitive enough to reproducibly detect 
phosphorylated (activated) ERK5, particularly the endogenous protein. In addition, the 
antibodies cannot be used in assays like immunofluorescence as they cross-react with 
activated ERK1/2 (Honda et al. 2015). While it is principally possible to measure ERK5 
activity directly using in vitro kinase assays (Müller and Morrison 2002), this technique is 
complex and not easily adaptable to larger sample sizes. It was therefore necessary to 
establish a technique to measure ERK5 activity in a reproducible fashion that is suitable for 
larger sample sizes. This included testing commercially available antibodies specifically 
recognising residues in the phosphorylated C-terminus of ERK5, antibodies recognising 
activated MEK5, as well as indirect measurements such as gel mobility shifts. 
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3.2. Results 
3.2.1. Establishment of required controls 
3.2.1.1. ERK5 is well detected in the HEK293 cell line 
In order to test different methods for detecting ERK5 activation, it was necessary to assure 
that ERK5 was detectable in the cell line used. For these initial experiments HEK293 cells 
were used. This cell line is well described in the literature and is well known to be easy to 
maintain and to express a large variety of proteins. ERK5 expression was therefore tested 
in HEK293 cells by western blotting. HEK293 cells were grown on 60 mm dishes (p60) and 
serum-starved overnight. On the following day, the cells were treated with 50 ng/ml or 100 
ng/ml EGF (or PBS as a negative control) for 15 minutes to stimulate ERK5 activity. Cells 
were lysed in RIPA buffer and the proteins were separated on a 10% polyacrylamide gel 
and analysed by Western blotting using an antibody directed against ERK5 that recognises 
ERK5 regardless of its activation status (Figure 3.1). The results demonstrate that ERK5 
can be efficiently detected by the antibody and that the levels of ERK5 does not change 
when the cells are stimulated with EGF. It should be noted that ERK5 is known to be 
detected as a band of approximately 105 kDa on SDS-PAGE, despite its theoretical MW of 
approximately 88 kDa. 
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HEK293 cells were grown in 60mm dishes, serum-starved and stimulated with EGF at 
the indicated concentrations (PBS was used as negative control). After 15 minutes, the 
cells were washed with PBS and lysed by adding 250 μl of RIPA buffer. Cells were 
separated on a 10% gel before Western blotting with antibodies directed against ERK5 
(Cell Signalling Technology). n=1 




3.2.1.2. ERK1/2 MAPK is efficiently activated by EGF in HEK293 cells 
EGF has been shown to activate both MAPK pathways: ERK1/2 (Gao et al. 2005) and ERK5 
(Drew et al. 2012). Before further investigating methods to detect ERK5 activation, EGF 
stimulation of MAPK signalling in HEK293 cells was validated under the conditions used. 
The cells were therefore grown in p60 dishes as above and serum-starved overnight. The 
cells were then treated with 10 ng/ml or 50 ng/ml EGF (or PBS as a negative control) for 15 
minutes to stimulate ERK1/2 (and ERK5) activity and lysed in RIPA buffer, as above. Cell 
lysates were separated on a 10% polyacrylamide gel and analysed by western blotting 
using antibodies directed against the activating sites of ERK1/2 (pERK1/2). This experiment 
demonstrates strong and equal activation of ERK1/2 by EGF at both concentrations of EGF 
(Figure 3.2). 
 
It is well described in the literature that ERK1/2 activation by EGF is normally only 
temporary, demonstrating fast activation with full activation in less than 5 minutes and 
returning to baseline levels after 30-60 minutes (Shu et al. 2019). To verify that this is also 
the case in the planned experiments, HEK293 cells were grown in p60 dishes as described, 
serum-starved overnight and then stimulated with 50 ng/ml EGF (or PBS as a negative 
control) for 5, 15, 30 and 60 minutes before lysis in RIPA buffer. Proteins were separated 
on a 10% polyacrylamide gel (SDS-PAGE) and Western blot analysis was performed with 
antibodies directed against activated ERK1/2 (pERK1/2) and total ERK1/2. The result 
clearly demonstrates that ERK1/2 MAPK is strongly activated by EGF at 5 and 15 minutes, 
with its activity returning to baseline levels at around 30 minutes (Figure 3.3). These results 
demonstrate that EGF effectively activates MAPK signalling and that the dynamics of the 
cellular response are intact. Similarly treated cells were therefore used to analyse ERK5 





Figure 3.2: ERK1/2 MAPK is efficiently activated by EGF at 15 minutes. 
HEK293 cells were grown in 6-well plates. The ERK1/2 MAPK pathway was stimulated 
by EGF for 15 minutes at the concentrations shown. PBS was used as negative control. 
The cells were washed with PBS and lysed by adding 250 μl of RIPA buffer. A. Proteins 
were separated on a 10% gel before western blotting with antibodies directed against 
activated ERK1/2 (pERK1/2; top panel) and total ERK1/2 (tERK1/2; bottom panel). B. 
ERK1/2 MAPK activation was quantified by using GeneTools software from Syngene. The 
quantification of ERK1/2 activation was accomplished by dividing the value obtained for 
the activated ERK1/2 (pERK1/2) by the value for the total ERK1/2 protein (tERK1/2). 
Expected molecular weights: ERK1=44kDa; ERK2=42kDa. Representative image of n=2 
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HEK293 cells were grown in 6-well plates. The ERK1/2 MAPK pathway was stimulated 
with 50 ng/ml EGF for the indicated times. PBS was used as negative control. The cells 
were washed with PBS and lysed by adding 250 μl of RIPA buffer. A. Proteins were 
separated by 10% SDS-PAGE before western blotting with antibodies directed against 
activated ERK1/2 (pERK1/2; top panel) and total ERK1/2 (tERK1/2; bottom panel) as 
indicated. B. ERK1/2 MAPK activation was quantified by using GeneTools software 
from Syngene. The quantification of ERK1/2 activation was accomplished by dividing 
the value obtained for the activated ERK1/2 (pERK1/2) by the value for the total 
ERK1/2 protein (tERK1/2). Representative image of n=2 
Figure 3.3: ERK1/2 MAPK is efficiently activated by EGF in a temporal fashion. 
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3.2.2. Phosphor-specific antibodies to detect ERK5 activation 
3.2.2.1. Antibodies directed against the phosphorylated activation sites of 
ERK5 (T218/Y220) 
For ERK1/2, antibodies recognising the phosphorylation sites located in the activation loop 
of the kinase (pT202/pY204) have been extremely valuable in characterising the pathway 
in numerous conditions (see also Figure 3.2 and Figure 3.3). Similar to ERK1/2, ERK5 is 
activated by MEK5 through phosphorylation at threonine 218 and tyrosine 220 in the 
activation loop of the ERK5 kinase domain. An equivalent antibody exists for ERK5 (Sigma 
07-507), recognising the phosphorylated residues T218 and Y220. This antibody was
therefore tested to determine whether it could be used to monitor endogenous ERK5 
activation in human cells. HEK293 cells were grown in 60 mm dishes as described above. 
To activate ERK5, the cells were treated with EGF (50 or 100 ng/ml) as indicated in Figure 
3.2. Cell lysates were prepared and separated by SDS-PAGE and Western blots performed 
with the anti-pERK5T218/Y220 antibody. The experiments demonstrate that the antibody does 
not efficiently recognise the endogenous activated ERK5 (Figure 3.4), even though ERK5 
is present in the cells (see Figure 3.1). Repeated experiments confirmed that this antibody 
(or at least the current batch purchased) does not reliably recognise endogenous activated 























(A) HEK293 cells were grown in 6-well plates. The ERK5 MAPK pathway was stimulated 
by EGF for 15 minutes at the concentrations shown. PBS was used as negative control. 
The cells were washed with PBS and lysed by adding 250 μl of RIPA buffer. Proteins were 
separated on a 7% gel before western blotting with antibodies directed against activated 
phosphoERK5 (pT218/pY220). Representative image of n=2 
(B) The same proteins as in (A) were separated on a 10% gel before Western blotting 
with antibodies directed against ERK5 (Cell Signalling Technology) to demonstrate the 
presence of ERK5 in the samples (reproduced from Figure 3.1). n=1 
Figure 3.4: Using phosphoERK5 (pT218/pY220) antibodies to detect ERK5 
activation. 
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3.2.2.2. Antibodies directed against the C-terminal phosphorylation sites  
It has been shown that multiple residues in the C-terminal domain of ERK5 undergo 
autophosphorylation upon ERK5 activation by MEK5, leading to the transactivation of 
transcription (Morimoto et al. 2007, Honda et al. 2015). Commercial antibodies directed 
against the phosphoS496 (pS496) and phosphoS731/phosphoT733 (pS731/T733) 
autophosphorylation sites were employed to test whether these phosphorylation events 
could be used to measure ERK5 activation. HeLa cells were grown on 60 mm dishes, 
serum-starved overnight, and stimulated with EGF or Sorbitol as indicated. The cells were 
lysed with RIPA buffer and subjected to SDS-PAGE and western blotting.  Unfortunately, 
these antibodies did not recognise ERK5 and cannot be used to monitor endogenous ERK5 
activity in lysates of human cells (Figure 3.5). 
3.2.2.3. Antibodies detecting MEK5 phosphorylation  
MEK5 directly activates ERK5 by phosphorylation of the activation loop of the kinase 
domain. Furthermore, MEK5 is the only known activator of ERK5. It would therefore be 
feasible to use MEK5 activity as an indirect marker for ERK5 pathway activation. Cell lysates 
prepared from HeLa cells serum-starved and stimulated with EGF or Sorbitol as above were 
therefore tested by western blotting using phosphoMEK5 (pMEK5) antibodies. However, 
Figure 3.6 shows that these antibodies also do not reliably detect endogenous, activated 




HeLa cells were grown in 60 mm cell culture dishes. The ERK5 MAPK pathway was 
stimulated with 50 ng/ml EGF for the times shown. Cells were also stimulated with 400 mM 
(lanes 8-9) or 300 mM (lane 10) Sorbitol. PBS was used as negative control. The cells were 
washed with PBS and lysed by adding 350 μl of RIPA buffer. Proteins were separated on 
three 7% gels before western blotting with antibodies directed against ERK5 
phosphorylated at pS496 (A) or pS731/pT733 (B) or total ERK5 (C). Representative images 
of n=2 
Figure 3.5: Using antibodies directed against the C-terminal phosphorylation sites to 
detect ERK5 activation. 
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HeLa cells were grown in 60 mm cell culture dishes. The ERK5 MAPK pathway was 
stimulated with 50 ng/ml EGF for the times shown. Cells were also stimulated with 400 mM 
(lanes 8-9) or 300 mM (lane 10) Sorbitol. PBS was used as negative control. The cells were 
washed with PBS and lysed by adding 350 μl of RIPA buffer. Proteins were separated on 
a two 10% gels before western blotting with antibodies directed against (A) phosphorylated 
(activated) MEK5 (pMEK5) or (B) total MEK5 (tMEK5). Representative image of n=2 
Figure 3.6: Using antibodies directed against the MEK5 activation sites (pMEK5) to 
detect ERK5 activation. 
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3.2.3. Detecting ERK5 activation using electrophoretic mobility shifts 
3.2.3.1. ERK5 activity measurement using a gel retardation assay 
Unfortunately, the commercial antibodies directed against a variety of activation sites in 
ERK5 and MEK5 were not able to reliably detect any activation of endogenous ERK5 in the 
performed assays. ERK5 has a unique feature in the elongated C-terminal domain, which 
becomes hyperphosphorylated upon ERK5 activation (Drew et al. 2012), in parallel with the 
activation loop of the kinase domain. It has therefore been shown that under certain 
conditions, ERK5 may undergo a visible electrophoretic mobility shift upon activation (due 
to the presence of a large number of phosphorylation sites) (Duff et al. 1995, Abe et al. 
1996, Abe et al. 1997). Therefore, it was tested whether this assay could be used to 
measure endogenous ERK5 activation. 
HeLa cells were grown in 60 mm dishes as above and stimulated with EGF (50 ng/ml) for 
5, 15, 30 and 60 minutes and Sorbitol (10, 20 minutes). A 7% polyacrylamide gel was used 
to separate the proteins after lysing the cells with RIPA buffer. To achieve a better 
separation of the potential ERK5 bands, the gel was run until the 80 kDa protein marker 
reached the bottom of the gel. The gel was blotted and the membrane probed with an ERK5 
antibody facilitating detection of the activation status of the ERK5 protein. From Figure 3.7, 
it can be seen that separation of ERK5 protein into species with diverse electrophoretic 
mobility was clearly visible. The lower band represents the non-phosphorylated (inactive) 
form of ERK5, while the upper bands represent the phosphorylated one (activated). This 
assay system was clearly capable of detecting the activation of endogenous ERK5 and was 
utilized in the successive experiments to monitor ERK5 activation in cell lines and primary 
cells. 
It is worthwhile to emphasize that ERK5 MAPK is activated by EGF between 15 and 30 
minutes of exposure (Figure 3.7); in sequence activity of ERK5 back down to baseline. 
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Unlike ERK1/2, EGF activates ERK5 slightly later (compare to Figure 3.3), in which it shows 
the role and importance of diversified dynamics on activation of protein kinase in spite of 
using the same growth factor. In addition, osmotic stress plays a key role in activation of 
ERK5 as indicated by the retardation of the ERK5 band upon treating the cells with 400 mM 
Sorbitol for 20 minutes. 
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Figure 3.7: Activation of ERK5 by growth factors and stress can be identified as a 
shift in electrophoretic mobility. 
HeLa cells were grown in 60 mm dishes. The ERK5 MAPK pathway was stimulated with 50 
ng/ml EGF for the times shown. Cells were also stimulated with 400 mM (lanes 8-9) or 300 
mM (lane 10) Sorbitol. PBS was used as negative control. The cells were washed with PBS 
and lysed by adding 250 μl of RIPA buffer. Proteins were separated on a 7% gel before 
western blotting with antibodies against ERK5 (Cell Signalling Technologies) (A). ERK5 
MAPK activation was quantified using GeneTools software from Syngene (B). Determination 
of ERK5 activity was accomplished by dividing the value for the upper band (phosphoERK5) 
by the sum of all bands (total ERK5). The resulting value for the control band was arbitrarily 
set to 1 and the other results normalised accordingly. Statistical analysis (n=3) was 
performed using a one-way ANOVA test, demonstrating significant differences between the 
samples (P<0.001). Subsequently, the Tukey HSD posthoc test was performed, confirming 
significant differences for treatment with EGF for 15 and 30 minutes (P=0.048, P=0.046) as 
well as for Sorbitol treatment (20 minutes at 400 mM; P=0.002). 
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3.2.3.2. A gel shift assay to analyse ERK5 activation using the phosTag gel 
system 
The PhosTag reagent has been shown to further decrease the mobility of phosphorylated 
proteins, thus improving the resolution between phosphorylated and non-phosphorylated 
isoforms (Kinoshita et al. 2006). In order to test whether the PhosTag reagent can improve 
the detection of ERK5 activation, HeLa cells were serum-starved overnight and stimulated 
with EGF to activate MAPK signalling. Cells were lysed in RIPA buffer and subjected to 
SDS-PAGE. ERK5 activation was investigated by western blotting using an antibody 
detecting the ERK5 protein. The results show two bands with different electrophoretic 
mobility (Figure 3.8). However, it is not clear what isoforms these bands represent. In 
addition, the PhosTag reagent did not improve on the good detection of ERK5 activation 
achieved by a simple gel retardation assay (Figure 3.7). Therefore, the simple gel 
retardation assay described above was used in future experiments. 
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HeLa cells were grown in 6-well plates. The ERK5 MAPK pathway was stimulated with 10 
and 50 ng/ml EGF for 15 minutes; PBS was used as negative control. The cells were 
washed with PBS and lysed by adding 250 μl of RIPA buffer. Proteins were separated on 
a 7% gel containing 5 mM PhosTag reagent before western blotting with antibodies 
directed against ERK5. Representative image of n=2 
Figure 3.8: Establishing a gel shift assay to analyze ERK5 activation (phosTag gel). 
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3.3. Discussion 
A reliable model to detect ERK5 activation and dynamics is central to research into the role 
of H2S in the vascular system. As it has been articulated above, ERK5 is part of the MAPK 
family, which can be activated by certain growth factors (e.g., EGF, FGF), cytokines (e.g., 
IL-6 and IL-8), and cellular and mechanical stress (Nithianandarajah-Jones et al. 2012). 
Detecting the phosphorylation of the TEY kinase activation motif is theoretically sufficient to 
gauge the kinase activity of ERK5. However, based on the findings shown here, the current 
methods and available antibodies are all unable to reliably detect phosphorylation of those 
residues for the endogenous protein (not overexpressed). 
In contrast to ERK5, the dynamics of ERK1/2 activation by EGF (50 ng/ml) in HEK293 cells 
stimulated for different amount of time ranging from 0, 5, 15, 30, 60 minutes were clearly 
detected. The highest peak of activation was at 15 minutes, which ERK1/2 activity steadily 
declining after that time point. It is obvious and clear from the results (Figure 3.2 and Figure 
3.3) that endogenous ERK1/2 activity can be measured in HEK293 cells using antibodies 
directed against the TEY activation motif of ERK1/2. On the other hand, while endogenous 
ERK5 levels were sufficiently high to be detected in HEK293 cells (Figure 3.1), it was not 
possible to determine the kinase activity using the equivalent phosphor-specific antibodies 
for ERK5. In fact, commercial antibodies directed against phosphorylation sites located in 
either the activation loop of the kinase (pERK5T218/Y220) or the C-terminal domain 
(phosphoS496 and phosphoS731/phosphoT733) were not effective in the experiments to 
measure ERK5 activation, even though ERK5 was present and EGF efficiently stimulated 
the cells (shown by ERK1/2 activation). An important aspect that also needs to be taken 
into account is the dynamics of ERK5 signalling. While the phosphorylation of the activation 
loop precedes C-terminal (auto-) phosphorylation, the exact timing may vary between 
experiments. However, the results in Figure  3.7 demonstrate significant C-terminal 
phosphorylation after 15 minutes of EGF treatment, demonstrating that ERK5 has been 
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significantly activated at that time. As all experiments in this Chapter have been performed 
using either 15 minutes stimulation or a time course covering this time window, it is unlikely 
that the failure of the antibodies to detect ERK5 activation is due to missing the correct time 
at which ERK5 has been activated. 
 
MEK5 is a major activator of ERK5 by phosphorylation of the activation loop of the kinase 
domain. As MEK5 catalyses dual phosphorylation at the TEY domain within the activation 
loop of ERK5 (Lee et al. 1995, Zhou et al. 1995, Kato et al. 1997), an antibody against 
activated MEK5 to detect ERK5 pathway activation was also used. However, this antibody 
was not suitable for reliable detection of ERK5 pathway activity. 
 
Ultimately, the establishment of a gel shift assay to detect and measure ERK5 activity was 
efficient and reproducible. While phosphorylation of ERK5 at both the activation loop of the 
kinase domain (by MEK5) and the C-terminus (by autophosphorylation) can lead to some 
conformational changes in the electrophoretic mobility of the ERK5 protein, it was therefore 
feasible to monitor ERK5 activity on the basis of a clearly visible electrophoretic mobility 
shift. (Figure 3.7). ERK5 activation has been previously linked to a gel mobility shift and this 
method has been determined to provide a good estimation of ERK5 activation 
(Nithianandarajah-Jones and Cross 2015). This assay will therefore be used in the 
remainder of this thesis to monitor ERK5 pathway activation. 
 
Overall, it has increasingly become clear that monitoring ERK5 activation is a challenging 
process. While phosphor-specific antibodies have been used to detect the phosphorylation 
of the TEY motif in a number of publications, most of these have been performed using 
overexpressed ERK5 (Obara et al. 2009). In addition, we and others have also observed a 
lack of consistency with the antibody, resulting in some batches to be better than others. 
While it is sometimes possible to use the phosphor-TEY motif antibody for endogeneous 
protein (Roberts et al. 2010), many batches of this antibody only detect overexpressed, but 
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not endogenous ERK5 (see figure 3.4). The finding that ERK5 MAPK activity could be 
potentially measured by electrophoretic mobility shift is therefore highly valuable, not only 
for the present research but also for other studies, where ERK5 MAPK pathway is involved 
in the development of disease. Examples of such diseases include: aggressiveness of 
cancer (e.g., breast cancer, prostate cancer), inflammation, endothelial dysfunction in 
vascular system (Stecca and Rovida 2019). 
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Chapter 4 
ERK5 is activated by H2S, a gaseous 
signalling molecule 
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4. ERK5 is activated by H2S, a gaseous signalling
molecule 
4.1. Introduction 
Altogether, the gaseous signalling molecules hydrogen sulfide (H2S), nitric oxide (NO) and 
carbon monoxide (CO) – also called gasotransmitters or gasomediators - are composed of 
a group of biologically active gases. They can permeate the cellular membrane freely, and 
their movements in the intracellular or intercellular domains do not depend on associated 
membrane receptors or other active transportation mechanisms. The generation of these 
gaseous signalling transmitters in mammalian cells can be attained endogenously, in 
parallel with particular substrates and enzymes, and their production is controlled to 
accomplish signalling messenger functions. It is worth emphasizing that they all have 
particular functions at the physiological levels. In addition to their involvement in signalling 
transduction, they can fulfil their functions by targeting specific cellular and molecular 
processes, such as the regulation of BKca channels or enhancing cGMP production (Wang 
2014). 
Gasotransmitters can be defined in many different ways, but in general they are best known 
as endogenously generated gaseous signalling molecule (Wang 2002). The first recognized 
gaseous signalling molecule was NO. Stimulation of NO production in a variety of 
mammalian cell types can be attained, in conjunction with using L-arginine as a substrate, 
by the role of different isoforms of NO synthase. Recently a better understanding of 
mammalian NO metabolism has occurred. It has illustrated that a molecule of gas can exert 
extraordinary signalling to maintain cellular functions. In addition to its plentiful biological 
implications, NO is well defined as an endothelium-derived relaxing factor (EDRF) 
(Erdmann et al. 2013).  
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Carbon monoxide (CO) is another gaseous signalling molecule produced from heme 
metabolism (Ferreira et al. 2011). Production of CO can be acquired by the role of two major 
enzymes: heme oxygenase-1 (HO-1) and HO-2. Intriguingly, HO-1 is identified as an 
inducible enzyme whereas HO-2 is present in a constitutive form. In terms of functions, 
there are several similarities between CO and NO (Wu and Wang 2005); for example, CO 
enhances relaxation of vascular tissue, decreases blood pressure, and preserves the heart 
from ischemia/re-perfusion damage (Wu and Wang 2005). 
 
After NO and CO, hydrogen sulfide (H2S) has been discovered to be the third 
gasotransmitter. It has been shown that hydrogen sulfide (known as rotten-egg gas) can be 
generated in mammalian cells in specific amounts by the enzymatic roles of cystathionine 
γ-lyase, cystathionine β-synthase, and 3-mercaptopyruvate sulfurtransferase (Kimura 
2014). L-cysteine and homocysteine or their derivatives play a crucial role as substrates of 
these H2S-generating enzymes (Wang et al. 2013, Wang 2014). The indispensable role of 
H2S would be envisaged in regulating many physiological functions at the levels of body 
organs and systems (Yang et al. 2008). Further, H2S plays an essential role as a signalling 
molecule in neurotransmission and neuromodulation, and is included in cognition processes 
such as learning and memory (Wang 2014). Similar to the EDRF role for NO, H2S has been 
shown to be an endothelium-derived hyper-polarizing factor (EDHF) (Mustafa et al. 2011, 
Tang et al. 2013). 
 
From around 1984 research on NO biology and physiology attained a vigorous interest from 
the scientists around the globe, followed by research toward CO and H2S, with the majority 
of publications being related to the toxicological and environmental concepts. (Wang 2014). 
Interestingly, the term ‘gasotransmitter’ for gaseous signalling molecules was conceived in 
2002 (Wang 2002), however, this term was not generally accepted. Nevertheless, a field of 
research has been started investigating novel cellular signalling mechanisms. Following the 
acknowledgement of an important role of gaseous signalling molecules in cellular 
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regulation, the physiological significance of the gaseous signalling molecules to the human 
body has started to be revealed in more detail (Wang 2014). 
Synthesis and generation of H2S in mammalian tissues can be attained via endogenous 
biological enzymes and non-enzymatic pathways, such as the reduction of thiols (Figure 
4.1). For example, hydrogen sulpfide can be generated in vascular endothelial cells and 
vascular smooth muscle through a chemical reaction catalyzed mainly by cystathionine γ-
lyase (CSE) (Li et al. 2011). Although much is known about H2S production and synthesis 
in the body, less is understood about its metabolism. To date, much effort has been centred 
Synthesis of H2S inside the cells can be attained by the action of cystathionine γ-lyase 
(CSE), cystathionine β-synthetase (CBS), or 3-mercaptopyruvate sulfurtransferase (3-
MST) from cysteine. Degradation and metabolism of hydrogen sulfide could be acquired by 
the action of cysteine aminotransferase (CAT), cysteine dioxygenase (CDO), and cysteine 
lyase (CL) from sulfur-containing amino acids. Altogether, GSSG, GSH, and R-SH 
represent oxidized glutathione, reduced glutathione, and a thiol-bearing intermediate, 
respectively. In addition, TSMT is thiol S-methyltransferase and SO represents sulfide 
oxidase. Figure taken from (Li et al. 2011). 
Figure 4.1: Synthesis and degradation of hydrogen sulfide. 
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toward H2S and its role on individual body systems (Li et al. 2011). The cardiovascular 
system and inflammation have enticed the majority of the attention in this field (Elsey et al. 
2010). Surprisingly, it has been reported in entire animals that administration of NaHS or 
other H2S donors such as ADT-OH, S-diclofenac and GYY4137 can reduce the chronic and 
acute symptoms of raised blood pressure, and high concentration of administrated NaHS is 
able to dilate blood vessels in vitro (Li et al. 2011). NaHS has also been shown to reduce 
heart rate and left ventricular developed pressure, while increasing coronary flow in the 
isolated perfused rat heart (Hussain et al. 2011). 
Discussing the main roles of hydrogen sulfide on cell signalling is important, as it is being 
reclassified from being an environmental poison/toxin to a mammalian intracellular 
signalling molecule (Li et al. 2011). Exposing cells to H2S displays some attenuation in ATP 
biosynthesis and oxidative phosphorylation. The KATP channel was the first reported target 
molecule of H2S in spite of the cytochrome c oxidase exception (Cooper and Brown 2008). 
Sulfhydration of the KATP channel is the only known mechanism by which the KATP channel 
is activated (Kiss et al. 2008). Recently, it has been reported that relaxation of the smooth 
muscle by NaHS administration occurs not only via opening of KATP channel, but also upon 
the effect of activation of myosin-light-chain phosphatase (Gastreich-Seelig et al. 2020). 
It has been reported that hydrogen sulfide can have a biological role on the regulation of 
kinases (Li et al. 2011). However, the effect of H2S on mitogen-activated protein kinase 
(MAPK) signalling varies in different cell types and H2S concentrations (Du et al. 2004). For 
example, administration of NaHS to cultured rat aortic vascular smooth muscle cells inhibits 
endothelin-provoked rises in p38 MAPK activity. However, it enhances p38 MAPK activity 
in cultured human umbilical vein endothelial cells (Li et al. 2011). Phosphorylation of ERK1/2 
can be attained in pigs exposed to coronary artery occlusion and reperfusion due to the 
action of H2S (Osipov et al. 2010). It has been reported that H2S induces a sustained 
activation/ phosphorylation of ERK1/2 in HEK-293 cells as a consequence of 
overexpression of CSE (Yang et al. 2004). H2S can also activate Akt in endothelial cells 
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(Elsey et al. 2010). In addition, it has been found that a brief administration of NaHS in 
isolated hearts predisposed to ischemic pre-conditioning would result in activation of both 
cardiac Akt and protein kinase C (PKC); which improves the mechanical performance of the 
heart and alleviates injury (Yong et al. 2008). Finally, the H2S-induced attenuation of cell 
apoptosis can inhibit caspase-3 activity, a downstream target of the H2S-ERK interaction 
(Yang et al. 2004). Interestingly, it has been shown in a recent study using human aortic 
smooth muscle cells (HASMCs) that ERK1/2 activation is also critical for H2S-induced 
apoptosis (Yang et al. 2004). Significantly, upon involvement of the ERK1/2 inhibitor U0126 
during H2S-induced apoptosis, it has been shown that ERK1/2 plays a key role in the 
process of apoptosis in many cell types.  
 
The importance of these gases underlines their critical role in cell signalling pathways; 
including the ERK5 MAPK pathway (Papapetropoulos et al. 2009). H2S exposure and ERK5 
activation share several downstream effects, such as AKT activation and cell and tissue 
protection from death. However, activation of the ERK5 MAPK pathway by H2S has not 
been shown. Thus, finding the link between ERK5 MAPK activation and H2S is an important 
question. Identification of the missing links in the ERK5 MAPK activation by H2S will lead to 
a refined understanding of the cellular and molecular mechanisms underlying H2S–induced 
cellular proliferation and angiogenesis. Novel mechanisms for many diseases linked to 




4.2.1. Activation of ERK5 by NaHS 
The main goal of the work conducted in this chapter is to test whether the ERK5 MAPK 
signalling pathway could be activated by the gaseous molecule H2S. To test this hypothesis, 
HeLa cells were treated with hydrogen sulfide. First, the cells were treated with 400 mM 
NaHS for the indicated times (Figure 4.2). NaHS is known to release H2S relatively quickly 
when exposed to an aqueous environment. Both EGF (50 ng/ml) and Sorbitol (400 mM) 
were employed in the experiment as a positive control for ERK5 activation. Figure 4.2 
demonstrates that EGF and Sorbitol treatment effectively activated ERK5. NaHS treatment 
resulted in some ERK5 stimulation, albeit to a lower degree. The differences were not 
statistically significant and ERK5 activation also did not change during the time course, up 
to 2 hours of treatment. 
97 
Figure 4.2: Activation of ERK5 bAy NaHS, a H2S donor molecule. 
HeLa cells were grown in 60 mm dishes. The ERK5 MAPK pathway was stimulated with 50 
ng/ml EGF, 400 mM Sorbitol, 400 mM NaHS for the indicated times. PBS was used as a 
negative control. The cells were washed with PBS and lysed by adding 350 μl of RIPA buffer. 
Proteins were separated on a 7% gel before western blotting with antibodies directed against 
ERK5. Quantification of ERK5 activity was accomplished by dividing the value for the upper 
band (phosphoERK5) by the sum of all bands (total ERK5) to yield a value for relative 
(percentage) activation. Statistical analysis (n=3) was performed using a one-way ANOVA 
test, which showed significant differences between samples. A subsequent Tukey HSD test 
demonstrated that both positive controls were significantly different from the control (P<0.001). 
However, NaHS treatment did not result in any statistically relevant differences. 
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4.2.2. Activation of ERK5 by GYY4137 
In addition to NaHS, GYY4137 was also used to stimulate the HeLa cells. GYY4137 is a 
water-soluble chemical that is well known to slowly release H2S over a longer time, up to 
several hours. It can be observed from Figure 4.3 that the ERK5 MAPK signalling pathway 
shows a trend of activation by GYY4137, as demonstrated by the ERK5 bands showing 
reduced electrophoretic mobility, although the difference was not statistically significant. 
The potential activation of ERK5 is most clearly seen at the 30 minutes time point (p=0.056). 




Figure 4.3: Activation of ERK5 by GYY4137, a H2S donor molecule. 
HeLa cells were grown in 60 mm dishes. The ERK5 MAPK pathway was stimulated with 
50 ng/ml EGF, 400 mM Sorbitol, 400 μM GYY4137 for the indicated times. PBS was used 
as a negative control. The cells were washed with PBS and lysed by adding 350 μl of RIPA 
buffer. Proteins were separated on a 7% gel before western blotting with antibodies directed 
against ERK5. Quantification of ERK5 activity was accomplished by dividing the value for 
the upper band (phosphoERK5) by the sum of all bands (total ERK5) to yield a value for 
relative (percentage) activation. Statistical analysis (n=3) was performed using a one-way 
ANOVA test, which showed significant differences between samples. A subsequent Tukey 
HSD test demonstrated that both positive controls were significantly different from the 
control (P<0.001). However, GYY4137 treatment did not result in any statistically relevant 
differences. Representative image of n=3 
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4.2.3. Subcellular localization of ERK5 after treatment with H2S 
Activated ERK5 has been shown to be translocated to the nucleus upon activation (Kondoh 
et al. 2006). It was therefore also analysed whether ERK5 is present in the cytoplasm or the 
nucleus upon stimulation of HeLa cells with H2S. The cells were plated on cover slips and 
transduced with an Adeno-Virus expressing wildtype ERK5. Cells were then serum-starved 
and treated with 400 µM GYY4137 for 60 minutes. Cells were stained with antibodies for 
ERK5 and with DAPI to stain the nucleus. Figure 4.4 clearly shows that while ERK5 MAPK 
is primarily located in the cytoplasm under resting conditions, it is efficiently translocated 
into the nucleus upon GYY4137 stimulation for 60 minutes (Figure 4.4). This further 
demonstrates that H2S activated the ERK5 MAPK, leading to nuclear translocation. 
HeLa cells were plated on cover slips and transduced with an Adeno-Virus expressing 
ERK5. The cells were serum-starved for 16 hours and stimulated with GYY4137, a slow-
releasing H2S donor for 60 minutes. Immunocytochemistry was performed using ERK5 
primary and Alexa488-conjugated secondary antibodies and DAPI was added with the 
mounting medium. Dimethyl sulfoxide (DMSO, 2µl) was used as the vehicle control. The 
results show that ERK5 MAPK is translocated into the nucleus upon GYY4137 stimulation, 
but not after DMSO treatment. Representative image of n=7 
Figure 4.4: Activation of ERK5 by H2S leads to its translocation to the nucleus. 
101 
4.3. Discussion 
The findings of this study suggest that ERK5 MAPK may be activated by hydrogen sulphide 
(H2S) in HeLa cells. While the differences are not significant and require additional 
investigations, there is an apparent reduction in the electrophoretic mobility of ERK5 in a 
gel-shift assay (Figure 4.3) in response to the H2S-releasing chemical GYY4137. In addition, 
in initial experiments, GYY4137 also led to the translocation of ERK5 to the nucleus of the 
cell (Figure 4.4), anindication that ERK5 is being activated. ERK5 MAPK pathway activation 
plays a critical role in various cellular functions, such as the prevention of cellular apoptosis, 
cell survival, proliferation and differentiation. Activation of ERK5 MAPK can be attained by 
osmotic and oxidative stress, a range of growth factors (e.g., EGF, VEGF), and certain 
cellular cytokines (e.g., IL-6, LIF) (Drew et al. 2012). Both EGF and sorbitol were employed 
here to standardize the results, as they surely activate the ERK5 MAPK pathway. GYY4137, 
a chemical that slowly releases hydrogen sulphide, was mainly the source of hydrogen 
sulphide due to its reproducible effects on the treated cells. It has been shown in a previous 
study using two strata of endothelial cells (primary endothelial cells and transformed 
endothelial cells), that H2S has the capability to stimulate cell proliferation and migration 
once the targeted signalling pathway was activated. Furthermore, pro-angiogenic effects 
were demonstrated in an in vitro study of endothelial cells in response to H2S where there 
was some augmentation in tube-like formation (Papapetropoulos et al. 2009). 
In contrast to GYY4137, activation of ERK5 MAPK by NaHS was weak and would require 
some optimization in terms of the concentration and incubation time. GYY4137 activated 
ERK5 in a more sustained way and remained higher than baseline for a longer period of 
time than NaHS. The most likely reason for this difference are the temporal differences in 
H2S release. While NaHS releases H2S very quickly once in an aqueous environment, 
GYY4137 acts much more slowly, releasing H2S over several hours. This is similar to an in 
vitro study of three forms of cancerous cells (Lee et al. 2011). In this study, a panel of human 
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cancer cell lines were generated (HeLa; HCT-116; Hep G2; U2OS) and compared with two 
normal human diploid fibroblast cell lines (WI-38 and IMR90). GYY4137 at a concentration 
of 400 µM efficiently reduced cell proliferation and survival, whereas NaHS was completely 
inactive. (Lee et al. 2011) 
There are plenty of known molecular targets for hydrogen sulphide, which can be classified 
broadly into effects on (a) protein (cysteine thiol), (B) intracellular cell signalling, (c) ion 
channels, and (d) metabolism (effects on mitochondria and ATP production) (Li et al. 2011). 
Interestingly, the effect of hydrogen sulphide on cell signalling is more likely related to the 
subject of this thesis, where the related molecular pathway associated with them needs to 
be explained. For example, the targeted molecular pathway of hydrogen sulphide activation 
could include phosphorylation and activation of phosphatidylinositol 3 kinase (PI3K) and 
signal transducer and activator of transcription 3 (STAT3). Upon activation of these 
pathways, numerous cellular primary functions such as prosurvival and preventing 
apoptosis would be evoked. Protein kinase C signalling pathway has been reported to be 
activated upon the action of hydrogen sulphide stimulation (Li et al. 2011). However, it is 
impracticable to predict the final outcomes of the intracellular events (e.g., final biological 
response and nuclear transcription) with receptor activation due to emerging of cross-talk 
(interaction) between cellular signalling pathway inside the cells (Robinson-White and 
Stratakis 2002). 
Also, inhibition of many cellular receptors and channels mediating transmission of the 
signalling pathway may be associated with ERK5 activation (e.g., KATP channels) (Modis et 
al. 2013). Thus, it would be of great advantages for the future research to test and determine 
if hydrogen sulphide can activate other signalling pathway rather than ERK5, and recognize 
the role of cross-talk between signalling pathway in activation of ERK5 MAPK. On the other 
hand, the unique C-terminal domain of ERK5 would also have a critical role in activation of 
ERK5 by hydrogen sulphide as they harbour threonine and serine residues that can be 
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activated by other signalling pathways and upstream effectors, CDK1 and ERK1/2 are 
examples. It has been reported that H2S can promote and phosphorylate ERK1/2 in pigs 
exposed to coronary artery occlusion and reperfusion (Li et al. 2011). Therefore, the 
mechanism by which H2S activates the ERK5 pathway needs to be investigated in more 
detail. 
 
ERK5 has been reported to translocate to the nucleus under a number of conditions, although 
its localisation within the cellular domain is variable (Buschbeck and Ullrich 2005). For 
example, the predominant nuclear patterns can be identified in COS-7, HeLa BT474 and 
SKBR3 cells (Kondoh et al. 2006), on the other hand, ERK5 can be allocated in an overall 
diffuse patterns in MCF7 cells (Esparis-Ogando et al. 2002). Several mechanisms have been 
described in its nuclear translocation, including MEK5-mediated phosphorylation, 
phosphorylation by CDK1 (cyclic-dependent kinase 1), MEK1/2-ERK1/2 –dependent 
mechanism and regulation of ERK5 nuclear shuttling by SUMOylation at the N-terminus 
(Tubita et al. 2020). Under basal conditions, i.e. in unstimulated cells, cytosolic ERK5 
presents in unphosphorylated inactive folded form, where the C-terminal half is bound to the 
N-terminal, resulting in concealing the NLS (nuclear localisation signal) and preventing 
nuclear translocation (Yan et al. 2001). Following ERK5 activation by MEK5-dependent 
phosphorylation at the TEY region, activated ERK5 is able to phosphorylate itself in the C-
terminus, thereby, leading to an open conformation and exposing the NLS sequence that 
facilitates ERK5 nuclear translocation (Erazo et al. 2013). Thus, it seems necessary for 
ERK5 to be phosphorylated at the MEK5 consensus for transporting to the nucleus. Beside 
MEK5-dependent activation, there are other mechanisms driving ERK5 nuclear 
translocation including overexpression of CDC37 in cancer cell lines, phosphorylation at the 
C-terminal half by other kinase and phosphorylation of ERK5 by ERK1/2 (Tubita et al. 
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2020). The exact mechanism by which H2S may facilitate the nuclear translocation of ERK5 
remains to be determined. 
Altogether, activation of ERK5 MAPK by hydrogen sulphide was noticeable, although not 
statistically significant. The highest level of activation was at 30 to 60 minutes time basis, 
then the degree of activation went down gradually till the baseline at 120 minutes. The 
subcellular localization of the MAPK components to the nucleus is well-known by its role 
in regulating the transmitted signals by MAPK cascade (Pouyssegur et al. 2002). Thus, it 
was suggested from the presented studies that ERK5 MAPK translocated to the nucleus upon 
its activation by hydrogen sulphide. The exact mechanism is yet to be revealed. 
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ERK5 is activated by H2S in primary 
endothelial cells
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5. ERK5 is activated by H2S in primary endothelial 
cells 
5.1. Introduction 
After the observation that H2S may activate ERK5 in an established cell line (see previous 
chapter), it was now investigated if H2S also has an effect on ERK5 in primary endothelial 
cells. The integrity of endothelial cells is very important in terms of maintenance of blood 
vessel function. In general, all blood vessels, ranging from the largest arteries and veins to 
the smallest capillary venules, are lined by endothelial cells (Ruoslahti and Rajotte 2000). 
The function of the endothelial cells is dependent on the localization of their corresponding 
blood vessels (Bouis et al. 2001). However, angiogenesis is a complicated biochemical 
process characterized by continuous changes in endothelial cell behaviour associated with 
remodelling of extracellular matrix, which enhances cellular growth and migration to be 
assembled and thus promotes capillary formations. 
 
Overall, there are two types of experimentally utilizable endothelial cell (EC) lines available: 
(a) prolonged life span of endothelial cell and (b) immortalized cell lines. In general, the 
overall requirements for human EC cell line should meet the following standards: (1) the life 
span of the ECs should cover the duration of the experiment (2) the consistent presentation 
of at least two specific endothelial markers, for instance WP-bodies (Weibel-Palade), vWF 
(von Willebrand Factor), ACE activity (Angiotensin-converting enzyme) (3) experimental 
expression of relevant markers (4) minimal indication of tumorigenic conversion of the cells 
(Bouis et al. 2001). 
 
There are a number of different endothelial cell types available. The overall behaviour of 
endothelial cells varies based on their vascular origin. For example, the morphology of 
human placental endothelial cells (HPEC) is different from HUVEC(human umbilical vein 
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endothelial cells); the cells are more elongated, form networks in sparse cultures and grow 
in expanded spiral structures of elongated cells at confluence (Schutz and Friedl 1996). 
HUVEC cells are commonly used for biochemical experiments. This is due to the 
abundance of the available information about in vitro experiments with human endothelial 
cells derived from umbilical veins (Jaffe et al. 1973). On average, HUVECs can be 
maintained up to 10 serial passages and kept in culture for up to 5 months, after which the 
cells enter senescence (Bouis et al. 2001). 
It has been reported that endothelial cells are a target and source of H2S (Papapetropoulos 
et al. 2009). The biological importance of each pathway modified by H2S is varied depending 
on several aspects including: cell types, organs, species. Examples of these pathways 
include: effects on metal ions (Fe, Zn), S-sulfhydration (NF-κB), MAPK family, and 
cAMP/PKA (Szabo 2007). As MAPK has an experimental relevance to the work in this 
thesis, it would be significant to reveal the outstanding literature that articulates the 
biological role of H2S on the MAPK family (Li et al. 2011). Four main members can describe 
the big MAPK superfamily: ERK1/2, p38, JNK and ERK5 (Cowan and Storey 2003). 
Otherwise, it has been shown that the mitogen activated protein kinase (MAPK ERK1/2 and 
p38) can be stimulated and phosphorylated upon exposure to Na2S, which in turn enhances 
the cell migration in HUVEC (Papapetropoulos et al. 2009). 
In terms of angiogenic activation, it has been described that KATP (upstream of MAPK 
pathway) channels can play a major role in the angiogenic pathway upon their activation. 
Profoundly, two independent researching groups (Cai et al. 2007, Papapetropoulos et al. 
2009) have reported the factual phenomenon that H2S plays a crucial role in proliferation 
and migration of endothelial cell in vitro (whether transformed or primary endothelial cells). 
Overall, angiogenesis response to H2S would undoubtedly follow a bell-shaped dose-
response pattern: the impact of H2S can be ranged from physiological, cytoprotective effects 
(which happen at low concentrations) to cytotoxic effects (which may occur apparently at 
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higher concentrations) (Li et al. 2011). Exposing endothelial cells to exogenous H2S has 
been shown to induce activation of multiple signalling pathways including: PI-3K/AKT axis 
and phosphorylation of members of the MAPK pathway (e.g., ERK1/2 and p38), with 
different time course. Once PI-3K/Akt is activated, tube-like structure formation in RF/6A 
cells would be regulated; meanwhile, activation of MAPK has been reported to play a crucial 
role in cell migration in HUVECs (Papapetropoulos et al. 2009). 
The present study aims to reveal the precise role of exogenous H2S on angiogenesis via 
ERK5 MAPK activation. In vascular tissues, the pro-angiogenic effect involves production 
of endogenous H2S by VEGF. The exact mechanism of interactions is yet to be elucidated. 
In analogy to endogenous H2S, an applied exogenous H2S would induce a pro-angiogenic 
effect via interaction of VEGF/H2S, leading to the activation of KATP channels. Suppression 
of those channels may inhibit VEGF-induced angiogenesis. In overall, it can be said that 
the major effect of H2S on cellular signalling pathway would be the activation, with little 
exception (Szabo and Papapetropoulos 2011). Incubation of endothelial cells with H2S can 
stimulate network like formation of ECs in vitro via capillary morphogenesis. Moreover, 
appearance of angiogenic phenotype can be a consequence of exerted positive effects of 




5.2.1. ERK5 is activated by H2S in primary endothelial cells 
To study whether H2S administration exerts activation effects on ERK5 MAPK in endothelial 
cells, HUVECs were treated with 400 µM GYY4137 - a water-soluble chemical that slowly 
releases H2S - for 60 minutes, after which the cells were serum-starved for at least 3 hours. 
Transient transfection of HUVEC cells was performed using Adenoviral Expression System 
containing the cDNA of wild-type (WT)-hERK5. A constitutively active MEK5 (MEK5DD) was 
used as a positive control for ERK5 activation.  
 
To determine whether ERK5 MAPK was phosphorylated and activated by H2S in HUVECs, 
lysates obtained from HUVECs were subjected to western blot analysis using an anti-ERK5 
antibody. Treatment of HUVECs with GYY4137 resulted in an activation of ERK5 MAPK, 
as indicated by enhanced gel retardation (Figure 5.1). In consequence, this experiment 
suggests that ERK5 might be activated by H2S in HUVECs. It is interesting to note that 
activation by H2S leads to a smaller mobility shift than co-transduction with activated MEK5. 
This observation suggests that not all C-terminal phosphorylation sites are phosphorylated 
in response to H2S, in contrast to full activation by MEK5DD. This potential difference will be 











Figure 5.1: Activation of ERK5 by GYY4137. 
HUVEC cells were plated on 60mm dishes and transduced with Adenoviruses expressing 
wildtype ERK5. Positive control cells also received MEK5DD-expressing Adenovirus where 
indicated as a positive control. Cells were starved and one set was treated with GYY4137 
for 60 minutes. Cells were lysed with RIPA buffer, lysates separated by SDS-PAGE and 
proteins visualized by western blotting using an antibody recognizing total ERK5 protein. 
Non-relevant lanes from the same gel have been removed for clarity. The shift in 
electrophoretic mobility signifies phosphorylation. Representative image of n=6 
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5.3. Discussion 
Gaseous signalling molecules s (e.g., H2S) play a pivotal role in angiogenesis (Altaany et 
al. 2013) and blood vessel formation requires a high degree of coordination associated with 
endothelial cell proliferation, migration, and differentiation (Patel-Hett and D'Amore 2011). 
Lately, the research on the roles of H2S in the homeostasis and pathogenesis of endothelial 
cells has been emphasized dramatically. Via different signalling pathways, H2S can protect 
the vascular system from onset of inflammation by inhibition or activation; including 
inhibition of p38 and nuclear factor kappa-light chain enhancer of activated B cells (NF-κB), 
or activation of HO-1 expression as well as activation of KATP and BKCa channels (Fiorucci 
et al. 2005, Zuidema et al. 2010). The endothelium also regulates angiogenesis and the 
processing of vascular remodelling. H2S orchestrates angiogenesis in the vascular system 
by inhibiting of vascular smooth muscle cell (VSMC) proliferation and phenotypic changes 
at one side, and on the other hand, it promotes endothelium replication and migration 
(Papapetropoulos et al. 2009). In vitro studies from aortic rings from CSE-KO mice have 
shown that VEGF-induced angiogenesis can be markedly repressed (Papapetropoulos et 
al. 2009). 
In the present study, it was found that H2S can activate ERK5 MAPK in the HUVEC cell line. 
The mechanism for H2S action is mainly attributed to the stimulation and phosphorylation 
of the ERK5 MAPK. It was also shown in chapter 4 (Figure 4.3) that H2S activates and 
phosphorylates ERK5 MAPK in HeLa cells in a dynamic way, which means the highest 
degree of activation was observed at 60 minutes, then the degree of activation started to 
reduce gradually from 60-90 minutes. Whether this is also the case in primary endothelial 
cells remains to be investigated. 
The finding of Moore and colleagues (Lee et al. 2011) has shown that H2S could induce a 
major effect on angiogenesis using Matrigel modulation (Papapetropoulos et al. 2009). The 
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finding that H2S promotes angiogenesis is also in agreement with the finding where ERK5 
MAPK is activated by H2S in primary endothelial cells. A new pathway downstream of 
effectors of H2S in ECs has therefore been recognized. It is well-documented that H2S can 
change the activation status of both ERK1/2 and p38 in a cell-type and stimulus-dependent 
way. In this study, it was initially described that ERK5 MAPK appears to be activated by 
H2S and the degree of activation can time-dependent in HeLa cells. While H2S did not affect 
ERK1/2 phosphorylation in transformed ECs (Papapetropoulos et al. 2009), the preliminary 
data from this study may suggest this it does activate ERK5. While more detailed 
experimentation will be necessary to address this hypothesis, this is an interesting finding. 
It has been shown that H2S activates the PI3K/AKT pathway to promote cell survival. ERK5 
activation also leads to AKT activation and the promotion of endothelial cell survival 
(Roberts et al. 2010). It is therefore possible that ERK5 activation represent the link between 
H2S signalling and the AKT-dependent anti-apoptotic signal of H2S. Future experiments will 
further investigate this potential link using a range of pharmaceutical treatments, including 
drugs modifying KATP channels and the AKT response. 
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Chapter 6 
Analysis of ERK5 phosphorylation
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6. Analysis of ERK5 phosphorylation
6.1. Introduction 
Activation of ERK5 requires a dual phosphorylation of the TEY motif by upstream, activated 
MEK5 (MAPK kinase) in response to EGF stimulation or different stresses. Thereafter, 
active ERK5 is phosphorylated at its C-terminal tail, which results in generating a series of 
events including: (1) segregation of the ERK5-Cdc37 complex from the cytosolic anchor 
Hsp90; (2) conformational changes in the ERK5 molecule, where the NLS motif is exposed; 
and (3) translocation to the nucleus (Gomez et al. 2016). 
ERK5 is a member of the MAPK family whose N-terminal domain is similar to the 
prototypical ERK1/2 MAPKs, and varies in having a unique C-terminal domain that is not 
present in other MAPK family (Nishimoto and Nishida 2006). This C-terminal domain has 
two proline rich regions that control the nucleo-cytoplasmic trafficking of ERK5, and shares 
no known predominant features with other proteins (Buschbeck and Ullrich 2005, Borges et 
al. 2007). Furthermore, this region has the ability to activate the transcription of a number 
of genes (e.g., c-Myc, Sap1a, c-Fos, Fra-1 and MEF2 family members) due to the presence 
of transcriptional activation domain (Kasler et al. 2000). It has been reported recently that 
the C-terminal region may undergo autophosphorylation and this phenomenon is important 
to regulate gene expression and promote the AP-1 activity (Morimoto et al. 2007). Deletion 
of the C-terminal coding region of the ERK5 gene, beyond the codon for amino acid 699, 
enhance the retention of ERK5 in the nucleus, and this grants resistance to death receptor-
induced apoptosis (Diaz-Rodriguez and Pandiella 2010). However, the exact molecular 
pathways regulating activity of the transcriptional activation of the ERK5 C-terminal region 
remains unclear (Morimoto et al. 2007). 
Using purified recombinant active ERK5 it has been shown that several Thr/Ser residues 
within the C-terminal region can be autophosphorylated by ERK5, including Ser421, 
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Ser433, Ser731, Thr733 (Mody et al. 2003), Ser760, Ser764 and Ser766 (Mody et al. 2003, 
Morimoto et al. 2007). However, it has been reported that the C-terminal tail of ERK5 can 
also be phosphorylated and activated by other kinases in a MEK5-independent pathway. 
For example, ERK5 is phosphorylated during mitosis at residues Ser567, Ser720, Ser731, 
Thre733, Ser753, and Ser830 and this is thought to be ERK5 kinase-independent (Diaz-
Rodriguez and Pandiella 2010). Significantly, such phosphorylation would enhance 
migration of a kinase-inactive form of ERK5, from cytoplasm toward the nucleus resulting 
in a second pathway of ERK5 phosphorylation (Gomez et al. 2016). Phosphorylation of 
these sites has been shown to be fulfilled by cyclin-dependent kinase-1 (Diaz-Rodriguez 
and Pandiella 2010, Inesta-Vaquera et al. 2010). 
Overall, different signals work together to phosphorylate the C-terminal domain of ERK5. 
shows the known C-terminal phosphorylation sites of ERK5, whose phosphorylation can 
result in nuclear translocation and activation of transcription by ERK5. Therefore, it can be 
inferred that ERK5 C-terminal phosphorylation can be classified into two major 
mechanisms. A MEK5-dependent mechanism would exemplify one pathway that combines 
signals such as growth factors (EGF) and oxidative and osmotic stresses to activate the 
MEK5-ERK5 pathway. However, phosphorylation of the C-terminus of ERK5 can also 
proceed by other kinase (e.g., CDK1), which induces ERK5-mediated activation of 
transcription as well as nuclear translocation, without implementing ERK5 kinase activity 
(Gomez et al. 2016). 
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Table 6.1: Known C-terminal phosphorylation sites of ERK5. 
List of published known C-terminal phosphorylation sites of ERK5. For better comparison, the 
position of phosphorylation is given relative to the human protein [the position for the 
homologous residues vary slightly for the mouse protein (Morimoto et al. 2007)]. The published 
article and a brief description of the involved methodology is also given. 
Phosphorylation sites 




 Ser 731/Thr 733
 Ser 803














Mutagenesis of potential 
phosphorylation sites 
(COS7 and NIH3T3 
cells) 























(isogenic HeLa cell lines) 
(Pearson et al. 2020) 
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6.2. Results 
6.2.1. Analysis of ERK5 phosphorylation by mass spectrometry 
The changes in ERK5 phosphorylation are still incompletely understood. While it is clear 
that the TEY motif is phosphorylated by MEK5 upon pathway activation, the phosphorylation 
of the C-terminus is not well understood. Which specific residues become phosphorylated 
under which environmental conditions needs further investigation, particularly in endothelial 
cells. To enable such studies the aim was to identify the residues that are phosphorylated 
upon ERK5 stimulation and to establish a method to monitor the phosphorylation of those 
sites. The best method to unambiguously identify specific phosphorylation events is using 
mass spectrometry. To test and establish this method, ERK5 protein was produced in HeLa 
cells to yield a sufficient quantity of ERK5 to perform the analyses. 
6.2.1.1. Overexpression and purification of ERK5 
To obtain sufficient material for the mass spectrometric analyses of ERK5, 20 p100 dishes 
of HeLa cells were transduced with an adenovirus expressing Flag-tagged wildtype ERK5. 
After two days, the cells were lysed with RIPA buffer. ERK5 was immunoprecipitated with 
an anti-FLAG antibody coupled to agarose beads, . After separation on a 7% SDS 
polyacrylamide gel, ERK5 was visualised by staining with colloidal Coomassie. This 
protocol resulted in the purification of a substantial quantity of ERK5 (Figure 6.1). In addition, 
three bands of ERK5 were visible, corresponding to the unstimulated (inactive) ERK5 (lower 
band) as well as to the two hyperphosphorylated forms (middle and upper band) 
(Komaravolu et al. 2015). The bands were excised with a clean scalpel and sent to the 
University of Warwick for analysis by mass spectrometry. 
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Figure 6.1: Immunoprecipitation of ERK5. 
FLAG-tagged ERK5 was expressed in HeLa cells and immunoprecipitated with an 
agarose-coupled anti-FLAG antibody. Purified ERK5 was separated by SDS-PAGE and 
stained with colloidal Coomassie. In (A), the image has been enlarged to illustrate the 
three bands of ERK5 that can be identified. (B) shows the whole gel to allow an estimate 
of protein purity. M = molecular weight standard. Representative image of n=4 
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6.2.1.2. Mass spectrometric analysis of ERK5 
The mass spectrometric analyses of the resulting tryptic peptides from the three individually 
investigated bands identified 29.5% of the total ERK5 protein between the samples (Figure 
6.2). Unfortunately, no phosphorylation sites could be identified. Close inspection of the 
ERK5 sequence reveals that most known ERK5 phosphorylation sites are in tryptic peptides 
that have not been identified by the MS analysis of any of the three bands (in either 
phosphorylated or non-phosphorylated form), including the most abundant lower band, 
indicating that this result is not due to limited sample quantities (see underlined residues in 
Figure 6.2). A potential reason for this lies in the distribution of the cleavage sites for trypsin. 
Table 2.1 shows all theoretical peptides arising from the digestion of ERK5 with trypsin. 11 
of these peptides are larger than 2 kDa and are likely to be missed by mass spectrometry. 
Indeed, the largest peptide comprises 145 amino acids and has a theoretical MW of almost 
14 kDa. The majority of the known C-terminal phosphorylation sites are located within this 
peptide, which is the likely reason that no phosphorylations could not be identified. 
To overcome the problem with limited tryptic digestion sites, the ERK5 sequence was 
inspected for other options regarding proteolytic cleavage. Unfortunately, cleavage sites for 
common enzymes such as GluV8 or AspN were also mostly absent within the larger tryptic 
peptides. The ERK5 protein was therefore digested with chymotrypsin, which cleaves 
proteins at the following amino acids: Trp, Tyr and Phe (high specificity) and also at Leu, 
Met and His (low specificity). ERK5 digested with chymotrypsin was then subjected to mass 
spectrometry as before. While cleavage with chymotrypsin is relatively unspecific and often 
results in excessive cleavage, several peptides could be identified with an overall protein 
coverage of 17.6% (Figure 6.3). This included 10.4% of ERK5 that was not detected in the 
tryptic digest, resulting in a total ERK5 coverage of 39.9%. Nevertheless, while Y220 (of the 
TEY motif) was shown to be phosphorylated in all samples (red residue in Figure 6.3), none 
of the C-terminal phosphorylation sites were identified. As above, this is unlikely due to 
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limited sample quantity, as most of the corresponding peptides (even in the 
unphosphorylated form) were still not detected in the most abundant lower band (Figure 
6.4). 
 
Overall, these experiments demonstrate that a comprehensive mapping of ERK5 
phosphorylation by mass spectrometry is very challenging and may not be possible with 

















Figure 6.2: Tryptic ERK5 peptides identified by mass spectroscopy 
The entire amino acids comprising the ERK5 protein is shown (full peptide sequence of 
ERK5). The highlighted yellow boxes represent the resulting peptides that were 
recognized by mass-spectrometry analysis, which it turns to comprise about 29.5% of the 
total ERK5 protein. The possible proteolytic cleavage sites for trypsin enzyme have been 
highlighted in the bolded letters of the peptide sequencing. Known phosphorylation sites 








Table 6.2: Theoretical peptides arising from the digestion of ERK5 with trypsin 



























258 APELMLSLHEYTQAIDLWSVGCIFGEMLAR 30 3394.966 
160 SVYVVLDLMESDLHQIIHSSQPLTLEHVR 29 3359.845 
73 SFDVTFDVGDEYEIIETIGNGAYGVVSSAR 30 3211.443 
293 NYVHQLQLIMMVLGTPSPAVIQAVGAER 28 3036.601 
369 YHDPDDEPDCAPPFDFAFDR 20 2369.46 
225 GLCTSPAEHQYFMTEYVATR 20 2304.577
816 EIQMDSPMLLADLPDLQDP  19 2141.436 
566 GAGASGGPSTDPLAGLVLSDNDR 23 2127.252 
197 DLKPSNLLVNENCELK 16 1829.098 
735 SQVEDPLPPVFSGTPK 16 1697.906
318 QPVPWETVYPGADR 14 1614.778 
22 EEDGEDGSAEPPGPVK 16 1612.624 
131 DILRPTVPYGEFK 13 1534.775 
391 EAIVAEIEDFHAR 13 1499.643 
505 DGPSAPLEAPEPR 13 1335.436
97 IPNAFDVVTNAK 12 1288.466 
181 YMHSAQVIHR 10 1241.433 
35 AEPAHTAASVAAK 13 1223.351 
168 YFLYQLLR 8 1115.34 
There are 76 cleavage sites that can be identified by trypsin enzymes. 11 peptides of these 
cleavage sites are bigger than 2 kDa, which it turns to complicate their identification by 
mass spectrometry. The largest peptide comprises 145 amino acids, having theoretically 
heavy molecular weights of almost 14 kDa, which it turns to be inferred that it is almost 
impossible to recognize this sequence by mass spectrometry. It is important to 
demonstrate that many known phosphorylation sites (highlighted in yellow) exist along 
these large peptides sequencing, whereas their identification by mass-spectrometry was 
almost unattainable.  
123 
304 AYIQSLPPR 9 1044.219 
84 LTGQQVAIK 9 957.138 
513 KPVTAQER 8 928.056 
118 HDNIIAIK 8 923.08 
476 DGAISDNTK 9 919.944 
205 IGDFGMAR 8 866.003 
326 QALSLLGR 8 857.021 
343 ISAAAALR 8 771.915 
349 HPFLAK 6 711.862 
335 FEPSAR 6 705.769 
265 QLFPGK 6 688.825 
6 MAEPLK 6 687.852 
41 NLALLK 6 670.85 
571 SLLER 5 616.715
374 EALTR 5 588.662 
400 QQIR 4 543.624 
228 WYR 3 523.592 
485 AALLK 5 514.666 
524 RRR 3 486.578 
396 EGIR 4 473.53 
574 WTR 3 461.521 
527 QER 3 431.449 
538 QER 3 431.449 
110 HFK 3 430.507 
329 MLR 3 418.555 
520 EEK 3 404.42 
480 AALK 4 401.506 
101 TLR 3 388.467 
104 ELK 3 388.464 
488 SLR 3 374.44 
107 ILK 3 372.508 
75 RR 2 330.39 
171 GLK 3 316.401 
376 ER 2 303.318 
517 ER 2 303.318 
531 ER 2 303.318 
540 ER 2 303.318 
543 ER 2 303.318 
515 QR 2 302.333 
492 LR 2 287.362 
533 EK 2 275.305 
295 VR 2 273.335 
490 SR 2 261.281 
378 IK 2 259.349 
43 AR 2 245.282 
529 AK 2 217.268 
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98 R 1 174.203 
259 R 1 174.203 
392 R 1 174.203 
521 R 1 174.203 
534 R 1 174.203 
535 R 1 174.203 
85 K 1 146.189 
467 K 1 146.189 



















The entire amino acids comprising the ERK5 protein can be identified easily through the 
outlined letters (full peptide sequence of ERK5). The highlighted regions represent the 
resulting peptides that were cleaved by chymotrypsin enzyme, and then identified by 
mass spectrometry analysis, comprising about 17.6% of the total protein. It is worthy to 
emphasize that 10.4 % of ERK5 that was not identified in the tryptic digestion, have been 
tested using the chymotrypsin digestion. In addition, Y220 was identified as a 
phosphorylated residue (red). Raw data are available in the appendix. 


























Figure 6.4: Total peptide coverage of ERK5. 
Full peptide sequence of ERK5. The highlighted gray boxes represent the resulting 
peptides that were identified after either trypsin or chymotrypsin cleavage. Total protein 
coverage is 39.9%. 
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6.2.2. Characterisation of a phosphor-specific antibody recognizing the ERK5 
C-terminus
Several residues in the C-terminus of ERK5 have been recognized to be phosphorylated, 
supposedly by autophosphorylation by activated ERK5 (Morimoto et al. 2007) (Figure 1.8). 
The aim of this section was to develop an antibody that recognises the phosphorylated C-
terminus of ERK5 to develop a new tool to detect ERK5 activation and C-terminal 
phosphorylation. As demonstrated in Chapter 3, the phosphor-specific antibodies currently 
available are of limited use for this purpose. It was therefore decided to develop a novel 
antibody recognising the phosphorylated C-terminus. The S770 site was chosen because 
it is known to be specifically phosphorylated (Gilley et al. 2012). 
6.2.2.1. Peptide design and antibody production 
The peptide was designed in collaboration with Eurogentec around the sequence of S770. 
A cysteine was added to the C-terminus to facilitate coupling to the affinity column, resulting 
in the final peptide: ac-GPQDGQAD-pS-ASL+C-nh2. The polyclonal antibodies were 
produced by Eurogentec using the Speedy anti-PTM protocol. Briefly, two rabbits were 
immunized with the peptide, intermediate control samples were taken, and the animals were 
sacrificed after 28 days. The antibodies were purified by Eurogentec using two consecutive 
affinity columns. The first column consisted of the phosphorylated peptide, with the eluate 
containing antibodies against both phosphorylated and unphosphorylated ERK5. The 
second purification step used the unmodified peptide to remove those antibodies that 
recognise the ERK5 protein but not ERK5 phosphorylated at S770, as those would be 
bound to the column. The flow-through of this step thus contained only the antibodies 
recognising phosphorylated, but not unphosphorylated, ERK5. 
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6.2.2.2. Testing of the pS770 antibody by western blotting 
Of the two antibodies obtained, the antibody with the higher affinity, based on the ELISA 
data provided from by Eurogentech, was further evaluated. First, the antibody was titrated 
to establish the dilution required for further experiments. In HeLa cells, transient transfection 
with Adenoviral Expression System containing the cDNA of wildtype ERK5 as well as a 
constitutively active MEK5, MEK5DD. Cell lysates were then separated by SDS-PAGE and 
western blots and probed with the anti-Ser770 antibody. The results shown in Figure 6.5 
demonstrate that the antibody recognised ERK5 and that the strength of the bands was 
directly proportional to the dilution of the antibody. Based on these results, the antibody was 
used at a dilution of 1:100 for subsequent experiments. 
The next step was to characterise the antibody regarding its specificity for the 
phosphorylated ERK5. For this purpose, HeLa cells were transduced with an adenovirus 
expressing wildtype ERK5. The cells then were serum starved for at least 18 hours prior to 
running the experiment. To standardize the experiment and to activate ERK5, cells were 
also transduced with a gene encoding constitutively active MEK5: MEK5DD. The cells were 
lysed and ERK5 analysed by SDS PAGE and western blotting with the pS770 antibody 
(specific for ERK5 phosphorylated at S770). The results confirm that the antibody 
recognises ERK5 (Figure 6.6). However, it became clear that this was not specific for the 
phosphorylated ERK5 (upper bands), but that the antibody also recognised ERK5 from the 
serum-starved cells, which likely represents the unphosphorylated form (lower band). 
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HeLa cells were grown and maintained in p60 dishes. The cells were transient transduced 
with Adenoviral Expression System containing the cDNA of wildtype ERK5 and a 
constitutively active MEK5 (MEK5DD) to activate ERK5. The cells then were serum-starved 
for 16 hours, washed with PBS and lysed by adding 350 μl of RIPA buffer. Proteins were 
separated on a 7% gel before western blotting with the specified antibodies. Note that the 
marker lane has been obtained through illumination with reflective light in a separate 
exposure. The pS770 antibody was specifically able to identify activated ERK5. Also, there 
were some proportionality between the strength of bands and the dilution of antibody. 
Representative image of n=4 
Figure 6.5: Detection of activated ERK5 and C-terminal phosphorylation using 
ERK5 pS770 antibody.
130 
Figure 6.6: Specificity of the pS770 ERK5 antibody (before purification). 
HeLa cells grown on 60mm plates were transduced with an Adenovirus expressing ERK5 
(left and right lanes) as well as MEK5DD (right lane only). After serum-starvation for 16 hours, 
the cells were lysed and subjected to SDS-PAGE and western blotting with the pS770 
antibody. All forms of ERK5 (non-phosphorylated and phosphorylated) are detected by the 
antibody. Representative image of n=4 
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6.2.2.3. Antibody purification and characterisation 
Based on the above results indicating that the antibody was likely not specific for the 
phosphorylated ERK5, it was decided to further purify it using an affinity column. For this 
purpose, the non-phosphorylated ERK5 peptide was coupled to agarose beads according 
to the instructions of the manufacturer (MicroLink Protein Coupling Kit, Pierce). The 
antibody was then incubated with the beads to bind the unspecific antibodies, i.e. those that 
recognize unphosphorylated ERK5. The flow-through containing the phosphor-specific 
antibodies was collected. The purified antibody was then tested again using ERK5 protein 
from HeLa cells expressing ERK5 (with or without MEK5DD) as above. The results 
demonstrate that this purified antibody does recognise ERK5 as before, but that it is now 
specific for the phosphorylated isoforms (middle and upper bands) and only weakly 
recognises the non-phosphorylated form (lower band) (Figure 6.7). 
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HeLa cells were grown and maintained in p60 dishes. The cells were transient transduced 
with Adenoviral Expression System containing the cDNA of wildtype ERK5 and a 
constitutively active MEK5 (MEK5DD). The cells then were serum-starved for 16 hours. The 
cells were washed with PBS and lysed by adding 350 μl of RIPA buffer. Proteins were 
separated on a 7% gel before western blotting with ERK5 antibodies (total α-ERK5 at 
1:1000 and purified α-pS770 at 1:100). Note that the purified antibody (right panel) 
recognises the middle and upper band, but only weakly the lower one (control lane). 
Representative image of n=3 
Figure 6.7: Characterization of the purified pS770 ERK5 antibody. 
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6.3. Discussion 
This chapter aimed at developing a method to monitor the C-terminal phosphorylation of 
ERK5. The first approach was to use mass spectrometry to monitor C-terminal 
phosphorylation. ERK5 was successfully purified and the three differentially phosphorylated 
bands were isolated (Figure 6.1). This method did specifically identify the ERK5 protein 
within all three bands (Figure 6.4). It has also detected phosphorylation of Y220, one of the 
activating phosphorylation sites within the activation loop of ERK5 (Figure 6.3). However, 
no C-terminal phosphorylation sites were identified. This is most likely due to the absence 
of suitable trypsin recognition sites within the C-terminus of ERK5. In addition, recognition 
sites for other common proteases were also absent. While it was possible to identify 
additional ERK5 peptides by using chymotrypsin, this enzyme has variable specificity 
depending on the enzymatic conditions and it did not reveal any additional C-terminal 
peptides harbouring known phosphorylation sites. While it may be possible to develop more 
sophisticated ways to fragment ERK5 that may yield usable peptides, it is clear that mass 
spectrometry will not be suitable for routine comprehensive monitoring of ERK5 
phosphorylation on a larger scale. 
 
It was therefore decided to develop a phosphor-specific antibody for one of the C-terminal 
phosphorylation sites. In this study, it was demonstrated that the activated ERK5 MAPK 
phosphorylates ERK5 at Ser770 upon transfection of the cells with a constitutively active 
form of MEK5DD. However, the role of phosphorylation at Ser770 by ERK5 remains unclear. 
There are some probabilities, where such site may encourage the nuclear translocation of 
ERK5, or promote efficient phosphorylation of ERK5 upon its binding to transcription factors. 
The results showed ERK5 phosphorylation at Ser770 using phosphor-specific antibodies. 
Interestingly, in association with phosphorylation status of the ERK5 TEY motif or ERK5 
kinase activity, ERK5 phosphorylation at Ser770 is induced. In addition to the canonical 
MEK5-dependent pathway, there is other pathway of ERK5 activation involved 
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phosphorylation of multiple serine and threonine residues in the ERK5 C-terminal by a 
cyclin-dependent kinase 1 including Ser706, Thr732, Ser753 and Ser773. These series of 
phosphorylation are significant for detention of ERK5 in the nucleus (Honda et al. 2015). 
ERK5 is the only MAPK containing a C-terminal domain that follows the kinase domain 
(Buschbeck and Ullrich 2005). In this study, the question of whether the presence of such 
phosphorylation sites along the C-terminal tail could be used to monitor ERK5 activity was 
addressed. For this reason, a specific antibody (anti-Ser770) was designed that can detect 
and bind to its correspondence amino acid in the C-terminal domain. Based on this method, 
it was clear that phosphorylation of ERK5 would be dependent on the activity of MEK5, as 
the cells were transfected with the active constitutive form of MEK5DD. This finding, besides 
demonstrating that ERK5 phosphorylation was MEK5 dependent, opened up the avenue to 
detect a specific residue involved in ERK5 C-terminal phosphorylation. In addition to what 
has been reported by two independent researching groups (Mody et al. 2003, Morimoto et 
al. 2007) that several Thr/Ser residues in the C-terminal tail would be autophosphorylated 
by ERK5, it was found here that Ser770 in the C-terminal domain could be 
autophosphorylated by active ERK5, and availed in monitoring ERK5 activity. This antibody 
represents therefore a new opportunity to evaluate ERK5 activation and has the potential 






This thesis is based on the hypothesis that H2S activates ERK5 to mediate vascular 
protection. This hypothesis is grounded on a number of observations. First, ERK5 has been 
shown to play a major role in the vascular system, for example, through the analysis of 
knock-out mice (Hayashi and Lee 2004). Secondly, ERK5 acts as a vascular protective 
factor by protecting endothelial cells from apoptosis (Roberts et al. 2010). Thirdly, H2S has 
been shown to protect vascular cells from damage and death and to enhance vascular and 
placental health (Elsey et al. 2010, Szabo and Papapetropoulos 2011). Studies using CSE 
knockout mice have also highlighted the critical role of hydrogen sulfide in angiogenesis 
and cardio-protection, with the defect discovered to occur within the endothelium. Finally, 
H2S and ERK5 signalling have both been shown to activate the AKT pro-survival pathway 
(Cai et al. 2007, Roberts et al. 2010). The aim of this thesis was therefore to investigate the 
activation of the ERK5 pathway by H2S and to initiate investigations into methods to monitor 
ERK5 MAPK activation in both human cell lines and endothelial cells. As a consequence, 
several preliminary discoveries have been revealed, which are discussed promptly. 
7.1. Development of assays to detect ERK5 activation 
The shortage in the current tools and methods to measure ERK5 activity required an 
investigation into the most reliable technique for detecting ERK5 activation within the 
context of cells. Currently, all the present methods to detect ERK5 activation in cells are 
dependent on in vitro kinase assays and phosphor-specific antibodies (Esparis-Ogando et 
al. 2002). However, there are some inconsistent data that could be produced upon using 
antibodies against phosphorylated proteins, as shown in chapter 3.2.2. Theoretically, ERK5 
activation requires dual-phosphorylation of Thr218/Tyr220 residues in the activation loop of 
the kinase domain of the ERK5 by sole upstream molecule MEK5 (Pearson et al. 2020). 
Then, numerous residues in the C-terminal domain of the ERK5 would undergo an 
autophosphorylation process resulting in enhancement of the transcriptional activity of 
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ERK5. Thus, the presence of these numerous phosphorylation sites in both kinase domain 
and the C-terminal domain of ERK5 is a unique feature (Honda et al. 2015). 
 
To test different methods to detect ERK5 MAPK activation, it was initially tested whether 
ERK5 protein could be produced in an established cell line (HEK 293) at a level that can be 
easily detected using an affordable technique (e.g., western blotting technique). Sufficient 
ERK5 levels were observed in the HEK 293 cells by western blotting using antibody directed 
against total ERK5. In addition, it was showed that EGF stimulated the intracellular 
signalling pathway by demonstrating the successful activation of ERK1/2 MAPK. Lysates 
from cells similarly treated were then used to investigate ERK5 activation. 
 
The most direct method to monitor the activation of a protein kinase is an in vitro kinase 
assay. It is also suitable for monitoring ERK5 kinase activity, but it is only valuable for a 
small sample sizing (Müller and Morrison 2002). To facilitate the identification and 
quantification of protein kinase activation, the basis of generating and exploiting phosphor-
specific antibodies against the phosphorylation sites of many pathways in different 
conditions has been proposed. For example, the activation of the ERK1/2 MAPK pathway 
can be efficiently monitored using a phosphor-specific antibody directed against the TEY 
activation motif. Unfortunately, the analogue pERK5T218/Y220 antibody directed against the 
TEY motif of ERK5 did not detect endogenous ERK5 activation (Figure 3.4). This antibody 
has been mainly used in the past to detect the activation of overexpressed ERK5 and has 
shown variable results with the detection of endogenous ERK5 (Sanchez-Fernandez et al. 
2016), which is consistent with the results presented here. In addition, pS496 and 
pS731/pT733, antibodies directed against the C-terminal phosphorylation sites were not 
efficiently able to recognize endogenous ERK5 activation too (Figure 3.5). Another 
phosphor-specific antibody tested was directed against activated MEK5, the upstream 
activator of ERK5. Unfortunately, this antibody also did not efficiently recognize endogenous 
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MEK5 (Figure 3.6). Thus, inconsistent and unreliable results are a major drawback of using 
phosphor-specific antibodies to detect endogenous ERK5 pathway activation (Kondoh et 
al. 2006). Unfortunately, it was demonstrated in this thesis that these commercial antibodies 
directed against a variety of activation sites on ERK5 and MEK5 have no efficiency in 
characterizing and analyzing the endogenous ERK5.  
ERK5 is unique among the mammalian MAPKs in that it contains a large C-terminal domain 
(Nishimoto and Nishida 2006). Upon activation of ERK5 kinase activity by MEK5, the C-
terminus of ERK5 becomes significantly hyperphosphorylated. In consequence, it has been 
shown previously that this can result in a visible electrophoretic shift under some conditions. 
It was clearly shown here that this assay succeeded in measuring and monitoring ERK5 
phosphorylation, which relates to its activity (Esparis-Ogando et al. 2002, Buschbeck and 
Ullrich 2005). The assay was optimised for better resolution for the potential ERK5 bands 
by allowing the gel to be run until the 80 kDa protein marker reached the bottom of the gel 
(note that ERK5 runs at an apparent MW of approximately 105 kDa on SDS-PAGE). In 
addition, it was determined that a 7% polyacrylamide gel gave the best resolution for the 
different ERK5 isoforms. Using this optimised assay, the lower band could be clearly 
distinguished from 2 upper bands representing the activated ERK5. It was even possible to 
detect ERK5 proteins with different degrees of phosphorylation in endothelial cells (Figure 
5.1). The efficiency of gel shift assay is tightly connected to reducing both time and cost of 
the conducted experiment. Therefore, it was decided to use this assay in the successive 
experiments to monitor ERK5 activation in both cell lines and primary cells. 
Interestingly, ERK5 activation followed a different pattern compared to ERK1/2 activation in 
the experiments presented. In HeLa cells, ERK1/2 activation was rapid and quickly returned 
to baseline activity (Figure 3.3), while ERK5 activation was delayed but lasted longer (Figure 
3.7). This demonstrates significant differences in regard to the dynamicity of the activation 
of the two different MAPK pathways. Similar results have been obtained previously in 
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endothelial cells, where ERK1/2 activation by VEGF preceded the activation of ERK5 
(Roberts et al. 2010). 
 
Overall, an efficient assay has been established to measure ERK5 activation that was able 
to truthfully reproduce ERK5 activation kinetics and that was able to efficiently detect the 
activation of endogenous ERK5. This assay was therefore used in the remainder of the 
thesis to monitor the dynamics of ERK5. 
 
7.2. Activation of the ERK5 MAPK pathway by H2S 
The present study suggests a potential activation of ERK5 MAPK by hydrogen sulfide (H2S). 
First, addition of GYY4137 (a donor of H2S) promoted a qualitative shift in the 
electrophoretic mobility of ERK5 (Figure 4.3). Secondly, translocation of the ERK5 MAPK 
from the cytoplasm to the nucleus is attained by GYY4137 stimulation (Figure 4.4). In 
addition, this study showed a similar gel shift in HUVECs, i.e. endothelial cells (Figure 5.1). 
 
The increased electrophoretic mobility of ERK5 induced by H2S followed a similar time 
course as activation by VEGF (Roberts et al. 2010). The optimum dose of GYY4137 (400 
μM) promoted ERK5 MAPK phosphorylation maximally at 60 minutes, then the degree of 
activation dropped down till the baseline at 120 minutes. This indicates that ERK5 activation 
by H2S is transient. Secondly, treatment of the cells with 400 μM of GYY4137 led to the 
translocation of the ERK5 MAPK into the nucleus. These results suggest that H2S induces 
ERK5 MAPK activation as well as its transcriptional activation function.  
 
Another interesting observation of this study was that, in contrast to stimulation by 
GYY4137, no gel shift could be observed following NaHS treatment. While this could be 
potentially related to differences in the dose required to activate ERK5 signalling, this is 
unlikely as a range of concentrations was tested for both chemicals (data not shown). A 
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more likely explanation lies in the different kinetics of H2S release by the two different 
chemicals. NaHS releases H2S almost instantly when in contact with an aqueous solution 
and H2S release stops when the chemical is exhausted, usually within 15-30 minutes. In 
contrast, it is well known that GYY4137 releases H2S over a much longer time in aqueous 
solutions. The results therefore indicate that ERK5 activation requires a sustained exposure 
to H2S rather than a temporary one. The ERK5 pathway may therefore only respond to H2S 
when the exposure is due to chronical changes in the body. 
The ERK5 MAPK pathway and its inhibitors are regulated by wide range of mitogenic stimuli 
(e.g., growth factors, G protein coupled receptor agonists, cytokines) and cellular stresses 
(e.g., hypoxia, shear stress) (Lin et al. 2016). To date, it has been found that, in cultured rat 
aortic vascular smooth muscle cells, NaHS (sodium hydrogen sulphide) can inhibit an 
endothelin-provoked rise in p38 MAPK activity, yet upregulation in p38 MAPK activity can 
be attained in cultured human umbilical vein cells, where stimulation of angiogenesis was 
associated with these effects (Li et al. 2011). In summary, H2S-induced cell proliferation and 
angiogenesis may be (partly) mediated by the activation of ERK5 MAPK pathway, leading 
to upregulation of phosphorylated ERK5 MAPK.  
While this study indicates that H2S may activate the ERK5 pathway in endothelial cells, the 
exact mechanism of activation ERK5 MAPK in human umbilical vein endothelial cells 
(HUVECs) by H2S is unclear. However, it has been reported in other studies that H2S 
actions may be due to KATP channel opening. Expression of KATP channels in endothelial 
cells occurs in the plasma membrane and in intracellular organelles. Inhibition of KATP 
channels by glibenclamide or 5-HD may attribute to block the migratory response to H2S. In 
addition, a concentration-dependent migratory response in endothelial cells can be induced 
by incubation of cells with the KATP channel opener SG209, where K+ efflux per se can 
control EC motility (Umaru et al. 2015). 
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It is established that angiogenic responses to VEGF are essential under both normal and 
pathophysiological conditions (Felmeden et al. 2003). Since inhibition of VEGF-stimulated 
angiogenic properties of endothelial cells can be acquired by the CSE inhibitor PAG or by 
CSE silencing, this observation suggests that exposure of endothelial cells to VEGF 
enhances H2S release (Asimakopoulou et al. 2013). Indeed, it has been shown in a previous 
study that the output of H2S would be increased upon incubation of human ECs with VEGF 
(Katsouda et al. 2018). Combined with the observation that ERK5 stimulates angiogenesis 
(Roberts et al. 2010), the ERK5 MAPK pathway may be mediating at least some of the 
effects of VEGF on endothelial cell survival as well as angiogenesis through H2S. 
If further experiments support the hypothesis that H2S activates ERK5 MAPK, two novel 
hypothesis could be inferred (a) ERK5 MAPK activation by H2S in primary endothelial cells 
could be a useful model in diseases states associated with poor diagnosis of reducing 
angiogenesis (e.g., pre-eclampsia) and (b) stimulation of endogenous ERK5 activation may 
be a useful target in conditions of pathological angiogenesis, particularly under conditions 
of deficiencies of H2S release. 
7.3. C-Terminal phosphorylation of ERK5 
It is well established that the residues Threonine 218 and Tyrosine 220 in the activation loop 
of the ERK5 kinase domain may undergo dual phosphorylation by the upstream, activated 
MEK5 in response to some growth factors, cytokines and stressing events (Drew et al. 
2012). However, in order to understand the mechanisms involved in ERK5 activation, 
particularly in endothelial cells, it was necessary to be able to evaluate the C-terminal 
phosphorylation of ERK5. This is important as this mechanism leads to the translocation of 
ERK5 to the nucleus and the activation of transcription of genes downstream of ERK5. The 
aim was therefore to monitor some residues in the C-terminal domain of the ERK5 that may 
undergo phosphorylation upon ERK5 stimulation. 
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Arguably, the best way to identify those phosphorylation sites is to use the mass-
spectrometry (Mody et al. 2003). For this reason, mass-spectrometry was applied to 
recognize those phosphorylation sites in the ERK5 (especially those that reside in the C-
terminal domain). In order to do this the ERK5 protein was over-produced in HeLa cells, 
resulting in an optimum quantity to be analyzed. In order to precipitate the ERK5 in the cell 
lysate, the immunoprecipitation technique was performed using an antibody against ERK5 
coupled to agarose beads. Three bands were obtained after Coomassie staining, where the 
lower band corresponding to the inactive ERK5, and the upper two bands corresponding to 
the activated one. The two upper bands likely have different degrees of C-terminal 
phoshporylation. In general, the mass spectrometry analysis of the resulting peptides tested 
using two different enzymes, trypsin and chymotrypsin, cleaving the ERK5 sequence 
between the sample into many short peptides. The overall ERK5 sequence identified by 
mass spectrometry was about 39.9% of the total ERK5 protein. Unfortunately, no 
phosphorylation sites apart from Y220 could be identified. Indeed, the distribution of the 
cleavage sites for trypsin was the major problem. The majority of the predicted 
phosphorylation sites are located within very large tryptic (and chymotryptic) fragments that 
were not suitable for analysis by mass spectrometry. In addition, other fragmentation 
techniques such as chemical treatment (e.g., CnBr) are less reliable and in silico digestions 
using PeptideCutter (Expasy) indicate that the resulting fragments would still be problematic 
for mass spectrometric analyses. Overall, it can be inferred from the previous examples that 
the process of comprehensive mapping of ERK5 by mass spectrometry is challenging. 
 
This thesis demonstrated that there are some limitation in using commercial antibodies 
(phosphor-specific antibodies) to measure and monitor ERK5 activation, but it was the only 
way for the experimental purpose to develop a novel phosphor-specific antibody that may 
recognize and bind to some phosphorylation sites on the C-terminal, and test its efficiency. 
The S770 site was used as it has been shown in the literature that it is one of the known 
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phosphorylation sites on the C-terminal that has not been investigated much yet (Gilley et 
al. 2012). To design and develop this antibody (anti-serine p770), a well-documented 
protocol was followed in collaboration with Eurogentec to fulfil this mission. The results in 
this thesis demonstrate that the antibody recognizes ERK5 effectively. However, to 
specifically recognize only the phosphorylated form, it was necessary to further purify the 
antibody using an affinity column. After purification, the anti-phospho Ser770 selectively 
recognized the upper (phosphorylated) bands with only weak detection of the lower band 
(Figure 6.7). However, it would be useful for further research to implement in vitro kinase 
assays using E.coli purified recombinant ERK5 (where it should not be phosphorylated) to 
unambiguously show whether this antibody does or does not recognize the non-
phosphorylated form. Indeed, it might be interesting for further studies to rule out the fact 
that the lower band might be phosphorylated. The final conclusion obtained from the result 
using the purified antibody has showed evidently that the phosphorylated site (S770) 
located on the C-terminal could be clearly identified and used to monitor ERK5 
phosphorylation. This antibody will be valuable to analyse the C-terminal phosphorylation 
of ERK5 in response to H2S in endothelial cells in the future. 
7.4. Conclusion 
Overall, this thesis has shown that an optimised gel shift assay is well suited to monitor 
ERK5 dynamics in different cell types, including endothelial cells. In addition, it was shown 
that H2S may activate ERK5 in HeLa and endothelial cells, which will be the subject of 
further studies. Finally, a new antibody was developed that recognizes ERK5 C-terminal 
phosphorylation that will be used in the future to monitor ERK5 dynamics. 
Using these tools will enable more detailed studies to define the role of ERK5 in human 
disease as well as investigating signalling crosstalk between different MAPK pathways. 
Ultimately we expect that this will unravel a key role for ERK5 as a viable target for 
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therapeutic intervention particularly in diseases associated with deficient angiogenesis, for 
example preeclampsia, and in targeting cancer. 
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9. Appendix: Mass spectrometry raw data







Charge Delta Da Delta PPM 
Retention 
Time 
Intensity TIC Start 
(K)AEPAHTAASVAA
K(N)
100% 102.95 612.3226 35 1,222.63 2 0.000038 0.03105 19.206 1.22E+07 14,085.60 23 
(K)AEPAHTAASVAA
K(N)
100% 86.189 612.3226 35 1,222.63 2 0.000038 0.03105 19.635 1.22E+07 13,872.90 23 
(R)RRLTGQQVAIK(
K)
100% 85.958 423.9298 84 1,268.77 3 -0.000178 -0.1402 20.493 2888200 18,103.30 74 
(R)RLTGQQVAIK(K
)
100% 96.665 557.3406 84 1,112.67 2 -0.000182 -0.1634 22.435 2.06E+07 7,134.87 75 
(R)RLTGQQVAIKK(
I)
100% 139.38 621.3881 85 1,240.76 2 -0.000222 -0.1788 19.908 5412400 12,579.90 75 
(R)RLTGQQVAIKK(
I)
100% 97.452 414.5945 85 1,240.76 3 -0.000218 -0.1756 19.924 4594500 22,094.20 75 
(R)LTGQQVAIKK(I
)
100% 155 543.3375 85 1,084.66 2 -0.000222 -0.2045 21.082 1.72E+07 86,667.90 76 
(K)KIPNAFDVVTNA
K(R)
100% 127.83 708.8959 97 1,415.78 2 -0.000102 -0.07199 36.084 3721900 6,408.30 85 
(K)KIPNAFDVVTNA
K(R)
100% 116.84 708.8959 97 1,415.78 2 -0.000102 -0.07199 36.507 3721900 3,434.66 85 
(K)KIPNAFDVVTNA
KR(T)
100% 122.66 524.9667 98 1,571.88 3 -0.000108 -0.06866 32.478 1768200 6,223.29 85 
(K)KIPNAFDVVTNA
KR(T)
100% 87.184 786.9465 98 1,571.88 2 -0.000102 -0.06485 32.874 341990 1,324.75 85 
(K)KIPNAFDVVTNA
KR(T)




































512.2803 131 1,533.82 3 -0.000238 -0.1551 40.761 537180 3,556.46 119 
(R)YFLYQLLR(G) 99% 84.359 
 
558.316 168 1,114.62 2 -0.000062 -0.05557 50.192 274760 2,832.09 161 
(R)GLKYmHSAQVIH
R(D) 
99% 72.652 Oxidation 
(+16) 





621.314 181 1,240.61 2 0.000038 0.03061 20.729 3499400 7,027.24 172 
(K)YmHSAQVIHR(D
) 
100% 120.45 Oxidation 
(+16) 
419.8768 181 1,256.61 3 0.00003699 0.02941 18.983 3654500 25,181.70 172 
(K)YmHSAQVIHR(D
) 
100% 93.143 Oxidation 
(+16) 
629.3115 181 1,256.61 2 0.00004299 0.03418 18.948 
 
8,100.79 172 
(K)IGDFGMAR(G) 99% 134.66 
 



















97% 59.426 750.3781 391 1,498.74 2 -0.000062 -0.04134 41.301 99,111.00 1,084.43 379 
(R)REGIRQQIR(F) 99% 75.043 385.895 400 1,154.66 3 -0.000138 -0.1194 18.825 455170 5,481.29 392 
(R)EGIRQQIR(F) 99% 138.37 500.2883 400 998.5621 2 -0.000142 -0.1421 20.351 3.64E+07 9,469.55 393 
(K)AALKAALLK(S) 100% 113.89 449.8078 485 897.6011 2 -0.000122 -0.1358 26.87 1208000 7,480.71 477 
(R)SRLRDGPSAPLE
APEPR(K)
98% 62.528 924.4898 505 1,846.97 2 -0.000202 -0.1093 26.034 363560 2,030.42 489 
(R)SRLRDGPSAPLE
APEPR(K)
97% 71.286 616.6623 505 1,846.97 3 -0.000218 -0.118 25.977 1627300 3,822.94 489 
(R)LRDGPSAPLEAP
EPR(K)
98% 70.332 802.9232 505 1,603.83 2 -0.000242 -0.1508 29.311 1295400 3,318.44 491 
(R)DGPSAPLEAPEP
R(K)
100% 129.88 668.3306 505 1,334.65 2 -0.000222 -0.1662 32.636 4.99E+07 18,706.30 493 
(R)DGPSAPLEAPEP
R(K)
100% 108.31 668.3306 505 1,334.65 2 -0.000222 -0.1662 34.937 1181100 8,716.26 493 
Trypsin lower (Experiment 2) 









Intensity TIC Start 




2 10 0.00009129 0.08665 20.238 12,675.40 2 
(R)SGGGFSSGSAGI
INYQR(R)
100% 223.08 829.4001 1,656.
79 












100% 123.26 642.7894 1,283.
56 
2 65 -0.000262 -0.204 28.307 2017500 19,676.30 50
(G)GGGGSFGAGGGF
GSR(S)
100% 92.943 614.2787 1,226.
54 
2 65 -0.000222 -0.1808 28.342 590910 10,614.20 51
(R)SLVNLGGSKSIS
ISVAR(G)
100% 112.91 563.3282 1,686.
96 
3 82 -0.000038 -0.02251 36.629 329460 8,852.13 66
(R)SLVNLGGSKSIS
ISVAR(G)
99% 82.908 844.4887 1,686.
96 
2 82 -0.000042 -0.02488 36.609 317260 3,285.96 66
(L)GGSKSISISVAR
(G)
100% 112.36 581.3329 1,160.
65 
2 82 -0.000042 -0.03616 24.353 446050 7,177.60 71
(K)SLNNQFASFIDK
VR(F)
100% 102.33 546.9581 1,637.
85 
3 199 -0.000008 -
0.004
881 
42.471 248130 7,524.24 186
(R)FLEQQNQVLQTK
(W)
100% 182.46 738.3963 1,474.
78 
2 211 -0.000182 -0.1233 31.692 8705600 10,318.50 200
(R)NKYEDEINKR(T
)
100% 183.72 654.8308 1,307.
65 
2 277 -0.000082 -0.06266 19.98 2963300 38,111.80 268
(R)NKYEDEINKR(T
)
100% 140.78 436.8896 1,307.
65 
3 277 -0.000098 -0.07489 19.987 2213800 34,496.60 268
(N)KYEDEINKR(T) 100% 131.62 398.8753 1,193.
60 
3 277 -0.000128 -0.1071 18.236 4349900 50,244.40 269
(K)YEDEINKR(T) 99% 124.59 533.7618 1,065.
51 
2 277 -0.000082 -0.07689 18.954 2400000 65,138.80 270
(R)TNAENEFVTIK(
K)
100% 139.43 633.3222 1,264.
63 
2 288 -0.000042 -0.03318 32.812 3950100 12,396.70 278
(R)TNAENEFVTIKK
(D)
100% 208.15 697.3697 1,392.
72 
2 289 -0.000082 -0.05883 26.694 9986200 32,100.50 278
(R)TNAENEFVTIKK
(D)
100% 166.11 465.2489 1,392.
72 
3 289 -0.000068 -0.04879 26.723 3372300 44,039.90 278
(K)KDVDGAYMTK(V
)
100% 132.25 564.2737 1,126.
53 















2 311 -0.000282 -0.1863 37.47 589280 5,434.65 299 
(E)LSQmQTQISE(T
) 




2 332 -0.000137 -0.1161 26.376 3675500 17,823.90 323 
(E)TNVILSmDNNR(
S) 
































2 376 -0.000002 -
0.001
492 







2 379 -0.000002 -
0.001
135 







2 376 -0.000002 -
0.001
777 














2 379 -0.000002 -
0.001
485 









































































2 84 -0.000182 -0.1634 3,252.48 2.66E+07 133076 75 




2 84 -0.000182 -0.1901 3,245.88 6.14E+07 94,829.20 76 




2 84 -0.000182 -0.1901 1,454.58 1480500 3,910.66 76 




2 205 -0.000142 -0.1639 3,288.60 3.15E+07 159314 198 




2 205 -0.000142 -0.1639 3,263.10 3.15E+07 177934 198 
176 




2 326 -0.000122 -0.1423 3,282.36 5.77E+07 488397 319 




2 343 0.000018 0.0233 3,274.20 1.38E+08 929069 336 












































































2 505 -0.000222 -0.1662 3,271.32 3.27E+08 798500 493 




2 513 -0.000082 -0.08831 3,269.82 2.86E+08 1279030 506 









































2 735 -0.000262 -0.1543 3,325.08 1.15E+07 31,253.90 720 
 
Trypsin middle 






























2 84 -0.000182 -0.1634 1,324.38 
 
97,102.60 75 




2 84 -0.000182 -0.1901 1,452.48 6.41E+07 30,016.90 76 
























99% 113.69 708.8959 1,415.
78 
2 97 -0.000102 -0.07199 2,259.96 2008200 13,547.80 85
(K)KIPNAFDVVTNA
KR(T)
100% 117.48 524.9667 1,571.
88 
3 98 -0.000108 -0.06866 2,266.56 16,952.00 85 
(K)KIPNAFDVVTNA
KR(T)
99% 109.07 524.9667 1,571.
88 
3 98 -0.000108 -0.06866 2,204.10 16,686.10 85 
(K)KIPNAFDVVTNA
KR(T)
99% 108.58 524.9667 1,571.
88 
3 98 -0.000108 -0.06866 2,177.52 15,302.20 85 
(K)IPNAFDVVTNAK
(R)
100% 144.55 644.8484 1,287.
68 
2 97 -0.000062 -0.04811 2,415.48 6203200 30,868.20 86
(K)IPNAFDVVTNAK
(R)
100% 125.68 644.8484 1,287.
68 
2 97 -0.000062 -0.04811 2,455.44 6203200 16,919.20 86
(K)IPNAFDVVTNAK
(R)
100% 115.7 644.8484 1,287.
68 
2 97 -0.000062 -0.04811 2,442.24 6203200 25,694.50 86
(K)IPNAFDVVTNAK
(R)
99% 107.45 644.8484 1,287.
68 
2 97 -0.000062 -0.04811 2,389.74 6203200 11,820.70 86
(K)IPNAFDVVTNAK
R(T)
99% 109.15 482.2684 1,443.
78 
3 98 -0.000068 -0.04707 2,218.26 20,946.00 86 
(K)IPNAFDVVTNAK
R(T)
96% 102.33 482.2684 1,443.
78 
3 98 -0.000068 -0.04707 2,105.58 25,123.20 86 
(K)YmHSAQVIHR(D
)




2 181 0.00004299 0.03418 1,125.12 1097100 12,029.90 172
(K)IGDFGMAR(G) 99% 179.16 433.7131 865.41
16 
2 205 -0.000142 -0.1639 1,920.42 2.11E+07 24,947.90 198
(K)IGDFGMAR(G) 99% 185.22 433.7131 865.41
16 
2 205 -0.000142 -0.1639 1,894.92 2.11E+07 62,174.20 198
(K)IGDFGMAR(G) 99% 98.418 433.7131 865.41
16 
2 205 -0.000142 -0.1639 1,869.60 2.11E+07 16,146.60 198
(R)AYIQSLPPR(Q) 99% 111.01 522.7955 1,043.
58 
2 304 -0.000082 -0.0785 1,875.30 15,953.30 296 
179 




2 304 -0.000082 -0.0785 1,936.98 
 
15,979.50 296 




2 304 -0.000082 -0.0785 1,835.10 1747000 17,482.40 296 




















2 318 -0.000162 -0.1003 2,538.24 2184500 7,452.46 305 




2 326 -0.000122 -0.1423 2,116.68 2.66E+07 157101 319 




2 326 -0.000122 -0.1423 2,091.24 2.66E+07 129823 319 




2 335 -0.000022 -0.01988 1,971.12 6990500 40,792.90 327 




2 335 -0.000022 -0.01988 1,919.88 6990500 46,406.00 327 




2 335 -0.000022 -0.01988 1,758.42 2.06E+07 54,154.60 327 




2 335 -0.000022 -0.01988 1,869.12 
 
50,659.40 327 




2 335 -0.000022 -0.01988 1,945.74 6990500 44,723.10 327 




2 335 -0.000022 -0.01988 1,996.32 6990500 34,713.30 327 




2 335 -0.000022 -0.01988 1,894.38 6990500 47,134.20 327 












2 335 -0.000022 -0.01988 2,046.84 6990500 25,813.70 327 




2 335 -0.000022 -0.01988 2,072.34 6990500 23,697.40 327 




2 335 -0.000022 -0.01988 1,707.06 2.06E+07 60,523.50 327 




2 335 -0.000022 -0.01988 1,672.92 2.06E+07 96,325.50 327 




2 335 -0.000022 -0.01988 1,732.32 2.06E+07 66,010.40 327 




2 335 -0.000022 -0.01988 1,811.22 
 
72,111.60 327 




2 343 0.000018 0.0233 1,546.56 8.48E+07 24,120.90 336 




2 343 0.000018 0.0233 1,572.36 8.48E+07 51,590.00 336 







































3 480 -0.000218 -0.1672 1,391.28 5300900 16,986.60 468 




2 485 -0.000122 -0.1358 1,575.24 7841400 14,308.70 477 
181 










































































































99% 102.72 616.6623 1,846.
97 
3 505 -0.000218 -0.118 1,706.58 7372300 46,311.40 489
(R)SRLRDGPSAPLE
APEPR(K)
98% 104.24 924.4898 1,846.
97 
2 505 -0.000202 -0.1093 1,624.92 6482800 10,256.70 489
(R)SRLRDGPSAPLE
APEPR(K)
98% 95.273 924.4898 1,846.
97 
2 505 -0.000202 -0.1093 1,830.84 3738000 16,237.70 489
(R)SRLRDGPSAPLE
APEPR(K)
97% 108.14 616.6623 1,846.
97 
3 505 -0.000218 -0.118 1,908.90 71,116.10 489 
(R)SRLRDGPSAPLE
APEPR(K)
97% 92.295 924.4898 1,846.
97 
2 505 -0.000202 -0.1093 1,650.78 6482800 9,791.89 489
(R)SRLRDGPSAPLE
APEPR(K)
95% 77.894 924.4898 1,846.
97 
2 505 -0.000202 -0.1093 1,805.70 3738000 13,858.20 489
(R)LRDGPSAPLEAP
EPR(K)
96% 117.93 802.9232 1,603.
83 




99% 114.34 804.7298 2,411.
17 




99% 111.3 804.7298 2,411.
17 




96% 104.77 804.7298 2,411.
17 




100% 134.58 709.6819 2,126.
02 




100% 129.77 709.6819 2,126.
02 





100% 130.47 1,064.02 2,126.
02 




100% 121.47 709.6819 2,126.
02 




100% 139.64 1,064.02 2,126.
02 




100% 123.63 1,064.02 2,126.
02 




100% 122.33 1,064.02 2,126.
02 




100% 119.56 1,064.02 2,126.
02 




100% 184 1,064.02 2,126.
02 




100% 117.37 1,064.02 2,126.
02 




99% 108.12 709.6819 2,126.
02 




98% 108.25 709.6819 2,126.
02 




100% 168.82 849.4409 1,696.
87 
2 735 -0.000262 -0.1543 2,629.32 1.31E+08 101123 720
(K)SQVEDPLPPVFS
GTPK(G)
100% 177.42 849.4409 1,696.
87 
2 735 -0.000262 -0.1543 2,552.64 1.31E+08 11,567.30 720
(K)SQVEDPLPPVFS
GTPK(G)
100% 172.76 849.4409 1,696.
87 
2 735 -0.000262 -0.1543 2,577.78 1.31E+08 448601 720
(K)SQVEDPLPPVFS
GTPK(G)
100% 120.6 849.4409 1,696.
87 
2 735 -0.000262 -0.1543 2,761.50 986320 7,719.61 720
(K)SQVEDPLPPVFS
GTPK(G)
100% 198.97 849.4409 1,696.
87 
2 735 -0.000262 -0.1543 2,603.58 1.31E+08 193656 720
(K)SQVEDPLPPVFS
GTPK(G)
100% 113.95 849.4409 1,696.
87 
2 735 -0.000262 -0.1543 2,668.98 1.31E+08 55,368.60 720
(K)SQVEDPLPPVFS
GTPK(G)
99% 122.18 849.4409 1,696.
87 
2 735 -0.000262 -0.1543 2,643.84 1.31E+08 120640 720
(K)SQVEDPLPPVFS
GTPK(G)
99% 120.55 849.4409 1,696.
87 
2 735 -0.000262 -0.1543 2,684.28 1.31E+08 34,146.10 720
Trypsin upper 








Intensity TIC Start 
(K)AEPAHTAASVAA
K(N)
100% 118.03 612.3226 1,222.6
3 
2 35 0.000038 0.03105 2,662.74 3318800 21,453.00 23
(R)LTGQQVAIK(K) 100% 138.24 479.29 956.565
5 
2 84 -0.000182 -0.1901 2,373.72 1122700 14,113.20 76
(R)LTGQQVAIK(K) 100% 129.68 479.29 956.565
5 
2 84 -0.000182 -0.1901 2,348.34 1122700 11,750.90 76
(R)LTGQQVAIK(K) 100% 115.46 479.29 956.565
5 
2 84 -0.000182 -0.1901 2,477.04 923050 17,972.90 76
(R)LTGQQVAIK(K) 100% 117.16 479.782 957.549
5 
2 84 0.9838 -19.73 
(+1








(R)LTGQQVAIK(K) 100% 115.46 479.29 56.5655 2 84 -0.000182 -0.1901 2,151.06 10,019.70 76 
(R)LTGQQVAIK(K) 100% 111.65 479.29 956.565
5 
2 84 -0.000182 -0.1901 2,247.30 12,572.90 76 
(R)LTGQQVAIK(K) 100% 108.09 479.29 956.565
5 
2 84 -0.000182 -0.1901 2,297.76 8,327.39 76 
(R)LTGQQVAIK(K) 100% 107.59 479.29 956.565
5 
2 84 -0.000182 -0.1901 2,323.02 612460 9,227.60 76
(R)LTGQQVAIK(K) 97% 96.19 479.29 956.565
5 
2 84 -0.000182 -0.1901 2,527.86 13,038.70 76 
(R)LTGQQVAIK(K) 96% 93.143 479.29 956.565
5 
2 84 -0.000182 -0.1901 2,502.54 15,632.00 76 
(R)LTGQQVAIK(K) 96% 101.28 479.29 956.565
5 
2 84 -0.000182 -0.1901 2,553.42 12,856.00 76 
(R)LTGQQVAIKK(I
)
100% 141.52 543.3375 1,084.6
6 
2 85 -0.000222 -0.2045 1,223.28 3662100 20,145.20 76
(K)IGDFGMAR(G) 99% 128.86 433.7131 865.411
6 
2 205 -0.000142 -0.1639 2,755.38 26,754.10 198 
(K)IGDFGMAR(G) 99% 157.99 433.7131 865.411
6 
2 205 -0.000142 -0.1639 2,806.32 31,068.10 198 
(K)IGDFGMAR(G) 99% 124.59 433.7131 865.411
6 
2 205 -0.000142 -0.1639 1,861.14 1329500 10,456.20 198
(K)IGDFGMAR(G) 99% 111.04 433.7131 865.411
6 
2 205 -0.000142 -0.1639 2,725.68 21,808.00 198 
(K)IGDFGMAR(G) 99% 115.46 433.7131 865.411
6 
2 205 -0.000142 -0.1639 2,781.24 27,476.60 198 
186 
(K)IGDFGMAR(G) 99% 115.46 433.7131 865.411
6 
2 205 -0.000142 -0.1639 2,701.14 19,037.60 198 
(K)IGDFGMAR(G) 99% 89.369 433.7131 865.411
6 
2 205 -0.000142 -0.1639 2,646.00 715630 18,319.70 198
(K)IGDFGMAR(G) 98% 94.662 433.7131 865.411
6 
2 205 -0.000142 -0.1639 2,771.88 1376700 26,328.10 198
(K)IGDFGMAR(G) 97% 90.777 433.7131 865.411
6 
2 205 -0.000142 -0.1639 2,729.52 23,013.30 198 
(K)IGDFGMAR(G) 95% 89.369 433.7131 865.411
6 
2 205 -0.000142 -0.1639 2,669.76 17,861.50 198 
(R)QALSLLGR(M) 99% 120.49 429.2638 856.513 2 326 -0.000122 -0.1423 2,921.94 65,351.10 319 
(R)MLRFEPSAR(I) 100% 134.48 553.7924 1,105.5
7 
2 335 -0.000022 -0.01988 3,081.96 9162100 74,011.70 327
(R)MLRFEPSAR(I) 100% 131.22 553.7924 1,105.5
7 
2 335 -0.000022 -0.01988 3,107.16 9162100 53,155.60 327
(R)MLRFEPSAR(I) 100% 139.88 553.7924 1,105.5
7 
2 335 -0.000022 -0.01988 3,056.46 9162100 68,000.60 327
(R)MLRFEPSAR(I) 100% 113.66 553.7924 1,105.5
7 
2 335 -0.000022 -0.01988 3,031.32 9162100 53,240.20 327
(R)ISAAAALR(H) 99% 128.86 386.7374 771.460
3 
2 343 0.000018 0.0233 2,571.06 38,953.90 336 
(R)ISAAAALR(H) 99% 128.38 386.7374 771.460
3 
2 343 0.000018 0.0233 1,537.50 2.62E+07 12,649.70 336
(R)ISAAAALR(H) 99% 119.56 386.7374 771.460
3 
2 343 0.000018 0.0233 2,736.48 58,537.80 336 
(R)ISAAAALR(H) 98% 108.98 386.7374 771.460
3 
2 343 0.000018 0.0233 2,647.02 55,185.40 336 
(R)ISAAAALR(H) 98% 105.2 386.7374 771.460
3 
2 343 0.000018 0.0233 2,613.72 51,122.60 336 
(R)ISAAAALR(H) 97% 108.98 386.7374 771.460
3 
2 343 0.000018 0.0233 2,584.14 39,581.90 336 
187 




2 343 0.000018 0.0233 2,264.52 948270 21,590.50 336 




2 343 0.000018 0.0233 2,621.58 
 
54,154.70 336 




2 343 0.000018 0.0233 2,490.18 2302000 35,570.00 336 




2 343 0.000018 0.0233 2,673.84 
 
49,616.10 336 




2 343 0.000018 0.0233 2,520.24 
 
45,634.80 336 




2 343 0.000018 0.0233 2,486.22 2302000 36,594.60 336 













































































2 505 -0.000222 -0.1662 1,939.74 1788000 15,443.90 493 




2 513 -0.000082 -0.08831 2,566.20 
 
32,537.80 506 




2 513 -0.000082 -0.08831 2,692.20 
 
36,902.90 506 




2 513 -0.000082 -0.08831 2,667.00 
 
36,450.70 506 




2 513 -0.000082 -0.08831 2,743.26 
 
30,025.90 506 





































2 735 -0.000262 -0.1543 2,957.58 1689300 8,695.23 720 
 
Chymotrypsin lower 






























































































2 172 -0.000182 -0.1437 2,249.88 1.29E+08 94,910.30 163 
(Y)FMTEyVATRW(Y
) 




2 226 0.00002652 0.01917 2,808.42 8.02E+07 63,205.30 217 
(Y)FMTEyVATRW(Y
) 



















2 226 0.00002652 0.01917 2,867.88 22,763.90 217 
(Y)FmTEyVATRW(Y
)






2 226 0.00003151 0.02251 2,506.80 1.87E+07 58,587.50 217




2 226 0.000006518 0.005271 2,306.52 9.68E+07 95,146.20 218






2 226 0.00001151 0.009189 2,124.54 3.57E+07 49,854.90 218
(F)MTEYVATRW(Y) 99% 118.74 578.7764 1,155.
54 
2 226 0.000018 0.01556 2,065.74 1.02E+08 136560 218






2 226 0.00001151 0.009189 2,176.92 46,407.00 218 




2 226 0.000002991 0.002551 1,916.94 2.66E+07 101160 218






2 226 0.00001151 0.009189 2,151.18 3.57E+07 38,142.90 218






2 226 0.00001151 0.009189 2,150.28 3.57E+07 37,234.20 218
(F)MTEyVATRWY(R
)















































































































































































































































2 745 -0.000182 -0.1357 1,842.90 1.79E+08 67,801.10 731 
 
Chymotrypsin middle 

















































































2 172 -0.000182 -0.1437 2,253.96 1.34E+07 79,449.90 163 
(Y)FMTEyVATRW(Y
) 














2 226 0.00003151 0.02251 2,502.12 9.06E+07 110367 217 
(Y)FMTEyVATRW(Y
) 




2 226 0.00002652 0.01917 2,807.34 3.98E+08 55,787.00 217 
(Y)FmTEyVATRW(Y
) 






2 226 0.00003151 0.02251 2,646.66 4.67E+07 54,807.60 217 
(Y)FmTEyVATRW(Y
) 






2 226 0.00003151 0.02251 2,568.24 4.67E+07 37,754.90 217 
(Y)FMTEyVATRW(Y
) 




2 226 0.00002652 0.01917 2,858.04 3.98E+08 78,446.50 217 
(Y)FmTEyVATRW(Y
) 






2 226 0.00003151 0.02251 2,594.46 4.67E+07 130910 217 
(Y)FmTEyVATRW(Y
) 













2 226 0.000018 0.01381 2,479.20 9788600 63,418.80 217 
(Y)FmTEyVATRW(Y
) 
















2 226 0.00003151 0.02251 2,674.86 41,896.60 217 
(Y)FmTEyVATRW(Y
)






2 226 0.00003151 0.02251 2,540.40 2866600 32,599.50 217
(F)MTEYVATRW(Y) 100% 130.56 578.7764 1,155.
54 
2 226 0.000018 0.01556 2,070.00 2.74E+07 147281 218




2 226 0.000006518 0.005271 2,305.02 4.97E+08 145808 218




2 226 0.000006518 0.005271 2,331.00 4.97E+08 167102 218






2 226 0.00001151 0.009189 2,158.08 1.47E+07 81,984.40 218






2 226 0.00001151 0.009189 2,132.58 1.58E+08 658446 218






2 226 0.00001151 0.009189 2,184.06 1.47E+07 80,127.40 218




2 226 0.000006518 0.005271 2,376.72 36,360.10 218 














2 239 -0.000062 -0.03823 2,366.16 8.78E+08 91,196.80 227 
(W)YRAPELmLSLHE
Y(T) 











2 239 -0.000062 -0.03823 2,395.62 8.78E+08 56,004.20 227 
(Y)RAPELmLSLHEY
(T) 











































































































































































































































































2 750 -0.000282 -0.1428 2,760.48 1.79E+07 40,065.90 731 
 
Chymotrypsin upper 


















































































2 172 -0.000182 -0.1437 2,274.72 
 
18,806.80 163 




2 172 -0.000162 -0.1635 1,744.02 8.67E+08 881887 165 
(Y)FMTEyVATRW(Y
) 




2 226 0.00002652 0.01917 2,804.22 1.27E+08 129570 217 
(Y)FMTEyVATRW(Y
) 




2 226 0.00002652 0.01917 2,829.72 1.27E+08 259594 217 
(Y)FMTEyVATRW(Y
) 

















100% 109.71 652.3106 1,302.
61 
2 226 0.000018 0.01381 2,472.72 8695200 86,260.20 217 
(Y)FMTEyVATRW(Y
)




2 226 0.00002652 0.01917 2,803.62 1.27E+08 108923 217
(Y)FmTEyVATRW(Y
)






2 226 0.00003151 0.02251 2,520.54 4.34E+07 105741 217
(Y)FmTEyVATRW(Y
)






2 226 0.00003151 0.02251 2,493.78 4.34E+07 106202 217
(Y)FmTEyVATRW(Y
)






2 226 0.00003151 0.02251 2,593.32 8534500 199592 217 




2 226 0.000006518 0.005271 2,316.96 1.72E+08 109433 218 




2 226 0.000006518 0.005271 2,291.46 1.72E+08 67,002.80 218 






2 226 0.00001151 0.009189 2,130.24 7.54E+07 62,872.90 218 






2 226 0.00001151 0.009189 2,156.16 1.23E+07 67,320.30 218 




2 226 0.000006518 0.005271 2,342.52 25,423.40 218 
201 






2 226 0.00001151 0.009189 2,182.86 1.23E+07 41,134.10 218 
(F)MTEYVATRW(Y) 99% 104.44 578.7764 1,155.
54 
2 226 0.000018 0.01556 2,054.28 1.18E+07 64,395.90 218






2 226 0.00001151 0.009189 2,209.14 1.23E+07 27,406.00 218 
(W)YRAPELMLSLHE
Y(T)
100% 129.89 811.4058 1,620.
80 
2 239 -0.000062 -0.03823 2,364.42 2.56E+08 138356 227 
(Y)RAPELMLSLHEY
(T)
99% 109.83 729.8741 1,457.
73 
2 239 -0.000082 -0.05621 2,197.14 7.81E+07 108402 228 
(Y)IQSLPPRQPVPW
(E)
100% 134.25 709.4012 1,416.
79 
2 309 -0.000202 -0.1425 2,354.34 2.43E+09 4573710 298
(Y)IQSLPPRQPVPW
(E)
100% 128.86 709.4012 1,416.
79 
2 309 -0.000202 -0.1425 2,328.72 2.43E+09 6502530 298
(Y)IQSLPPRQPVPW
(E)
99% 109.66 709.4012 1,416.
79 
2 309 -0.000202 -0.1425 2,252.46 2.43E+09 664244 298
(Y)IQSLPPRQPVPW
(E)
99% 109.66 709.4012 1,416.
79 
2 309 -0.000202 -0.1425 2,302.98 2.43E+09 8782000 298
(Y)IQSLPPRQPVPW
(E)
99% 107.21 709.4012 1,416.
79 
2 309 -0.000202 -0.1425 2,379.72 2.43E+09 2698400 298
(Y)IQSLPPRQPVPW
(E)
99% 106.88 709.4012 1,416.
79 
2 309 -0.000202 -0.1425 2,277.72 2.43E+09 8356940 298
(Y)IQSLPPRQPVPW
(E)
99% 91.265 709.4012 1,416.
79 
2 309 -0.000202 -0.1425 2,410.74 2.43E+09 1999810 298
(Y)IQSLPPRQPVPW
(E)
98% 87.258 709.4012 1,416.
79 




98% 84.615 709.4012 1,416.
79 
2 309 -0.000202 -0.1425 2,384.88 2.43E+09 3343420 298
(Y)IQSLPPRQPVPW
(E)
97% 79.148 709.4012 1,416.
79 
2 309 -0.000202 -0.1425 2,882.04 42,883.70 298 
(F)EPSARISAAAAL
RHPF(L)
96% 172.58 565.3093 1,692.
91 








2 365 -0.0004873 -0.2167 2,363.40 7.05E+07 41,651.90 347
(F)SGTPKGSGAGYG
VGF(D)
100% 132.17 671.3253 1,340.
64 
2 745 -0.000182 -0.1357 1,830.72 6912700 35,164.80 731 
